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Abstract 
The ageing of the population is expected to lead to increases in the prevalence of chronic 
conditions, multimorbidity, and raised demand for primary care services. To enable health 
systems to respond to these increases, the prevalence of chronic conditions and 
multimorbidity need to be measured in an accurate and timely manner. However, 
prevalence estimates of multimorbidity vary widely due to inconsistent definitions and 
measurement methods used in research. The aim of this thesis is to develop a reliable and 
practical method of measuring multimorbidity in Australia. 
The research reported in this thesis is based on two sets of sub-studies of the Bettering the 
Evaluation and Care of Health (BEACH) program, a continuous national survey of Australian 
general practice activity.  
The first survey was conducted between August 2008 and May 2009, and involved 290 
randomly selected general practitioners (GPs) who recorded all diagnosed chronic 
conditions in 8,707 patients at their encounters.  
Having GPs record patients’ diagnosed chronic conditions avoids the limitations of self-
reported data used in most large population prevalence studies. However, patients 
sampled at GP encounters are not representative of the population as only about 87% of 
people visit a GP in any year and because older people are more likely to attend and to 
attend more often. To estimate population prevalence, I weighted each age-sex group to 
match the distribution of the population. I then weighted the outcome by the proportion in 
each age-sex group who visited a GP at least once in the survey year, assuming those who 
did not see a GP did not have a diagnosed chronic condition. 
I estimated that two-thirds (66.3%) of patients at GP encounters had at least one diagnosed 
chronic condition as did half (50.8%) of the Australian population. Hypertension was the 
most prevalent condition, 26.6% of patients at GP encounters and 17.4% of the population 
having this diagnosed condition. 
While multimorbidity has been most often defined as 2+ chronic conditions, there have 
been recent moves towards using 3+. There have been calls for standardisation of 
multimorbidity research, inconsistent definitions and methods having led to large variance 
in estimated prevalence between studies. I examined the independent effects on 
prevalence estimates of:  
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1. how ‘morbidity’ is defined either as a single chronic condition or a ‘group’ of 
conditions using the chapter/domain structure of the International Classification of Primary 
Care (Version 2) (ICPC-2), the International Classification of Disease (10th revision)(ICD-10), 
or the Cumulative Illness Rating Scale (CIRS);  
2. the number of ‘morbidities’ required in the definition of multimorbidity;  
3. the number of diagnosed chronic conditions included in the study.  
I found that data grouped by ICPC-2 chapters, ICD-10 chapters or CIRS domains produced 
similar multimorbidity prevalence estimates. Multimorbidity defined as 2+ morbidities 
provided similar estimates whether individual conditions or groups of conditions were 
counted and whether as few as 12 prevalent chronic conditions were studied or all chronic 
conditions, but it lacked the specificity to be useful, especially among older people. 
Multimorbidity, defined as 3+ morbidities, required more measurement conformity and 
inclusion of all chronic conditions, but provided greater specificity than the 2+ definition.  
These results led to a set of guidelines for multimorbidity researchers, which if followed, 
will produce results that can be compared with results from other studies adhering to the 
same guidelines. I also proposed the concept of ‘complex multimorbidity’, the co-
occurrence of three or more chronic conditions classified in three or more different body 
systems within one person, without defining an index chronic condition. Using ‘complex 
multimorbidity’ may identify high-need individuals. 
I estimated that: 47.4% of patients at GP encounters and one-third (32.6%) of the 
population had multimorbidity (2+); further, that 27.4% of patients at GP encounters and 
17.0% of the Australian population had complex multimorbidity. The most prevalent 
pattern of three conditions was hypertension + hyperlipidaemia + osteoarthritis (5.5% of 
patient at encounters and 3.3% of the population).  
In my second, larger, survey, conducted between November 2012 and March 2016, 1,449 
randomly selected GPs recorded all diagnosed chronic conditions for 43,501 patients. They 
also recorded the number of times each patient had seen a GP in the previous 12 months. 
Data collected in Survey 1 had not allowed adjustment for high and low attenders within 
each age-sex group. The individual attendance data in survey 2 allowed me to adjust for 
each patient’s chance of being in the survey sample.  
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My prevalence estimates for patients at encounters were similar to those from Survey 1, 
with 26.5% of patients at encounters having diagnosed hypertension, 51.6% multimorbidity 
and 30.4% having complex multimorbidity. However, the population prevalence estimates 
produced with the new method were significantly lower than those from the previous 
method, an estimated 12.4% of the population having diagnosed hypertension, 25.7% 
multimorbidity and 12.1% complex multimorbidity. This suggests that patients with more 
chronic conditions attend more often than others in their age-sex group. Adjusting for 
individual patient attendance is therefore required to produce reliable population 
estimates from data collected from patients sampled at GP encounters. 
My final task was to develop a parsimonious model to predict patient GP-visit rate, testing 
the assumption that the number of chronic conditions is driving GP service use. In Survey 2, 
the number of diagnosed chronic conditions alone accounted for a significant proportion of 
the variance (25.5%) in patient GP-visit rate. The number of body systems involved also 
explained a significant proportion of variance (23.9%). Including patient age, sex and 
Commonwealth concession health care card status only marginally increased the predictive 
value of the model to 27.9%. 
In summary, this thesis demonstrates a practical method of measuring multimorbidity in 
Australia, using GPs as expert interviewers and adjusting for each patient’s individual 
attendance. I have shown that to produce robust results that can be compared with other 
studies, multimorbidity researchers should ideally define multimorbidity as 3+ conditions 
and include as many chronic conditions as possible in their study. Finally the measure has 
practical application as the number of diagnosed chronic conditions in an individual is the 
most significant driver of general practice service use. The results of this research will help 
inform health policy makers in their response to the challenges posed by continued growth 
in the prevalence of multimorbidity. 
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Glossary 
Throughout this thesis terms that are defined in the glossary are marked with the symbol ‘Ŧ’ 
where possible. Terms are only marked the first time they are used in the text. 
Active patient: A patient who has seen a GP at least once in the previous 12 months. 
Chronic condition: A medical condition that: has a duration that has lasted, or is expected 
to last, at least 6 months; has a pattern of recurrence, or deterioration; has a poor 
prognosis; and produces consequences, or sequelae that impact on the individual’s quality 
of life as defined by O’Halloran et al. 
CIRS domains: The main division within CIRS. There are 14 domains which represent 
different body systems. 
Commonwealth concession health care card: Patients holding a Health care/benefit card 
which entitles the holder to a higher level of Government subsidy for health services (for 
example, reduced-cost medicines under the Pharmaceutical Benefits Scheme). Examples of 
patients who may be eligible include pensioners, unemployed, low-income earners. 
Concessional patient: A patient who holds a Commonwealth concession health care card – 
see above. 
Comorbidity: Any distinct additional entity that has existed or may occur during the clinical 
course of a patient who has the index disease under study as defined by Feinstein. 
Complex multimorbidity: co-occurrence of three or more chronic conditions affecting three 
or more different body systems within one person without defining an index chronic 
condition. 
Encounter: Any professional interchange between a patient and a GP. 
General practitioner (GP): A medical practitioner who provides primary, comprehensive 
and continuing care to patients and their families within the community. 
Health Care Homes: A model similar to the ‘Patient Centred Medical Home’. Current Health 
Care Homes in Australia is a trial of voluntarily enrolment of patients with multiple 
diagnosed chronic conditions with a single practice which will receive capitation payments 
for the management of the enrolled patient's chronic conditions (but not their non-chronic 
issues). 
xvi 
ICD-10 chapters: The main divisions within ICD-10. There are 22 chapters primarily 
representing the body systems. 
ICPC-2 chapters: The main divisions within ICPC-2. There are 17 chapters primarily 
representing the body systems. 
Indexation: A technique to adjust payments by means of a price index, usually in attempt 
to maintain the payment’s relative value after inflation. 
Medicare: Australia’s publicly funded, universal health care system, established to provide 
affordable medical, optometrical and hospital treatment. Contributions to the Medicare 
system are based on income and made through taxes. 
Medicare Benefits Schedule (MBS) item: Each item number identifies a service funded 
through Medicare. The MBS lists all the Medicare services subsidised by the Australian 
Government, their claimable amount and conditions for use.  
Morbidity: The distinct entities that are counted when measuring comorbidity or 
multimorbidity. Most commonly they are chronic conditions or groups of chronic 
conditions. 
Multimorbidity: While there is no clear definition, in this thesis it refers to someone with 
multiple morbidities, without an index morbidity. 
National Health Survey (NHS): A large population based study of Australia’s health 
conducted by the Australian Bureau of Statistics every three to six years since 1977-78. The 
measurement of chronic condition prevalence is based on respondent self-report via 
personal interview. 
Pharmaceutical Benefits Scheme (PBS): Australian Government program that subsidises 
the cost of necessary and lifesaving medicines for Australian residents. 
Significant: A statistically significant result. In this thesis, statistical significance between 
point estimates is determined by non-overlapping 95% confidence intervals. 
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Structure of thesis 
Chapter 1: Introduction 
This chapter describes the need to measure the prevalence of chronic conditions and 
multimorbidity. It discusses the current challenges in measuring multimorbidity and the 
need for standards in definitions and methods multimorbidity research.  
Chapter 2: The aims of this thesis and the candidate’s contribution 
This chapter outlines the six aims of the thesis and describes the candidate’s contribution to 
its conception, design, conduct and creation. 
Chapter 3: Prevalence of chronic conditions in Australia (Published in PLOS ONE 2013) 
This published paper describes the first survey used in this thesis and introduces a new 
method to estimate population prevalence of chronic conditions from GP-patient 
encounter data.  
Chapter 4: Examining different measures of multimorbidity, using a large prospective 
cross-sectional study in Australian general practice (Published in BMJ Open 2014) 
This published paper uses the data and methods described in Chapter 3, to explore the 
independent effect of changing study parameters on multimorbidity prevalence estimates. 
Parameters investigated include: the number of conditions studied; the minimum number 
of ‘morbidities’ required to have multimorbidity; and counting groups of conditions versus 
individual conditions.  
Data grouped by ICPC-2 chapters, ICD-10 chapters or CIRS domains produces similar 
multimorbidity prevalence estimates. Multimorbidity defined as 2+ morbidities provides 
similar estimates whether individual conditions or groups of conditions are counted or 
whether as few as 12 prevalent chronic conditions or all chronic conditions are studied, but 
it lacks the specificity to be useful, especially among older people. Multimorbidity, defined 
as 3+ morbidities, requires more measurement conformity and inclusion of all chronic 
conditions, but provides greater specificity than the 2+ definition. The concept of complex 
multimorbidity is put forward as having at least one chronic condition classified to each of 
3+ body systems. 
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Chapter 5: The prevalence of complex multimorbidity in Australia (Published in ANZJPH 
2016) 
This published paper is the third and final paper using data from survey 1. It examines the 
patterns and prevalence of multimorbidity and complex multimorbidity (as defined in 
Chapter 4) among patients at GP encounters. It estimates the prevalence of multimorbidity 
and complex multimorbidity in the population using the methods from Chapter 3. 
Chapter 6: The prevalence of diagnosed chronic conditions and multimorbidity in 
Australia: A method for estimating population prevalence from general practice patient 
encounter (Published in PLOS ONE 2017) 
This published paper uses data from survey 2, which also surveyed the number of times the 
patient had seen a GP in the previous 12 months. This additional improves the method first 
described in Chapter 3, as it allows adjustments for individual patient visit rate. This 
adjustment method provides more reliable estimates and allows estimation of population 
prevalence within age-sex specific groups. This improved method is used to estimate 
prevalence of chronic conditions, multimorbidity and complex multimorbidity among 
people in the population.  
Chapter 7: Predicting patient use of general practice services in Australia (Under review at 
ANZJPH) 
This paper uses the data from survey 2 to create a predictive model explaining patient GP-
visit rate. It shows that the number of diagnosed chronic conditions is the strongest single 
predictor of patient GP-visit rate. The final parsimonious model includes the patient’s: 
number of diagnosed chronic conditions; age, sex; and Commonwealth concessional health 
care card status. This chapter also reports early results from the next study which show the 
strongest predictor of patient complexity of care is also the number of diagnosed chronic 
conditions. 
Chapter 8: Discussion and conclusions 
This chapter discusses the results from all five papers in relation to the six aims of the thesis 
and draws final conclusions. 
1 
Chapter 1: Introduction 
The rise of chronic conditions 
Globally in 2015, chronic conditionsŦ (also known as non-communicable diseases) were the 
leading cause of death, with 71.3% of deaths attributed to them. Between 2005 and 2015, 
the total number of deaths attributed to chronic diseases rose by 14.3%, while the number 
of deaths from communicable, maternal, neonatal and nutritional diseases decreased by 
19.7%. Cardiovascular diseases caused the highest mortality (17.9 million deaths), followed 
by cancers (8.8 million deaths) and chronic respiratory diseases (3.8 million deaths).1 The 
proportion of mortality attributed to chronic conditions is higher in developed countries. In 
2014, chronic conditions accounted for 91% of deaths in Australia, 89% in the Netherlands, 
in New Zealand and in the United Kingdom(UK) and 88% in the United States (US) and 
Canada.2 
The prevalence of chronic conditions is increasing worldwide. From 2005 to 2015, while the 
world’s population increased by 12.7%,3 the total number of people with: peripheral 
vascular disease increased by 34.4%; osteoarthritis increased by 32.9%; diabetes increased 
by 30.6%; chronic kidney disease increased by 26.8%; ischaemic heart disease increased by 
25.9%; major depressive disorder by 17.8%; chronic obstructive pulmonary disease by 
17.0%; and anxiety disorders increased by 14.9%.4 
In Australia, the National Health SurveyŦ found that the proportion of people with at least 
one self-reported “long-term” condition increased from 77.9% in 2001 to 79.7% in 2014–
15, the prevalence of diabetes (Type 1 or 2) rose from 3.3% to 5.1%, while prevalence of 
osteoporosis more than doubled from 1.6% to 3.5%.5 In 2011, chronic conditions accounted 
for the majority of the total burden of disease in Australia.6 
The increase in chronic conditions has been reflected in general practitionerŦ (GP) 
workload. In 2000–01, 48.2 (95% CIs: 46.6–49.8) chronic conditions were managed per 100 
GP-patient encounters and they accounted for 33.2% (95% CIs: 32.4–34.1) of all problems 
managed.7 By 2015–16, 53.3 (95% CIs: 51.4–55.3) chronic conditions were managed per 
100 encounters and they accounted for 34.6% (33.6–35.5)A of all problems managed.8 In 
                                                          
A 95% confidence intervals were calculated separately as they were not published in the annual 
report referenced 
2 
the same year, 47.3% (95% CIs 46.0–48.6) of all medications prescribed in general practice 
were for the management of chronic conditions.B  
The increase in the prevalence of diagnosed chronic conditions is being driven by three 
factors – the ageing of the population,9 earlier detection of chronic conditions through 
enhanced screening10 and the increase in prevalence of obesity.11,12 
The ageing of the population 
The world's population is ageing, with increases in both the absolute number and the 
proportion of people who are aged 60 years or older (60+). From 2000 to 2015, the number 
of people aged 60+ increased by 48% to 901 million. In 2015, people aged 60+ accounted 
for 12.3% of the world’s population. The increase is expected to accelerate, with the 
projected number of people aged 60+ being 1.4 billion in 2030, a 56% increase over the 
number in 2015.13 
The ageing phenomenon is currently more pronounced among the populations of 
developed countries. In 2015, 33% of Japan’s population was aged 60+, while in Germany 
and Italy people aged 60+ accounted for 28% of their populations. However from 2015 to 
2030, the number of people aged 60+ in developing countries is expected to increase at a 
faster rate than in developed countries. While the global increase in the number of people 
aged 60+ is expected to be 56% over this period, Latin America & the Caribbean are 
projected to have a 71% increase, Asia a 66% increase and Africa a 64% increase in the 
number of people aged 60+.13 
While many of the reports on ageing focus on the number of people aged 60+, the number 
of people aged 80 years and over is increasing at a faster rate, by 77% from 2000 to 2015, 
and is expected to increase a further 61% by 2030.13 
Australia is no exception to the ageing population phenomenon. From June 2000 to June 
2015, the proportion of people who were aged 60+ increased from 16.6% to 20.4%, while 
the proportion aged 80+ increased from 2.9% to 3.9%. From 2015 to 2030, the proportion 
aged 60+ is projected to increase from 20.4% to 23.8%, while the proportion aged 80+ is 
projected to increase from 3.9% to 5.4%.14 
The two main reasons for global population ageing are a reduction in the fertility rate, and 
increased life expectancy. 
                                                          
B Unpublished data from the Bettering the Evaluation and Care of Health project 
3 
Reduction in fertility rate 
The global fertility rate fell from 4.96 in 1950–55 to 2.51 in 2010–15.3 Over this period the 
fertility rate in many developed and high income countries dropped below that required to 
replace the mother and her partner in the population.3 This reduction has meant that the 
proportion of children in the population is decreasing, while the proportion of older people 
is increasing.  
Australia’s fertility rate has been below its replacement rate of 2.1 children per woman 
since the mid-1970s.15 In 2015, the fertility rate was approximately 1.81 children per 
woman.15 
Increased life expectancy 
The global average life expectancy at birth in 1950–55 was 46.8 years. By 2010–15 it had 
increased to 70.5 years.13 Therefore over this period, average life expectancy at birth 
increased by nearly 5 months for every year that passed. 
The increase in life expectancy has been driven by reduced mortality in younger people in 
lower income countries and by improved survival of those aged 60+ in higher income 
countries.13,16 A large study examining death registration data from higher income countries 
found that between 1980 and 2011, the risk of dying between the ages of 60 and 80 years 
decreased by 1.5% per year for men and 1.7% per year for women in these countries.17 
These gains were attributed to reduced tobacco use in men and improved cardiovascular 
disease and diabetes health outcomes for both sexes. Other research has found that about 
half the reduction in mortality from cardiovascular disease came from new treatments for 
these conditions while the remainder was the result of better management of risk factors 
of cardiovascular disease (e.g. hypertension, hyperlipidaemia and tobacco smoking).18 
The ageing of the population is driving an increase in the prevalence of diagnosed chronic 
conditions since older people are more likely to be diagnosed with a range of chronic 
conditions than younger people.19 As the proportion of older people in the population 
increases, the prevalence of chronic conditions common among older people will also rise. 
This is being compounded by the improved management of chronic conditions, such as 
cardiovascular disease.18 As a result people are living longer with diagnosed chronic 
conditions.  
4 
Earlier diagnosis of chronic conditions 
Part of the improved management of chronic conditions is the drive to diagnose chronic 
conditions earlier. For many chronic conditions, early diagnosis improves patient outcomes 
and helps prevent further deterioration of health.20 In Australia, the drive for early 
detection of chronic conditions has come from both Government initiatives and community 
based non-profit organisations. 
Government initiatives include large screening programs such as the National Bowel Cancer 
Screening Program21 and the provision of funds through specific health insurance rebates 
for GPs to screen patients at risk of chronic conditions. These items include health 
assessments for patients at different stages of life, starting with the ‘healthy kids checks’ for 
children (now retracted), Type 2 diabetes risk evaluation for a patient aged 40–49 years, 
health checks for patients aged 45–49 years who are at risk of developing chronic 
conditions, annual health checks for permanent residents of a residential aged care facility, 
and for patients aged 75 years and over.22 Recognising the disparity in health outcomes 
among Australia’s Indigenous community, the Government provides funding for health 
assessments of Indigenous patients at all stages of their lives. The Australian Government 
Department of Health (DoH) states that the aim of this funding is “to help ensure that 
Aboriginal and Torres Strait Islander people receive primary health care matched to their 
needs, by encouraging early detection, diagnosis and intervention for common and 
treatable conditions that cause morbidity and early mortality.”23 
Community based non-profit organisations often seek to raise awareness of a condition and 
encourage people who are at risk of a condition to be checked by their GP. For example: 
the Cancer Council of Australia provides information on how a person can lower their risk of 
cancer, and about the signs and symptoms that people should have checked by a GP;24 
Beyondblue, seeks to raise awareness of mental health issues, but also tries to lower the 
barriers to diagnosis by attempting to destigmatise mental health conditions.25 
Earlier diagnosis increases the length of time a patient is diagnosed with the condition over 
their life time, further increasing the overall prevalence of diagnosed chronic conditions in 
the community. The diagnosis of chronic conditions earlier in life alters the relationship 
between age and the prevalence of a chronic condition so that it is not constant over time. 
We therefore cannot use the historical age-sex prevalence of a condition to predict its 
future prevalence based on population projection alone. 
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The ‘obesity epidemic’ 
An additional influence on the increasing prevalence of chronic conditions, independent of 
the ageing population, is the increasing prevalence of obesity. Defined as having a Body 
Mass Index (BMI) of 30 or greater, obesity has been increasing globally, from 3.4% of adult 
(aged 18+ years) men and 6.4% of adult women in 1975 to 10.8% for men and 14.9% for 
women in 2014.26 
The prevalence of obesity in Australia is one of the highest in the world, 27.6% of adult men 
and 27.9% of adult women being considered obese in 2014.26 The rise in prevalence of 
obesity has been reflected among patients at GP encountersŦ. In 2000–01, 20.2% of adult 
patients sampled at GP-patient encounters were classed as obese.7 By 2015–16, this figure 
had increased to 28.8%.8 
This is a concern because obesity has been associated with higher prevalence of a wide 
range of chronic conditions including, but not limited to: Type 2 diabetes;11,27 arthritis;27 
asthma;27,28 cancer;11,29 high blood pressure or hypertension;11,27 high cholesterol;27 chronic 
renal failure;30 and heart disease.11,12 A report by the Organisation for Economic Co-
operation and Development (OECD) suggested that since obesity is related to preventable 
chronic conditions, it should be treated as a public health priority in Australia.31 
The fact that obesity has an independent effect on the prevalence of many chronic 
conditions is another reason it would be inappropriate to use historical age-sex prevalence 
of a condition to estimate its future prevalence based on population projections alone. 
Concern about rising prevalence of chronic conditions 
With the ageing of the population, improvements in the management and detection of 
chronic conditions and the increasing prevalence of obesity, it is expected that the 
prevalence of chronic conditions will also continue to rise.10 There are concerns that this 
will overwhelm the Australian healthcare system and make our current model 
unsustainable.32 
GPs are usually the first port of call in the Australian healthcare system and they act as 
gatekeepers to secondary and tertiary care. Patients are free to visit any GP, in any practice 
at any time. The cost of visiting a GP in Australia is covered (all or at least in part) through a 
universal Government funded medical insurance scheme (called Medicare Ŧ)33 and many 
medications are subsidised through the Government’s Pharmaceutical Benefits Scheme Ŧ 
(PBS).34 
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In 2015–16, 87% of Australians visited a GP at least once.8 Currently, GPs are reimbursed 
for their patient consultations on a fee-for-service basis. Due to concern that healthcare 
costs will be unsustainable under the current funding model, since 2014 the Australian 
Federal Government has proposed several changes to Medicare funding of general 
practice.35 These have included: a freeze on indexation of the amount paid for GP services 
claimed through Medicare, from July 2014 to June 2020;36 proposed patient co-payments 
for general practice services37 (currently withdrawn); proposed minimum consultation 
length of 10 minutes to claim ‘standard’ service items37 (currently withdrawn); a proposed 
$5 reduction in the rebate for commonly claimed items of service37 (currently withdrawn); 
and increased patient co-payments (above indexation) for medications subsidised through 
the PBS ($0.80 for concessional patients and $5 for non-concessional patients)35 (awaiting 
ratification by Parliament). Primary Health Care reform is still underway with the most 
recent proposal being ‘Health Care Homes’ Ŧ, a trial of voluntarily enrolment of patients 
with multiple diagnosed chronic conditions with a single practice which will receive 
capitation payments for the management of the enrolled patient's chronic conditions (but 
not their non-chronic issues).38,39 
Initiatives such as the trial of capitation payments for the management of chronic 
conditions among eligible patients require accurate prevalence estimates of chronic 
conditions to appropriately plan and fund them. However, due to the confluence of an 
ageing population, improved detection and an increasing prevalence of obesity, the 
prevalence of diagnosed chronic conditions needs to be measured regularly and in a timely 
manner. 
Measuring the prevalence of chronic conditions 
Large population surveys using respondent self-report 
The most common way governments measure the prevalence of diagnosed chronic 
conditions among their citizens is to use large population health surveys that rely on 
respondent self-report. For example, the US has the “National Health Interview Survey”, 
conducted by the Center for Disease Control,40 Canada the “Canadian Community Health 
Survey”, conducted by Statistic Canada;41 and the UK has the “Health Survey of England”, 
conducted by the UK National Health Service.42  
In Australia, every three to six years since 1977-78, the Australian Bureau of Statistics has 
conducted the National Health Survey (NHS) (previously known as the Australian Health 
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Survey). The 2014–15 the NHS surveyed 19,259 people from 14,723 households. While 
some data elements were measured (the respondent’s blood pressure, waist 
circumference, height and weight) respondent self-report was used for estimation of the 
prevalence of chronic conditions.5 
The advantage of these large population health surveys is that they are usually quite 
representative of the entire population compared to smaller or localised studies. However, 
respondent self-report has its disadvantages, mainly the questionable validity and reliability 
of patient recall. A study comparing patient-reported and GP reported reasons for 
encounter and diagnoses found that there was disagreement in at least 30% of paired 
comparisons within individual encounters. They suggested “that diagnoses recalled by 
patients at later household interview are at best only a rough approximation of the 
diagnoses recorded by the doctor”.43 Other studies have found similar phenomena where 
patients have reported having asthma or chronic obstructive pulmonary disease (COPD) 
when the GP has recorded another type of respiratory illness.44 Research suggests that 
patient-recall is better for well-defined conditions,45 worse for other conditions,46-49 and 
worse among patients with lower levels of education.50 Some suggest that medical record 
data may be needed in conjunction with patient self-report to increase accuracy,47 while 
others suggest that clinical ascertainment of patient self-reported morbidity would improve 
accuracy.46 
Health record review 
Due to the issues surrounding the reliability and validity of patient self-report, patient 
health records (paper and/or electronic) to estimate the prevalence of chronic conditions 
have regularly been used as the 'gold standard’ for comparisons with self-reported data.48,51 
However, the quality of information in health records is often compromised through 
inaccurate52,53 or incomplete records.47,49,52-55 
While large reviews of electronic health records (EHRs) can be performed in countries like 
the UK56,57 and the Netherlands,58 the same cannot be done in Australia. This is because of 
differences in the structure of the Australian healthcare system and our current 
infrastructure. In Australia, patients are not registered to a practice and are free to visit as 
many different GPs at as many different practices as they choose. Further there is currently 
no reliable linkage of data across practices and other sections of the health system (i.e. 
hospitals). Combined, these two issues mean that any review will not provide a full picture 
of the patient’s medical history if they have visited more than one practice. 
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Finally, the biggest issue with extracting data from patient EHRs in Australia is the lack of 
standards across the many software providers.59-61 As stated simply by Britt et al. “we still 
have no mandated standards for EHR structure, data elements, definitions, terminologies 
and classification systems, and no minimum data set required about the patient, their past 
history, family history and their encounter.”61All these factors combined make it extremely 
difficult to extract reliable data from EHRs in Australia.  
A recent Deeble Institute issues brief by Gordon et al examined the issues with Australia’s 
current EHR system, and outlined a set of recommendations to solve them. They 
recommended: the implementation of an EHR data model, which would standardise the 
structure of GP EHRs; standardising data element labels and definitions; the use of 
standardised clinical terminology sets for each data element; standardised mapping of 
terminologies to classifications for data extraction and data analytics; GP EHR software 
accreditation, to ensure that software vendors adhere to the above standards; and the 
involvement of all relevant stakeholders (including but not limited to medical professional 
associations, software vendors and Australian Government Departments of Health).62 
Administrative data review 
Some researchers have used the prescribing of a certain type of medication as a proxy for 
the patient having a certain diagnosis, such as assuming someone who is prescribed an 
antidepressant also has diagnosed depression.63 This has special appeal to researchers in 
Australia as all prescribed medications subsidised through the PBS are recorded and kept by 
the Government. However, there are several issues with using medication as a proxy for a 
diagnosis in Australia. Using depression as an example, it has been shown that only about 
70% of antidepressants prescribed by Australian GPs were for the management of 
depression.64,65 Further, not all patients with diagnosed depression have it managed with 
anti-depressants.66 Further, while the PBS records all medications that it subsidises, not all 
antidepressants are subsidised through the PBS. Medications that fall below the rebate 
threshold are not counted and since patients without a health concession card have a 
higher cost threshold, they are less likely to have their medication covered by the PBS. Also 
the PBS does not record medications that are fully paid for privately. Finally, the PBS only 
records medications that have been dispensed. Some patients may have a script written for 
them by a clinician, but never fill the prescription. The PBS would have no record of those 
prescriptions. 
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Population screening studies 
Studies that screen the population, such as the Australian Diabetes, Obesity and Lifestyle 
Study (AusDiab),67 avoid most of the issues of patient self-report and chart review by 
measuring the clinical indications for conditions. They have the added advantage of being 
able to measure the prevalence of undiagnosed chronic conditions in the population. 
However, these studies have their own disadvantages. They are usually limited to a specific 
disease or group of diseases and are relatively expensive—the most recent AusDiab study 
cost over $2.5 million.68 
The use of clinicians as expert participants/interviewers 
Another method researchers have used to avoid the problems associated with respondent 
self-report and with chart review is to recruit clinicians to actively collect data as a 
participant and/or interviewer. Clinicians are more likely than patients (through self-report) 
to label the chronic condition correctly. They may use the patient’s health record, but 
unlike simple chart review by a third party, they also have their own knowledge of the 
patient, and if the patient is present, patient report of their own diagnosed conditions. 
The largest study in Australia to employ such a method was the Bettering the Evaluation 
and Care of Health (BEACH) study.8 
The BEACH study 
The BEACH program was a continuous, national, cross-sectional study of general practice 
activity in Australia which operated from April 1998 to March 2016 inclusive. While the 
BEACH program began in April 1998, it was the culmination of about 20 years of research 
and development work.8 The aims of BEACH were to provide a valid and reliable general 
practice data source that was responsive to the ever-changing needs of information users, 
and provide insight into the evolving nature of general practice in Australia.8 
BEACH methods 
The BEACH methods have been described in great detail elsewhere.8 In summary, each year 
a new random sample of about 1,000 GPs took part in the project. The Australian 
Government Department of Health drew the random samples of eligible GPs from those 
with at least 375 Medicare items claimed for their services in the previous three months. 
This ensured that full-time and part-time GPs were included, but not those who were only 
working occasionally (e.g. academic GPs who do clinical work half a day per week and may 
not give a true reflection of GP clinical activity), nor those registered GPs who were 
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currently not practising, retired, or on leave. Twenty-five GPs were recruited for each of 50 
weeks of each year, with a two week break over Christmas and New Year. Of the 25 GPs 
recruited each week, we expected 20 to complete the project for an average 80% 
completion rate, giving a total sample of about 1,000 GPs per year. 
After agreeing to participate, each GP was mailed a recording pack which included:  
• a set of instructions on how to complete the survey (see Appendix A) 
• a patient information card, that described the survey and its purpose to the patient 
including the option for the patient to opt out if they wish (see Appendix B) 
• a short questionnaire about the GP and their practice (see Appendix C) 
• a pad of patient encounter recording forms (see Appendix D) 
Each GP was asked to record all the details of 100 consecutive encounters with consenting, 
unidentified patients on the structured paper encounter recording forms. Patients provided 
the GP with oral consent to take part in the study. We intentionally collected no 
information that identified the patient, and therefore written patient consent was not 
required. The BEACH program and all sub-studies were approved by the Human Research 
Ethics Committee of the University of Sydney (Reference number 2012/130).  
Details collected about the encounter included patient characteristics, the problems or 
diagnoses that were managed at the encounter and how each of these problems was 
managed.  
With approximately 1,000 GPs each recording 100 consecutive encounters in each year, the 
BEACH study collected information on about 100,000 GP-patient encounters annually. The 
representativeness of the data was tested each year against Medicare claims data and 
published in the annual GP activity book.8 Since the data were representative of patients at 
Medicare-claimed GP-encounters, the results could be extrapolated to the total GP-patient 
visits each year, which are published by the Department of Health on the web.69 
The BEACH project was intentionally paper based, rather than electronic, for several 
reasons. Firstly, not all GPs have a computer at their desk, let alone use it to store the 
patient’s health record.70 Not all GPs have access to a reliable internet connection to allow 
transfer of data extracted from the patient's health record. To participate in BEACH, a GP 
only required a pen, a postal address and access to postal services to return the recording 
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form. This more inclusive approach ensured that the GPs who completed BEACH 
represented all active GPs, irrespective of their level of use (if any) of EHRs for clinical 
purposes. The BEACH encounter forms only allowed for recording of information about 
what happened at each encounter. For instance, if a patient had Type-2 diabetes, but did 
not have it managed at that encounter, it was not recorded on the encounter form. There is 
obvious value in collecting data about the patient that are not necessarily related to the 
current GP-encounter. To collect this additional information sub-studies were devised. The 
sub-studies were positioned along the bottom of the patient encounter form (Appendix D). 
Over the years of the BEACH program, in over 100 such sub-studies the topic of interest 
was the prevalence of a specific chronic condition or multiple chronic conditions.71 
The BEACH sub-studies provided chronic condition prevalence data that was nationally 
representative of patients at GP-encounters and avoided the issues surrounding self-report 
and chart review. The prevalence of chronic conditions among patients at GP encounters is 
valuable in itself, as it reflects the prevalence of conditions across the GP workload. 
However, the results could not be generalised to the wider Australian population because 
patients at GP encounters are more likely to be older and more likely to be female than 
people in the population, and not all of the population visit a GP in any given year.19 
Earlier research estimating the prevalence of chronic conditions 
using BEACH data 
Prior to the start of this thesis, I was the analyst on a paper (Knox et al19) for which I 
developed a method to convert GP-encounter prevalence estimates to national population 
prevalence estimates. We ran a series of BEACH sub-studies in late 2005 where we asked 
the GP “Does this patient have any of the following conditions which require ongoing 
management?”. There were 23 common chronic conditions listed, each with a tick box for 
ease of response. The conditions covered were those in the Australian Government’s 
National Health Priority Areas at the time, with the exception of injuries which were not 
included due to their largely acute nature. We also included other chronic conditions 
demonstrated to be frequently managed in general practice.19 
Calculating the GP-encounter prevalence was a simple matter of measuring the unweighted 
proportion of patients in the sample that had the condition of interest. Calculating 
population prevalence estimates was more involved. The likelihood of a patient being 
sampled in our study was dependent on their visit frequency, with frequent attenders (who 
were generally older and may have more chronic conditions) being more likely to be 
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sampled than infrequent attenders. We therefore weighted each patient age-sex group to 
match the age-sex distribution of patients who attended general practice at least once from 
April 2005 to March 2006. In effect this meant that young adults (particularly men) were 
weighted up, and older patients were weighted down. We made an assumption that if a 
patient had not seen a GP in the previous 12 months, then that patient did not have a 
diagnosed chronic condition requiring ongoing management. To adjust for those who did 
not see a GP in that year, we weighted the outcome data by the proportion of people in the 
population who had made a claim for at least one a GP Medicare item of service in the 
previous 12 months (88% in 2005–06) to produce population prevalence estimates.19 
This method gave us prevalence estimates that were significantly different to our GP 
encounter prevalence estimates and similar to the 2004–05 National Health Survey 
prevalence estimates. However it was a crude method, as it assumed there was no 
difference between each age-sex group in the proportion of people who saw a GP at least 
once. In reality, older people were far more likely to see a GP at least once in a year (based 
on Medicare claims data supplied the Australian Government Department of Health and 
Ageing). This meant that using this earlier method we were weighting older patient results 
down more than was appropriate. 
The healthcare system’s single disease focus and the 
complexity of patients with multiple chronic 
conditions 
Health care delivery has been criticised for being single disease focussed.72 Clinical care 
guidelines are usually single disease focussed73-79 and patients are referred to medical 
specialists for the management of specific conditions. While this structure of healthcare 
may work well for patients with a single chronic condition, complexities in care arise when 
a patient has multiple diagnosed chronic conditions (MCCs). 
Clinical trials 
Ideally the management of patient health should follow clear guidelines based on sound 
scientific evidence, largely from clinical trials.74 However, clinical trials of medications and 
other treatments usually exclude patients with MCCs as the additional chronic conditions 
are seen as confounding variables,80,81 even though the majority of patients eligible for 
clinical trials have MCCs.81  A recent study showed of all the registered randomised control 
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trials (RCTs) that assessed an intervention targeting adults with one of 10 selected common 
chronic diseases conducted 1st January 2014–31st January 2015, 79% excluded patients 
with MCCs. In an extreme example, the study found that even though 97% of patients with 
heart failure had other chronic conditions, 83% of trials targeting patients with heart failure 
excluded those with any other chronic condition.80 Therefore the outcomes of these clinical 
trials cannot be generalised to patients with MCCs,82 even though having MCCs is very 
common among patients with a chronic condition.80 
Clinical guidelines 
The dearth of evidence from clinical trials on how to manage patients with MCCs has led to 
deficiencies in current guidelines for the management of chronic conditions, because they 
do not account for the presence of other diagnosed chronic conditions.73,74,83 Following all 
the guidelines for the management of each chronic condition in a patient with MCCs, may 
have unintended negative outcomes,83 from interventions that will likely cause more harm 
than benefit,75 or lead to excessive polypharmacy,84,85 which in turn increases the risk of 
adverse drug events.85-87 Simple adherence to all the recommended guidelines for the care 
of all the conditions in a patient with MCCs can lead to harmful combinations of 
medications.88 Potentially serious drug interactions were found to be relatively common if 
GPs applied the UK’s National Institute of Health and Care Excellence (NICE) clinical 
guidelines to patients with MCCs.79,88 One US study showed that 22.6% of patients with 
MCCs had received at least one medication that may worsen a coexisting condition.89  
Probably the most famous demonstration of the shortcomings of adhering to all clinical 
practice guidelines for a patient with MCC was provided by Boyd et al.83 In their study, they 
applied all the relevant clinical practice guidelines to a hypothetical 79 year old woman with 
diagnosed osteoarthritis, osteoporosis, Type 2 diabetes, hypertension and chronic 
obstructive pulmonary disease. They found that this hypothetical patient would be 
prescribed 12 separate medications which required 19 doses per day between them, being 
taken over 5 periods during a typical day with one medication being taken weekly. There 
were 14 recommended nonpharmacological activities including daily monitoring of some 
conditions. Adherence to all the guidelines not only resulted in possible interactions 
between medications, but included conflicting nonpharmacological recommendations (such 
as whether the patient should undertake load bearing exercise). While some have argued 
that this example may overstate the scale of the problem,88 it does highlight the complexity 
and treatment burden of managing MCCs within patients. 
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Prioritisation of care 
An additional complexity of managing patients with MCCs is the competing demands for 
treatment between the multiple chronic conditions.90 Due to the management burden and 
the risks posed by managing all conditions in strict adherence to guidelines, clinicians will 
often have to prioritise the management of some of the patient’s conditions over 
others.79,90 This can mean that in competing for care, some conditions can go under-treated 
due to the management of another condition.91 
Another layer of complexity is that a patient's outcome priorities for their care may differ 
from those of their clinician.92 Fried et al found that 76% of elderly patients ranked their 
independence as their most important health outcome,93 while only 11% ranked ‘staying 
alive’ as top priority. The most common ranking of priorities (29% of patients) was 
independence, followed by ‘pain relief’, ‘symptom relief’ and finally ‘staying alive’.93 A 
mismatch between patient and clinician priorities, may lead to poor treatment compliance 
by the patient.92 
Higher health utilisation 
Having MCCs has been repeatedly shown to increase patient use of health services94-99 
which increases overall health spending on these patients.95 Patients with MCCs also visit a 
wider variety of healthcare professionals. They have increased: visits to general practice,94-
98 medical specialists,96 and hospital outpatients,95 more hospital admissions,95 and 
avoidable hospitalisations.99 
Barbara Starfield had concerns about over-reliance on medical specialists in the care of 
patients with MCCs, especially in the US. 100 She found that the number of different 
specialists a patient saw was positively related to the number of diagnosed chronic 
conditions in the patient.101 This was of concern as she had shown that the high use of 
specialists is very costly, potentially dangerous and ultimately unnecessary.102 Even after 
adjusting for other confounders (including the number of chronic conditions) patients who 
had seen a higher number of different specialists had higher costs, more procedures and 
medications prescribed.103 
People with MCCs see a variety of healthcare professionals for the care of their various 
conditions and this can lead to fragmentation of their care. There is evidence that patients 
with multiple chronic conditions are less likely to receive continuity of care, even though 
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they would probably benefit from it most.94 Other research suggests that continuity of care 
in primary care lowers the number of specialists seen by patients with MCCs.103 
Patient treatment burden 
As shown by the examples given by Boyd et al.83 and again by Hughes et al.79, the 
adherence to each clinical guideline for the management of each chronic condition in 
patients with MCCs can create a complex and heavy treatment burden for the patient. 
Islam et al found that the time patients spent on health care increased with the number of 
diagnosed chronic condtions.104 Due to this increased burden, patients with MCCs have 
more trouble with self-care than those with only a single chronic condition,105 including 
managing their medication,105 and self-management of risk factors.105 Further, the presence 
of multiple conditions can mask the early warning signs of exacerbation.105 Fortunately, 
patients with multiple chronic conditions seem to be more willing to learn self-
management skills than patients with a single condition.106  
Overall, patients with MCCs also have a decreased quality of life107 and health-related 
quality of life,108 are at increased risk of avoidable complications when in hospital,99 and 
have increased risk of mortality.109,110 
How can the healthcare system adapt? 
Most researchers agree that the single disease focus of modern medicine is lacking when it 
comes to the care of patients with MMCs.72,79,85,101,105,111-113 Some believe that improving our 
clinical guidelines to account for patients with MCCs would improve their care.73-79 
It has been argued that there needs to be a shift from disease-specific care to patient-
centred care72,74,111 and that this should be complimented by strengthening and supporting 
primary care.72,99,101 Primary care physicians by their very definition are patient (not single 
disease) oriented85,114 and research has shown that patients with MCCs have better 
outcomes in countries with strong primary care systems.115,116 Patients with MCCs are more 
willing to accept team-based primary care than patients without MCCs.106 Improved 
coordination of care between the different arms of the healthcare system is another 
popular suggestion. 72,99,101 The OECD health policy overview of Australia suggested that to 
meet the challenge of rising chronic disease, our healthcare system needs to move from its 
current fragmented state to better co-ordination of patient care.31 
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As Barbara Starfield stated “Those who make their living by focusing on disease resist 
understanding that health is a pattern. Without grasping the pattern, management is at 
best an approximation of adequate care.”85 
Issues with research on patients with multiple 
chronic conditions 
There is clearly a growing body of evidence that patients with MCCs have a range of 
negative outcomes and that there are deficiencies in how the healthcare system manages 
their care. However, there has also been concern with the different ways that patients with 
MCCs have been defined and measured in these studies.117-119 If there is too much variation 
in the way patients with MCCs are studied, the generalisability and comparability of the 
findings is limited. For instance, prevalence estimates of patients with MCCs among studies 
has ranged from 3.5%82 to 98.5%.120 It is clear that different types of patients in these 
studies are being identified as having MCCs. For results of studies measuring MCCs to be 
truly comparable and generalisable, they require standards. The first is a standard 
definition for the terms used to describe these patients. 
Comorbidity 
In studies of patients with MCCs, the first term used to describe the phenomenon was 
“comorbidity”Ŧ. In 1970, Feinstein first coined the term “comorbidity” to describe “Any 
distinct additional entity that has existed or may occur during the clinical course of a patient 
who has the index disease under study”. He believed this term would highlight the issue 
that patients with additional disease entities (beyond the index disease being treated), had 
worse outcomes than patients who had only the index disease being managed.121 
As the study of patients with multiple conditions progressed, the term ‘comorbidity’ was 
applied in various ways that did not align with Feinstein’s definition. One of the most 
famous examples is the Charlson comorbidity index. Charlson et al. developed a method to 
predict the likelihood of one year mortality of a patient, based on the presence/absence of 
each of 22 diagnosed chronic conditions. Each condition is assigned a value based on the 
risk of the patient dying from the condition. The total value of these scores is used to 
predict the patient’s likelihood of mortality over the next 12 months.109 While it is called a 
‘comorbidity index', there is no index disease in the Charlson tool, making its use of the 
term fundamentally different to that of defined by Feinstein. A recent bibliometric analysis 
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by Amirall & Fortin found that 17% of papers that used the term ‘comorbidity’, did not have 
an index disease or medical condition under study.119  
Multimorbidity 
From 1976,122,123 the term multimorbidityŦ was increasingly used by health researchers to 
describe patients with multiple chronic conditions, particularly in Germany. However, the 
term was used in different ways, to refer to: patients with an index disease under study 
who had other chronic conditions;124,125 patients with multiple chronic conditions without 
defining an index disease;126-129 and to describe both.130 
Due to the growing ambiguity around the use of the terms comorbidity and multimorbidity, 
in 1996 Van Den Akker et al suggested clear definitions for both terms.131 They suggested 
that comorbidity be defined according to Feinstein - “Any distinct additional entity that has 
existed or may occur during the clinical course of a patient who has the index disease under 
study” and that multimorbidity be defined as “the co-occurrence of multiple chronic or 
acute diseases and medical conditions within one person”.131 
In 2010 Boyd & Fortin provided a simpler definition of multimorbidity: “the co-existence of 
two or more chronic conditions, where one is not necessarily more central than the 
others”.111 
The distinction of whether a patient with multiple conditions has an index disease under 
study may seem trivial. However, it is important because it reflects the way different arms 
of the healthcare system view patients with multiple chronic conditions. The concept of 
comorbidity is more useful in secondary and tertiary care settings while the concept of 
multimorbidity is more useful in a primary care setting. For example, a patient with 
diagnosed chronic kidney disease, Type 2 Diabetes and hypertension, when seeing their 
nephrologist is considered by the specialist to have chronic kidney disease with 
comorbidities of Type 2 Diabetes and hypertension. When seeing their endocrinologist they 
are considered to have Type 2 diabetes with chronic kidney disease and hypertension being 
comorbid conditions. However, at visits to the GP, the patient has multimorbidity, as a GP’s 
focus is not one particular condition, but on the holistic care of the patient.  
While the concept of comorbidity may be useful to specialists, its disease-centric focus 
helps cement the health care system’s single disease structure. Multimorbidity is a more 
helpful way to view patients with MCCS because its focus is on the patient as a whole, 
aligning with the concept of patient-centred care.132 The exception to this may be patients 
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who have a condition that dominates their care and wellbeing, for whom the concept of 
comorbidity may be more appropriate.83,112,133 
Research on multimorbidity 
Since the turn of the century, the use of the term multimorbidity in research has 
dramatically increased. A simple search in Google scholar for the term ‘multimorbidity’ 
returns 86 related articles published in the year 2000. In the year 2011, when I was 
preparing to start this thesis, 1,050 articles relating to multimorbidity were published. Just 
five years later, the number had increased almost five-fold to 5,050 articles published in the 
year 2016. 
This rapid increase in research on multimorbidity has come with a similar increase in the 
number of ways that it has been defined and measured. Concerningly, an analysis in 2013 
found that only 49% of published papers that used the term multimorbidity described how 
they defined it.119 In the same year a systematic review by Le Reste et al found 132 
definitions of multimorbidity involving 1,631 different criteria.134 This number has no doubt 
grown since then, due to the exponential increase in research and publications on this 
topic. Multimorbidity is most often measured through a simple count of chronic 
conditions,135 however it is frequently also measured using indices such as the Charlson 
comorbidity index109 or the Cumulative Illness Rating Scale (CIRS).136 The lack of standards 
has led to multimorbidity prevalence estimates that range from 3.5%82 to 98.5%.120 
Over the years there have been many calls for guidelines and standards for multimorbidity 
research.112,117,118,131 When Van Den Akker et al put forward their definition of 
multimorbidity in 1996, they already had concerns about the variety of ways multimorbidity 
had been studied. They argued that “attention should be paid to the choices made in 
multimorbidity research regarding the inclusion of patients, the type of conditions studied 
and the measurement used. Choices made have consequences with respect to comparability 
to other studies and generalisability.”131 
What conditions should be included in the study? 
While most studies on multimorbidity only consider chronic conditions,119 some also 
include acute conditions.137,138 Indeed, Van Den Akker et al’s definition of multimorbidity 
“the co-occurrence of multiple chronic or acute diseases and medical conditions within one 
person”131 explicitly includes acute diseases and medical conditions. The European General 
Practice Research Network not only includes acute conditions in their definition, but 
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biopsychosocial and somatic risk factors, defining multimorbidity as “any combination of 
chronic disease with at least one other disease (acute or chronic) or biopsychosocial factor 
(associated or not) or somatic risk factor.”134 Some have made the distinction by using only 
chronic conditions in 'multimorbidity' and referring to patients as having ‘acute 
multimorbidity’ when they have an acute condition along with chronic conditions.137 
The addition of an acute condition to a patient with chronic conditions may indeed make 
the management of the patient more complex in a way similar to an additional chronic 
condition.137 This would mean that counting acute conditions may well be important in 
situations involving acute care. However, due to the temporary nature of acute conditions, 
if acute conditions were included in all measures of multimorbidity, the patients who were 
identified with multimorbidity would change over time. Because this measure would not 
identify the same group of patients over time, it would limit the application of using 
multimorbidity to predict outcomes such as patient health care use and need over time. 
This thesis will not focus on the issues of acute care, but the broader applications of a 
measure of multimorbidity. For this broader application, multimorbidity should be based on 
the number of chronic conditions within patients. 
That leads to the question of what is a chronic condition? There is no clear agreement in 
the literature on the definition of a chronic condition.139 The long-term duration of chronic 
conditions has been one of the most common traits used to define them, however, there is 
no agreement on the definition of 'long term'. Some suggest a minimum of 3 months is 
optimal with a minimum of 12 months being too long.140 Others suggest 12 months should 
be the minimum with 3 months being too short a period as it may capture acute conditions 
with long recovery periods.141 Some have also wondered whether risk factors, such as 
hyperlipidaemia, should be considered chronic conditions when measuring 
multimorbidity.142 
The clearest definition of a chronic condition was developed by O’Halloran et al139 after a 
thorough review of the literature. They defined chronic conditions as having four major 
characteristics: 
• “have a duration that has lasted, or is expected to last, at least 6 months 
• have a pattern of recurrence, or deterioration 
• have a poor prognosis 
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• produce consequences, or sequelae that impact on the individual’s quality of 
life.”135 
O’Halloran et al. 139 applied these criteria to all the International Classification of Primary 
Care (version 2) (ICPC-2) rubrics and ICPC-2 PLUS terms. The list of terms and rubrics were 
published alongside their paper. They considered long-term risk factors such as 
hypertension, hyperlipidaemia and obesity to be chronic conditions. In 2016, O’Halloran 
reviewed the current inclusions and found that they did not need to be updated (personal 
communication).  
How many disease entities should be studied? 
The number of conditions considered in multimorbidity studies varies widely and this is 
suspected of causing the biggest difference between prevalence estimates.117,118 Diederichs 
et al118 and Fortin et al117 both suggested that studies considering only a few conditions 
produced lower prevalence estimates than those examining many conditions. In their 
respective systematic reviews Fortin et al117 found that the number of conditions included 
in different studies of multimorbidity ranged from five conditions to all conditions, while 
Diederichs et al118 reported a range of 4–102 conditions (mean 18.5 and median 14). The 
latter hypothesised that conditions included in each study may often have been chosen for 
pragmatic reasons (i.e. data availability), as most authors did not give reasons for their 
selection of included conditions. When authors did provide reasons for selecting conditions, 
a high prevalence or high impact on patients were the most common reasons given.118 
Both Fortin and Diederichs suggested that multimorbidity researchers should include a 
specified minimum number of chronic conditions in order to reduce the variance in 
prevalence estimates. Fortin et al117 suggested that any 12 prevalent conditions should 
suffice to measure multimorbidity accurately. Diederichs et al118 suggested a minimum of 
11 specified chronic conditions that are prevalent in elderly people (cancer, diabetes 
mellitus, depression, hypertension, myocardial infarction, chronic ischaemic heart disease, 
heart arrhythmias, heart insufficiency, stroke, chronic obstructive pulmonary disease and 
arthritis).  
What is the ‘morbidity’ that is to be counted? 
Ideally, morbiditiesŦ being counted should be distinct. However, in practice this distinction 
is not always clear. Most multimorbidity studies count the number of individual diagnosed 
chronic conditions in a patient. Issues can arise with measuring the number of individual 
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conditions when a condition such as hypertension, that over time develops into 
complicated hypertension, might then receive a slightly different label or code in the 
medical record. Even though it is a continuum of the same condition it may be counted 
twice due to the different labels recorded. Another issue would be two inter-related 
conditions (e.g. transient ischaemic attacks and stroke) that may be considered as two 
separate conditions by one clinician while another may record them as a single condition in 
their notes. As Salisbury et al. summarised “One problem with operationalising 
multimorbidity based on a count of chronic diseases entered in routine medical records is 
that the same disease may be coded in different ways and therefore counted twice in the 
same individual.”94 
Researchers have tried to overcome this problem in some multimorbidity studies, by only 
counting groups of related chronic conditions once, even if the patient has multiple similar 
conditions, to ensure that the count was of distinct morbidities. Examples of this are studies 
that use the Cumulative Illness Rating Scale’s (CIRS) 14 domains to group chronic conditions 
by body system.143,144 Fortin et al117 suggested that this approach may simplify coding and 
data collection. A similar example is counting the number of disease groups/body systems 
of the International Classification of Disease (10th revision; ICD-10)145 in which at least one 
condition had been classified.138 Salisbury et al.94 used the “expanded diagnostic clusters” 
(EDCs) of the Johns Hopkins University Adjusted Clinical Groups Case-mix system.146 
How are the data collected? 
Since studies of multimorbidity first need to identify the diagnosed chronic conditions 
within study subjects, these studies face the same issues around data collection methods as 
studies of prevalence of a single chronic condition. The issues of participant self-report 
data, chart review and clinical screening studies have been discussed.  
What minimum number of disease entities is required? 
Multimorbidity is most commonly defined as two or more (2+) diagnosed disease entities 
present in the patient, but recently there has been debate about whether three or more 
(3+) may be a better measure. Fortin et al117 argue that using 2+ disease entities identifies 
such a high proportion of patients as having multimorbidity that the measure lacks 
specificity, especially among older patients. When multimorbidity was defined as 2+ disease 
entities, the age-specific prevalence of multimorbidity was an ‘S’ shaped curve with a flat 
plateau for older ages. When multimorbidity was defined as 3+ disease entities, there was a 
more linear increase in prevalence by age, providing greater differentiation among older 
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patients. The authors further argued that using 3+ disease entities is likely to identify 
patients with greater health needs and is therefore more useful to clinicians.117 
Severity 
While most studies of multimorbidity simply count the number of chronic conditions, there 
are some that also measure the severity of each of the conditions being counted120,144,147. In 
one of his earliest papers on the topic, Fortin et al argued that “Although a conceptual 
framework for measuring multimorbidity has yet to be proposed, it seems obvious that such 
a measure should include a means of evaluating the severity of the medical conditions.”120 
In this study, Fortin et al used CIRS scores to judge whether a patient had multimorbidity 
(5+ and 10+). 
What population is being studied?  
The validity and generalisability of multimorbidity studies can also be affected by the 
population under study. Often multimorbidity studies will only include older 
patients,46,95,148-155 and the results from these studies may not be applicable to younger 
people with multimorbidity. Certainly, older people are more likely to have a higher 
number of chronic conditions and multimorbidity.143 
The setting in which the data are collected can also effect the generalisability. People who 
are sitting in a GP waiting room are not representative of people in the wider 
population/community.156 They are more likely to be female, older and have a higher 
prevalence of multimorbidity.19,143 The same applies to patients admitted to hospital.157,158  
First national study of multimorbidity in Australia 
I was fortunate to be the analyst and a co-author on the first national study of 
multimorbidity in Australia. Britt et al143 used the same data as the Knox et al19 study of 
prevalence of individual conditions, described earlier in this chapter. In the study of 
multimorbidity we collapsed the 23 individual chronic conditions studied into the domains 
of the CIRS. The list of chronic conditions was limited, only representing 8 of the 14 CIRS 
domainsŦ. The surveyed chronic condition ‘malignant neoplasm’ was too broad to be 
allocated to a single domain, so a separate domain was created for it, giving us nine 
morbidity domains in total.143 
Multimorbidity was defined as 2+ domains, though the prevalence of 3+ and 4+ domains 
was also reported. The patterns of the domains in patients with multimorbidity were 
examined. Prevalence was reported at both the GP-encounter level and for the Australian 
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population. The Australian population prevalence estimates were based on the same crude 
method I used in Knox et al.19 
The Britt et al study143 had the advantages of: being a large national study; using the GP as 
an expert interviewer/participant; and using the validated grouping structure of the CIRS. 
However, this study had two major limitations. Firstly, we did not collect all diagnosed 
chronic conditions. It has been suggested using a limited number of chronic conditions in a 
study leads to lower prevalence estimates. Secondly (as mentioned above), the weighting 
of the data to estimate the Australian population prevalence was the same crude method 
used in Knox et al.19 
The opportunity provided by the BEACH study 
The BEACH program provided an ideal opportunity to further investigate the issues raised 
above around the study and measurement of multimorbidity. BEACH provided access to a 
large, nationally representative, ever changing sample of GP participants and the patients 
they managed at encounters. The sub-studies of BEACH could be adapted quickly to meet 
the changing needs for different types of information about the patients.  
By undertaking a large, national prospective study of multimorbidity using the BEACH 
project, I could improve on the earlier methods of Britt et al.143 and Knox et al.,19 and also 
investigate the effect on prevalence estimates of using different measures of 
multimorbidity, which is not possible by systematic review alone. The results from such a 
study would provide valuable information for Australia’s health policy planners, and for 
multimorbidity researchers globally. 
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Chapter 2: The aims of this thesis and the 
candidate’s contribution 
Aims 
1) To improve on earlier methods of measuring the population prevalence of chronic 
conditions in using general practice data. 
2) To measure the prevalence of chronic conditions among patients at GP encounters 
and in the Australian population, applying these methods. 
3) To investigate the effect of different methods of measuring multimorbidity on who 
is identified as having multimorbidity.  
4) To develop a method to measure multimorbidity in Australia that is valid, reliable, 
generalizable, and useful. 
5) To investigate the relationship between multimorbidity and utilisation of general 
practice services. 
6) To measure the patterns and prevalence of multimorbidity among patients at GP 
encounters, and the wider Australian population. 
The candidate's contribution 
The research in this thesis was performed using the data and resources of the BEACH 
program at the Family Medicine Research Centre (FMRC), University of Sydney. The 
candidate began working with FMRC in January 2002 as a research assistant on the BEACH 
team. In the first few years, he was tasked with cleaning and maintaining the BEACH data as 
a junior analyst. During this time, he developed and produced individual GP reports for 
each GP who took part in BEACH. He was also involved in the analysis of results for the 
BEACH annual reports. In 2006, he was promoted to the position of Senior Research Analyst 
to reflect the more advanced data analyses he was performing. He became deeply involved 
with promoting and disseminating the BEACH data to not only the wider research 
community, but to Government and Industry groups to help maintain funding. He was 
employed with the FMRC up until its closure in August 2016 due to withdrawal of funding 
(due to no fault of the candidate). He was given the honour of becoming the data custodian 
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of the BEACH data when it was moved to the Menzies Centre for Health Policy at the 
University of Sydney, where he is currently still employed. 
The candidate has been involved in the publication of numerous peer reviewed publication 
and books that were based on BEACH data. Over the decade between 2007 and 2016, he 
amassed a h-index of 16 according to Scopus. He especially proud to have led numerous 
studies, including examining: gaps in the predicted Australian GP workforce;1 differences 
between male and female GPs in their management style;2 and the effect of the roll-out of 
the HPV vaccination in Australia.3 The common theme of these papers was their focus on 
relevance to policy at a National level. 
In 2007, the candidate became interested in the effect would be in the future, of the ageing 
of the Australian population on the healthcare system. Around this time he was asked to be 
the analyst on a study examining the prevalence of chronic conditions and multimorbidity 
among patients at GP encounters. His collaborators on these projects were the Director of 
the FMRC, Professor Helena Britt, the centre’s principal analyst Ms Stephanie Knox, the 
Deputy Director, Dr Joan Henderson and the Medical Director, Associate Professor Graeme 
Miller. The candidate helped write both these papers associated with this study. While 
undertaking the literature review for multimorbidity paper, the candidate came to learn of 
the importance of multimorbidity and the challenges it was creating for the healthcare 
system. Seeing the value in population prevalence estimates, it was the candidate’s idea to 
attempt to convert the GP encounter level results to estimates the prevalence among 
people in the Australian population. 
After the papers were published, the candidate could already see ways in which his 
adjustment method could be improved. He also believed that the concept of 
multimorbidity would be incredibly important for primary healthcare research in the 
coming decades. Following discussions with, and encouragement from, the Director of the 
BEACH program (Professor Health Britt), the candidate decided to further investigate better 
ways to measures multimorbidity in Australia. This investigation forms the basis of the 
following thesis. 
The candidate was fully involved in all aspects of this thesis. This included conceptualising 
the topic and developing the aims. He planned, designed and conducted the research and 
performed all the analyses.  
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This thesis was based on a series of BEACH sub-studies which the candidate designed with 
advice from several senior members of the BEACH research tem (Dr Joan Henderson, 
Deputy Director and Dr Clare Bayram BEACH program Manager).The candidate oversaw the 
design of the databases for data entry which was created by the centre’s IT manager, Mr 
Tim Chambers. The candidate assisted Dr Clare Bayram in her normal role of supervising 
data entry, with the candidate resolving all data entry issues on the sub-studies. The 
candidate performed all the data cleaning for these sub-studies, with Associate Professor 
Graeme Miller advising on questions of a clinical nature that arose.  
The candidate planned and performed all the analysis of data for the studies reported in 
the thesis. The candidate occasionally sought statistical advice from a fellow BEACH analyst 
(Dr Allan Pollack) and sought specific statistical advice for Chapter 7 from Dr Kevin 
McGeechan (Senior Lecturer, specialising in biostatistics, Sydney School of Public Health). 
The preparation of this manuscript was entirely the work of the candidate. This includes the 
introduction, the literature review, the presentation and interpretation of results, and the 
conclusions drawn from the results. This thesis contains five papers that the candidate led 
with the help of his three supervisors (Professor Helena Britt, Associate Professor Graeme 
Miller and Dr Joan Henderson) who are co-authors on all five papers. Author contribution 
statements and permission from co-authors to reprint them in this thesis have been signed 
by all authors for each paper. (See Appendix F)  
References for Chapter 2 
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2011;195(4):192-6. 
 3.  Harrison C, Britt H, Garland S, Conway L, Stein A, Pirotta M et al. Decreased 
management of genital warts in young women in Australian general practice post 
introduction of national HPV vaccination program: results from a nationally 
representative cross-sectional general practice study. PLoS One 2014;9(9):e105967. 
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Chapter 3: Prevalence of chronic conditions 
in Australia 
  
Prevalence of Chronic Conditions in Australia
Christopher Harrison*, Helena Britt, Graeme Miller, Joan Henderson
Family Medicine Research Centre, Sydney School of Public Health, University of Sydney, Parramatta, NSW, Australia
Abstract
Objectives: To estimate prevalence of chronic conditions among patients seeing a general practitioner (GP), patients
attending general practice at least once in a year, and the Australian population.
Design, setting and participants: A sub-study of the BEACH (Bettering the Evaluation and Care of Health) program, a
continuous national study of general practice activity conducted between July 2008 and May 2009. Each of 290 GPs
provided data for about 30 consecutive patients (total 8,707) indicating diagnosed chronic conditions, using their
knowledge of the patient, patient self-report, and patient’s health record.
Main outcome measures: Estimates of prevalence of chronic conditions among patients surveyed, adjusted prevalence in
patients who attended general practice at least once that year, and national population prevalence.
Results: Two-thirds (66.3%) of patients surveyed had at least one chronic condition: most prevalent being hypertension
(26.6%), hyperlipidaemia (18.5%), osteoarthritis (17.8%), depression (13.7%), gastro-oesophageal reflux disease (11.6%),
asthma (9.5%) and Type 2 diabetes (8.3%). For patients who attended general practice at least once, we estimated 58.8%
had at least one chronic condition. After further adjustment we estimated 50.8% of the Australian population had at least
one chronic condition: hypertension (17.4%), hyperlipidaemia (12.7%), osteoarthritis (11.1%), depression (10.5%) and asthma
(8.0%) being most prevalent.
Conclusions: This study used GPs to gather information from their knowledge, the patient, and health records, to provide
prevalence estimates that overcome weaknesses of studies using patient self-report or health record audit alone. Our results
facilitate examination of primary care resource use in management of chronic conditions and measurement of prevalence of
multimorbidity in Australia.
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Introduction
The ageing of the population [1] is expected to lead to increases
in prevalence of chronic conditions, multimorbidity [2], and the
demand on primary care [3]. To enable the health systems to
respond to these increases, the prevalence of chronic conditions
needs to be measured in an accurate and timely manner. There
are three major methods by which prevalence is usually measured:
respondent self-report; health record audit; and screening.
Many governments use large population health surveys that rely
on respondent self-report to measure the prevalence of chronic
conditions [4–6]. One such study is the National Health Survey
[7] (NHS), one of Australia’s largest studies of chronic conditions,
which relies primarily on respondent self-report despite well
documented concerns about the validity and reliability of self-
reported health information [8–12].
Using health records (paper and/or electronic) to estimate
prevalence is often seen as superior to patient self-report [13–15].
However, the quality of information in health records can be
compromised through inaccurate [16–18] or incomplete records
[9,15], and there are often issues in obtaining patient consent.
Studies that screen the population, such as the Australian
Diabetes, Obesity and Lifestyle Study (AusDiab) [19], avoid these
issues, but are usually limited to a specific disease or groups of
diseases and are relatively expensive - the most recent AusDiab
study costing over $2.5 million [20].
Australia has a universal medical insurance scheme called
Medicare which (fully or partially) covers the individuals cost of
visits to general practitioners (GPs). GPs provide the bulk of
primary care and act as gate keepers to government-subsidised
health care from other medical specialists. The BEACH (Bettering
the Evaluation And Care of Health) program is a study of general
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practice activity in Australia. Sub-studies of the BEACH program
can provide national prevalence estimates for chronic conditions,
free of the limitations of health record audits and patient self-
report. Our earlier research [21] showed that by embedding sub-
studies within the national BEACH program [22], we could gain
timely, accurate prevalence estimates of common chronic condi-
tions. Accuracy was achieved by using the GP as an expert
interviewer and informant, drawing on their knowledge of the
patient, the patient’s knowledge and the patient’s health record.
This paper builds on our earlier methods by expanding the
study’s scope to include all chronic conditions (rather than a
selection of common chronic conditions) and by improving the
method of dealing with non-attenders when estimating population
prevalence. This paper will show that by utilising the GP as an
expert interviewer within the existing BEACH infrastructure, we
can overcome the limitations of patient self-report, or patient
health record review alone, to estimate prevalence of chronic
conditions in Australia, at a marginal cost to the overall BEACH
program.
Methods
In this study, patients attending a subsample of GPs participat-
ing in the BEACH program were surveyed. BEACH is a
continuous, national cross-sectional study of general practice
activity in Australia. Its methods are described in detail elsewhere
[22]. In summary, an ever-changing, random sample of about
1,000 GPs per year each records information about encounters
with 100 consecutive consenting patients, on structured paper
forms [22].
In sub-studies of BEACH, the GP records information
additional to the encounter data, in discussion with the patient.
The full methods for sub-studies are reported elsewhere [22]. In
this sub-study, 375 participating GPs were each asked to record
diagnosed chronic conditions for each of 30 consecutive patients
within their 100 BEACH records over three five week recording
periods between 15th July 2008 and 4th May 2009.
Questions were brief, reducing the response burden on GPs and
patients. GPs were asked, ‘‘Does the patient have any of the
following chronic diseases/problems?’’ Common chronic condi-
tions were listed (tick boxes) with additional blank spaces allowing
free text descriptions of other unlisted chronic conditions (Figure 1).
A ‘‘no chronic conditions’’ option was also provided. GPs were
instructed to ‘‘Use your own knowledge, patient knowledge and
health records as you see fit, in order to answer these questions’’.
Chronic conditions listed were primarily those most frequently
managed among Australian general practice [22]. Other less
frequently managed conditions (such as chronic kidney disease and
obesity) were included where previous research had indicated they
were prevalent in general practice patients [22]. All current
National Health Priority area conditions were included [23]. Free
text conditions were classified according to the International
Classification of Primary Care (Version 2) (ICPC-2) [24].
Data analysis
To ensure as many patients as possible were kept in the
denominator, we examined GPs’ response patterns for missing
data. Where GPs ticked one or more conditions for some patients
and did not tick any option (including ‘‘No chronic problems’’) for
other patients, the patients with no responses were compared with
the total sample and the ‘‘No chronic problems’’ group. If patients
with missing data resembled patients in the ‘‘No chronic problems
in this patient’’ group in terms of age, sex and problems managed
at encounter, we assumed the patients with no options ticked had
none of the listed conditions, and they were counted as such.
Patients with no options ticked but with any chronic condition (as
defined by O’Halloran et al [25]) managed at encounter were also
included in the sample, with the recorded chronic condition(s)
counted in the sub-study.
BEACH sub-studies have a single-stage cluster design, with each
GP having 30 patients clustered around them. The cluster effect
was accounted for using SAS 9.2.
Sample prevalence estimates were the proportion of patients
with the morbidity in the total sample and can be interpreted as
prevalence among patients found in GP waiting rooms.
As patients were sampled at GP consultations, the likelihood of
being sampled is dependent on visit frequency. Therefore frequent
attenders (such as older patients who may have more health
problems) were more likely to be sampled than infrequent
attenders. Sample prevalence estimates were adjusted for this
likelihood by weighting the sub-study sample against the age–sex
distribution of the people who visited a GP at least once in 2008–
09 (supplied by the Australian Government Department of Health
and Ageing from Medicare claims data). We used 10 year age
groups through to 90 years and over. Worked examples of all our
weightings are in table 1. Applying these weights resulted in
prevalence estimates for the general practice patient population
(ie. those who saw a GP at least once that year).
To estimate national prevalence, we first weighted the sub-study
sample against the age–sex distribution of the Australian
population in June 2008–09 [26]. We assumed that people who
did not attend a GP that year had no diagnosed chronic
conditions. After the above weighting we multiplied the outcome
(condition count) for each patient, by the proportion of their age-
sex group who saw a GP at least once that year. This accounted
for those who did not see a GP. This approach differs from our
previous method where the general practice patient population
prevalence was multiplied by the proportion of the whole
population that attended at least once [18]. This new method
will be more accurate if a higher proportion of older patients (than
younger) attend at least once and if older patients are more likely
to have a chronic condition.
We compared our national population prevalence with
estimates from our previous paper [21] and from the NHS [7].
Significant differences with our earlier paper were determined by
non-overlapping 95% confidence intervals (CIs). As CIs for the
NHS [7] were not publicly available, we assumed that NHS
Figure 1. BEACH sub-study questionnaire on prevalence of chronic conditions.
doi:10.1371/journal.pone.0067494.g001
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estimates not within the 95% CIs of our population estimate were
significantly different.
Ethics statement
During the data collection period for this study the BEACH
program was approved by the Human Research Ethics Commit-
tee of the University of Sydney and the Ethics Committee of the
Australian Institute of Health and Welfare. Our method involves
the collection of data from unidentifiable, consenting patients. A
patient information card is supplied in the research kit, which GPs
are instructed to show to patients in order to obtain informed
consent (an example shown in Britt et al [22]). If the patient
chooses not to participate their encounter details are not recorded.
GPs are instructed to note the patient’s consent in the patient’s
record, but are asked not to provide written consent to the
research body, as this prevents patients remaining anonymous.
These methods comply with the Ethics requirements for the
BEACH program.
Results
Completed research packs were returned by 290 GPs (77.3%)
who responded for 8,333 (95.7%) patients out of a total 8,707. ‘‘No
chronic problems in this patient’’ was ticked for 2,620 (31.4%)
patients and 5,713 (68.6%) had at least one chronic condition
recorded. Only 374 patients (4.3% of 8,707 patients sampled) had
no response recorded. These were similar to patients with ‘‘No
chronic problems’’–with both groups being younger on average
than the total sample and the majority of problems managed at
their encounters were acute, whereas in the total sample these
were mainly chronic problems. Sixty-four ‘no response’ patients
had one or more chronic conditions managed at the encounter
and were included as having these conditions while the remaining
310 ‘no response’ patients were added to the ‘‘No chronic
problems’’ group. In total there were 8,707 patients in our sample
with 5,777 (66.3%) having at least one chronic condition indicated
and 2,930 (33.7%) with none.
The age-sex distribution of the final patient sample did not
significantly differ from that of patients at all GP encounters
claimed (as items of service) through Medicare in 2008–09 and
was older than the population that attended a GP at least once that
year (Table 2). The likelihood of at least one chronic condition
increased significantly with patient age but did not differ among
males and females.
Sample prevalence
Cardiovascular problems were the most common, 31.3%
having at least one, most prevalent being hypertension (26.6%)
and ischaemic heart disease (8.7%) (Table 3). One or more
endocrine/nutritional/metabolic diseases were present in 30.8%
of patients, most commonly hyperlipidaemia (18.5%) and Type 2
diabetes (8.3%). Musculoskeletal conditions were present in 26.4%
of patients, 19.7% having at least one type of arthritis (largely
osteoarthritis 17.8%). One or more psychological problems were
present in 22.1% of patients (13.7% depression and 8.3% anxiety).
Asthma was indicated for 9.5% of patients and chronic obstructive
airways/pulmonary disease (COAD/COPD) in 4.1%.
General practice patient population
After adjustment, estimates for the general practice patient
population were generally lower than sample estimates (Table 3)
with 58.8% having at least one chronic condition. In particular,
cardiovascular disease, arthritis and diabetes, (conditions com-
mon in older age), were significantly less prevalent after
adjustment. Estimated prevalence of asthma and of psycholog-
ical problems were largely unaffected by adjustment suggesting
more similar prevalence of each across attending population age
groups.
Population prevalence
In 2008–09, 83% of the Australian population visited a GP at
least once. After adjusting for non-attenders in each age-sex group,
we estimated that 49.6% of the Australian population had at least
one chronic condition, most commonly: endocrine problems
(21.3%); cardiovascular problems (19.6%) and musculoskeletal
problems (16.7%). Arthritis (any type) was present in 11.9%,
asthma in 7.8% and gastro-oesophageal reflux disease (GORD) in
7.5% of the population. No estimate was made for obesity since it
did not meet the assumption that it would not be present in non-
attenders.
This study’s estimate of the proportion of the population with at
least one chronic condition was not significantly different to the
2005 study’s estimate. For individual chronic problems there were
Table 1. Worked examples of weighting method.
Formulas
Worked example: 80–89 year old
female patient with condition X
Worked example: 10–19 year old
male patient with condition X
A= Proportion of population that saw a GP at least once that year that was
selected age–sex group
2.03% 5.83%
B= Proportion of the sample that was in the selected age–sex group 4.83% 3.03%
C=A/B (GP attenders weight) 0.42 1.92
D= Proportion of the total Australian population 1.87% 6.52%
E=D/B (National weight) 0.38 2.15
F =Number that saw a GP at least once that year (MBS GP item claims*) 362,815 1,040,270
G=Number in population (Australia Bureau of Statistics) 401,097 1,476,395
H= F/G (Proportion of age–sex group that saw a GP at least once that year) 90.46% 70.46%
Adjustment of outcome (or numerator) to estimate national prevalence = E*H Condition X count = 0.34 Condition X count = 1.51
Denominator for national estimate (for both patients with and without
condition) = E
0.38 2.15
*data supplied by the Australian Government Department of Health and Ageing.
doi:10.1371/journal.pone.0067494.t001
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few differences found between the two studies: our estimates for
osteoarthritis, back pain and anxiety were significantly lower than
our earlier study and the malignant neoplasm estimate signifi-
cantly higher. Compared with the NHS, our population preva-
lence estimates were significantly higher for most cardiovascular
conditions, hyperlipidaemia, osteoarthritis, diabetes mellitus,
depression, anxiety and malignant neoplasms and significantly
lower for rheumatoid arthritis, back pain, osteoporosis and
asthma. There was agreement between the two estimates for
congestive heart failure, COAD/COPD and alcohol and drug
problems. No comparative results were available from NHS for
GORD, sleep disorders, and the endocrine, gastrointestinal, and
respiratory problem groups.
Discussion
Despite differences in both the range of conditions surveyed and
the data weighting methods, our prevalence estimates are
consistent with our earlier study [21]. This study has shown that
nearly two-thirds of patients sitting in front of the GP and half of
the Australian population had at least one chronic condition.
These sample prevalence estimates provide a measure of
underlying health needs of patients attending general practice,
distinct from demand for health care measured by general practice
morbidity management rates. However, not surprisingly, the most
prevalent problems in our sample were similar to those most often
managed in general practice [22].
Inclusion criteria may explain some of the differences between
NHS estimates and our estimates. For example, our definition of
‘‘back pain’’ was limited to chronic back pain whereas the NHS,
included all types of back issues. Another possible cause for
differences is the NHS’s reliance on respondent self-report, e.g.
confusion between terms ‘‘arthritis’’ and ‘‘rheumatism’’ may
explain why the NHS produced a far higher estimate of the
prevalence of ‘‘rheumatoid arthritis’’.
While our prevalence estimate of psychological problems
(16.6%) was about 50% higher than the NHS estimate it was
closer to the 2007 National Mental Health and Wellbeing Survey
estimate, that one-in-five Australians had experienced a psycho-
logical problem during the previous year [27]. Our prevalence
estimate for hypertension (16.6%) lay between that of the NHS
(9.4%) and 2005 AusDiab [28](31.1%) estimates. However, one
would expect AusDiab’s result to be higher for two reasons. Firstly,
they measured blood pressure only once as per WHO guidelines
for field testing [29] whereas a GP will use repeated measures
before diagnosis [30]. Secondly, they included patients whose
blood pressure was normal, but were taking antihypertensives.
This would have included those without diagnosed hypertension
prescribed antihypertensives to lower their cardiovascular risk
from another condition such as diabetes [30].
The largest difference in estimates was for obesity. Our study
suggested that only 8.0% of patients sitting in front of the GP are
obese. This is far lower estimate than the 25.0% of adult patients
found in the NHS [7] and 26.7% in other large BEACH sub-
studies where patients self-report height and weight [22]. Many
may find the low prevalence found in our study of concern,
especially when one considers that obesity is infrequently managed
in general practice as a condition in its own right [22]. However,
while obesity is not frequently managed as an identified condition,
in the management of other problems counselling about diet and
exercise is one of the most frequent treatments given by GPs in
Australian general practice [22]. When obesity is managed in
general practice, the majority of the time the patient has raised it
as an issue they want managed [31]. This suggests that patients’
desire for treatment plays a strong role in whether a GP manages
obesity as a condition in its own right. Our prevalence estimate of
8.0% does however match the 8.1% of patients with morbid
obesity (BMI of 35+) found in previous research [32]. This may
suggest that GPs in our study are identifying patients who have a
more extreme ‘‘chronic’’ level of obesity.
Table 2. Age/sex distribution of sampled patients compared with all patients at GP service items claimed through Medicare and
with the Australian general practice attending population.
Patient Age/Sex
Number in
sample
Percent of sample
(95% CIs)
Percent of Australian
general practice
service claims*
Percent of Australian
general practice
population{
Proportion of the sample
with at least one chronic
condition (95% CIs)
Male
,15 years 595 6.9% (6.2–7.6) 7.3% 9.6% 19.8% (16.4–23.3)
15–24 years 272 3.2% (2.8–3.6) 3.3% 5.8% 32.7% (27.4–38.1)
25–44 years 735 8.5% (7.7–9.4) 8.6% 12.2% 56.3% (51.9–60.7)
45–64 years 1,020 11.8% (10.9–12.8) 11.8% 12.5% 82.1% (79.2–85.1)
65–74 years 487 5.7% (5.0–6.3) 5.8% 3.9% 96.1% (94.4–97.8)
75+ years 486 5.6% (5.0–6.3) 5.5% 2.8% 97.9% (96.7–99.2)
Female
,15 years 565 6.6% (5.9–7.2) 6.5% 9.1% 16.8% (13.6–20.0)
15–24 years 497 5.8% (5.2–6.4) 6.0% 6.8% 39.4% (34.6–44.3)
25–44 years 1,297 15.1% (14.0–16.1) 14.5% 15.2% 52.1% (49.1–55.2)
45–64 years 1,405 16.3% (15.3–17.3) 15.6% 13.9% 81.0% (78.6–83.4)
65–74 years 550 6.4% (5.8–7.0) 6.7% 4.2% 94.2% (92.1–96.2)
75+ years 703 8.2% (7.1–9.2) 8.5% 4.1% 98.2% (97.1–99.2)
95 patients had either/both age or sex missing.
*Total MBS GP service items claimed during the 2008–09 BEACH year.
{Distribution of all patients that had at least one GP service item claimed in 2008–09.
doi:10.1371/journal.pone.0067494.t002
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Our slightly higher prevalence estimate of at least one chronic
condition compared with our previous study is probably due to our
inclusion of all chronic conditions rather than only a selection.
However, the ageing population or increases in diagnoses could
also have contributed to this difference.
Our study has limitations. We assumed that people who did not
see their GP in the previous year did not currently have a
diagnosed chronic condition. This assumption may not hold for
conditions such as asthma, where it is mild and did not necessitate
a GP attendance that year. This may explain our lower prevalence
estimate for asthma compared with NHS.
An issue with measuring diagnosed chronic conditions is that,
like most prevalence studies, we can only provide estimates for
those conditions already diagnosed. As the Ausdiab study shows, a
significant proportion of Australians have undiagnosed diabetes
and hypertension [28].
Finally our sample was drawn from patients attending general
practice, so we were more likely to sample people who attend more
frequently. While we adjusted for higher attendance of female and
older patients, our method could not adjust for high attenders
within a specific ten year age-sex group. If patients with particular
conditions consistently attend more often than the average for
Table 3. Prevalence of selected chronic conditions in sample, attending population and Australian population.
Condition Sample prevalence
Prevalence in
those who attend
at least once
Population
prevalence
Knox et al.
population
estimates
(2005) [21]
NHS
estimates
(2007) [7]
At least one chronic condition 66.3 (64.4–68.3) 58.8 (56.7–60.8) 49.6 (47.8–51.4) 46.8+ (45.0–48.5) N/A
Cardiovascular 31.3 (29.4–33.1) 22.7 (21.2–24.2) 19.6 (18.3–20.9) 19.7 (18.4–21.0) 16.4
Hypertension 26.6 (24.9–28.4) 19.2 (17.8–20.6) 16.6 (15.4–17.8) 15.5 (14.4–16.6) 9.4
Ischaemic heart diseases 8.7 (7.7–9.8) 5.7 (5.0–6.4) 5.0 (4.4–5.6) 5.7 (5.0–6.3) 3.81
Cerebrovascular accident 2.9 (2.3–3.5) 1.8 (1.4–2.1) 1.5 (1.2–1.8) 2.1 (1.7–2.6) 1.22
Congestive heart failure 2.9 (2.4–3.4) 1.7 (1.4–2.1) 1.5 (1.2–1.8) 1.8 (1.5–2.1) 1.33
Endocrine, nutritional and metabolic
diseases
30.8 (29.0–32.6) 24.7 (23.2–26.3) 21.3 (19.9–22.6) N/A **
Hyperlipidaemia 18.5 (17.0–20.0) 14.1 (12.9–15.3) 12.3 (11.3–13.4) 11.2 (10.2–12.1) 5.74
Diabetes mellitus 9.2 (8.3–10.1) 7.0 (6.3–7.7) 6.1 (5.5–6.7) 5.8 (5.3–6.4) 4.0
Type 1 0.9 (0.6–1.2) 0.8 (0.6–1.0) 0.7 (0.5–0.9) 0.5 (0.3–0.7) 0.4
Type 2 8.3 (7.5–9.1) 6.2 (5.6–6.9) 5.5 (4.9–6.0) 5.0 (4.5–5.5) 3.5
Obesity (BMI.30) 8.0 (7.0–8.9) 7.1 (6.2–7.9) *** N/A 25.05
Musculoskeletal system and connective
tissue
26.4 (24.6–28.2) 19.6 (18.1–21.1) 16.7 (15.5–18.0) N/A 30.7
Arthritis 19.7 (18.1–21.4) 13.8 (12.6–15.0) 11.9 (10.8–12.9) 14.8 (13.6–16.0) 15.2
Rheumatoid 1.0 (0.7–1.2) 0.7 (0.5–0.9) 0.6 (0.4–0.7) 0.7 (0.5–0.8) 2.1
Osteoarthritis 17.8 (16.2–19.4) 12.2 (11.0–13.3) 10.4 (9.4–11.4) 12.6 (11.5–13.7) 7.8
Other and unknown 2.0 (1.7–2.4) 1.6 (1.4–1.9) 1.5 (1.2–1.7) N/A 6.1
Back pain 6.4 (5.5–7.2) 5.1 (4.4–5.8) 4.4 (3.8–5.0) 7.4 (6.5–8.2) 13.86
Osteoporosis 4.8 (4.2–5.5) 3.0 (2.6–3.4) 2.4 (2.1–2.8) N/A 3.4
Psychological problems 22.1 (20.6–23.7) 20.0 (18.5–21.5) 16.6 (15.3–17.8) 19.4 (18.1–20.8) 11.2
Depression 13.7 (12.6–14.7) 12.1 (11.1–13.1) 10.0 (9.2–10.8) 11.3 (10.3–12.4) 7.47
Anxiety 8.3 (7.3–9.4) 7.6 (6.6–8.5) 6.2 (5.4–7.0) 8.4 (7.4–9.3) 3.3
Sleep disorder 3.0 (2.5–3.6) 2.6 (2.1–3.2) 2.2 (1.8–2.6) N/A N/A
Alcohol & drug problems 1.0 (0.6–1.4) 1.1 (0.7–1.5) 1.0 (0.6–1.3) N/A 0.8
Gastrointestinal 14.6 (13.4–15.8) 11.3 (10.3–12.2) 9.6 (8.8–10.4) N/A **
GORD 11.6 (10.5–12.6) 8.8 (8.0–9.6) 7.5 (6.8–8.2) 9.2 (8.2–10.1) N/A
Respiratory disease 13.7 (12.6–14.7) 12.5 (11.5–13.5) 10.5 (9.7–11.4) N/A **
Asthma 9.5 (8.7–10.3) 9.4 (8.6–10.3) 7.8 (7.1–8.5) 9.3 (8.5–10.2) 9.9
COAD/COPD 4.1 (3.4–4.7) 2.8 (2.3–3.3) 2.5 (2.1–2.9) 2.3 (1.9–2.6) 2.48
Malignant neoplasms 5.0 (4.4–5.7) 3.6 (3.1–4.1) 3.1 (2.7–3.6) 2.0 (1.7–2.3) 1.6
N/A – Not available;
**Groups not comparable due to different inclusions;
***Did not meet management assumption; GORD=gastro-oesophageal reflux disease; COAD/COPD= chronic obstructive airways disease/chronic obstructive
pulmonary disease; +95% Confidence intervals were not reported in the earlier paper, they have been calculated for this paper;
NHS groups 1: Angina+other ischemic disease; 2: Cerebrovascular disease; 3: Odema+heart failure; 4: High cholesterol; 5: proportion of adults 18 years and older; 6: Back
pain/problems, disc disorders; 7: Mood disorders; 8: Long term bronchitis+emphysema.
doi:10.1371/journal.pone.0067494.t003
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their age and sex, this could lead us to overestimate prevalence of
these conditions.
Conclusion
This study provides the only current prevalence data that
uses the GP as an expert interviewer and informant to gather
information from the patient, their knowledge of the patient,
and the health record. For a marginal cost to the BEACH
program, this investigation could be run on an annual basis
and could be expanded to 30,000 patients per year if larger
samples were required. Our estimates can be used to examine
primary care resource use in management of these chronic
conditions. Importantly, the increased scope of this study
allows measurement of prevalence of all chronic conditions
and can therefore be used to measure prevalence of multi-
morbidity in Australia. To further increase the accuracy of
estimates, the next version of this study will include a question
on the number of patient visits to any GP in the past year so
we can adjust for intra age-sex group variation in visit
frequency.
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Further examining the under-recognition of obesity  
In this study I found that GPs only considered 8.0% of patients at encounters to have 
chronic obesity while the larger series of BEACH sub-studies had found that 26.7% of adults 
at GP-encounters were obese based on patient reported height and weight.1 We 
hypothesised that GPs in our study were identifying patients who have a more extreme 
‘chronic’ level of obesity. In collaboration with Mrs Carmen Wong, a colleague at the Family 
Medicine Research Centre (FMRC), we tested this hypothesis in a separate set of sub-
studies in which we collected the patient’s reported height and weight (to measure BMI) 
and examined whether GPs were able to identify if the patient was overweight or obese.2 
We found that GPs in this new study were twice as likely to identify patients as being obese 
(18.3%) as they were in the study reported in this chapter, correctly identifying 60% of 
obese patients. It was thought that the higher identification of obesity in the Wong et al. 
study was due to either prompting the GP to record the patient’s height and weight, which 
may have helped them to identify obese patients, or that in our first survey, GPs judged 
some obesity not to be ‘chronic’.2 Wong et al. postulated that the “increasing prevalence 
and normalisation of overweight and obesity may be a contributing factor to under-
recognition.”2  
Another colleague from the FMRC, Lisa Valenti, completed her Master’s thesis on the topic 
of general practitioner management of overweight and obesity. She found that 
overweight/obesity was rarely managed as a problem in its own right (1.35 per 100 
encounters) even though clinical advice/education for nutrition/weight, exercise and 
lifestyle were commonly provided by GPs at encounters (5.2 per 100 encounters) in the 
management of other conditions. She found that overweight or obesity was most 
frequently managed as a problem at encounters where the patient had raised it as a reason 
for the encounter. She hypothesised that “GPs currently do not see overweight and obesity 
as a ‘clinical entity’ in its own right, in the way they perceive diabetes as a ‘clinical entity’ for 
example.” It might be that because GPs manage obesity as part of care for other conditions 
rather than in its own right, that they do not consider it to be a chronic condition.3 
A reason GPs may not consider obesity to be a chronic condition is that there is still a 
debate around whether risk factors, such as obesity, should be considered chronic 
conditions or disease at all. In 2000, a report by WHO stated that “Obesity is a chronic 
disease, prevalent in both developed and developing countries, and affecting children as 
well as adults.”4 In 2004, O’Halloran et al classified obesity as a chronic condition in their 
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paper on defining chronic conditions.5 In June 2009, the Australian House of Representatives 
Standing Committee on Health and Ageing tabled a report on its inquiry into obesity in 
Australia whereby they recommended that the MBS consider obesity a chronic disease and 
allow it to become eligible for chronic disease management plan items (which provide 
specific remuneration for the GP).6 However, in their response in February 2013, the 
Government chose not to change the guidelines to include obesity as a chronic disease for 
these management plans.7 In June 2013, the American Medical Association classified 
obesity as a chronic disease.8 If it is true that some GPs do not consider obesity to be a 
chronic condition, multimorbidity prevalence estimates based on GP recognition of chronic 
conditions may slightly underestimate its true prevalence. 
As discussed in the introduction, the rise in the prevalence of obesity in the population is 
one of the main independent drivers in the increased prevalence of many chronic 
conditions. If GPs are to help manage and curb this increase, they first must recognise 
obesity among their patients. Wong et al. suggested that increased awareness and 
documentation of obesity would increase its management by GPs.2 
Comparisons of multimorbidity in family practice–
issues and biases. 
After the publication of the paper reproduced in this chapter and before I submitted the 
next paper in this thesis (basis of chapter 4), I collaborated with Professors Martin Fortin 
and Moira Stewart on a research highly relevant to this thesis.9 In response to the wide 
variance in definitions and methods used by researchers measuring multimorbidity, this 
study compared prevalence estimates from three major studies based in general practice: 
the BEACH study from Australia led by Professor Britt; the DELPHI (Deliver Primary Health 
Care Information) project from South-western Ontario led by Professor Stewart, Canada; 
and the original Saguenay study from Quebec, Canada led by Professor Fortin. 
We found that the estimated prevalence of multimorbidity varied significantly from 34% in 
the DELPHI study, 46% in the BEACH sub-study to 95% in the Saguenay study. A long list of 
variables that may affect the proportion of people identified with multimorbidity was 
agreed upon by all authors. They included the study: “design”; “population and sampling”; 
“data and definition”; and “outcomes”. These we called “Method crystals for 
multimorbidity”. We argued that researchers should report all these variables in their 
methods section to allow their results to be fully considered in comparison to other studies. 
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We hypothesised that the different definitions of multimorbidity used may have a large 
effect on multimorbidity prevalence estimates. Specifically, the number of chronic 
conditions studied, the minimum number of ‘morbidities’ required for someone to be 
considered as having multimorbidity, and how a morbidity was defined (individual chronic 
conditions or ‘groups’ of chronic conditions) were all thought to effect multimorbidity 
prevalence estimates. While we were not able to test this hypothesis in our comparative 
paper, the large prospective survey I undertook (see Chapter 3) provided an ideal setting 
for testing the effect of these variables independently. Chapter 4 will now describe the 
testing of these hypotheses. 
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ABSTRACT
Objectives: Prevalence estimates of multimorbidity vary
widely due to inconsistent definitions and measurement
methods. This study examines the independent effects
on prevalence estimates of how ‘disease entity’ is defined
—as a single chronic condition or chapters/domains in
the International Classification of Primary Care (V.2;
ICPC-2), International Classification of Disease (10th
revision; ICD-10) or the Cumulative Illness Rating Scale
(CIRS), the number of disease entities required for
multimorbidity, and the number of chronic conditions
studied.
Design: National prospective cross-sectional study.
Setting: Australian general practice.
Participants: 8707 random consenting deidentified
patient encounters with 290 randomly selected general
practitioners.
Main outcome measures: Prevalence estimates of
multimorbidity using different definitions.
Results: Data classified to ICPC-2 chapters, ICD-10
chapters or CIRS domains produce similar
multimorbidity prevalence estimates. When
multimorbidity was defined as two or more (2+) disease
entities: counting individual chronic conditions and
groups of chronic conditions produced similar estimates;
the 12 most prevalent chronic conditions identified about
80% of those identified using all chronic conditions.
When multimorbidity was defined as 3+ disease entities:
counting individual chronic conditions produced
significantly higher estimates than counting groups of
chronic conditions; the 12 most prevalent chronic
conditions identified only two-thirds of patients identified
using all chronic conditions.
Conclusions: Multimorbidity defined as 2+ disease
entities can be measured using different definitions of
disease entity with as few as 12 prevalent chronic
conditions, but lacks specificity to be useful, especially in
older people. Multimorbidity, defined as 3+, requires
more measurement conformity and inclusion of all
chronic conditions, but provides greater specificity than
the 2+ definition. The proposed concept of “complex
multimorbidity”, the co-occurrence of three or more
chronic conditions affecting three or more different body
systems within one person without defining an index
chronic condition, may be useful in identifying high-need
individuals.
INTRODUCTION
Research into the coexistence of multiple
chronic health conditions in an individual
was initially concerned with comorbidity,
deﬁned as “the existence or occurrence of
any distinct additional disease entity in a
patient who has the index disease under
study.”1 However, since the early 1990s, inter-
est has progressed to ‘multimorbidity’, com-
monly deﬁned as the “co-occurrence of two
or more diseases within one person without
deﬁning an index disease.”2
Interest in multimorbidity is growing due
to its expected increase resulting from the
ageing of the world’s population.3 4 Studies
have shown that multimorbidity is associated
with increased patient mortality, demand on
health resources, complexity of care and
reduced patient quality of life.5 6 However,
prevalence estimates of multimorbidity have
ranged from 3.5%7 to 98.5%,8 the wide vari-
ance thought to be due to the lack of stan-
dards deﬁning multimorbidity and how it is
measured. A recent systematic review found
Strengths and limitations of the study
▪ A large, representative, prospective study of mul-
timorbidity, involving 290 general practitioners
and 8707 patients, allowed testing of the inde-
pendent effect of variables on prevalence esti-
mates, something not possible with systematic
reviews.
▪ This study investigated all chronic conditions,
not a selection of conditions.
▪ This study used the general practitioner as an
‘expert interviewer’, drawing on the patient’s
knowledge, the patient’s health record and their
own knowledge to indicate the patient’s current
chronic conditions. Most multimorbidity studies
rely on only one of these sources of data.
▪ This study only considered chronic conditions,
whereas some authors now include acute condi-
tions when defining multimorbidity.
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132 deﬁnitions involving 1631 different criteria.9 There
have been many calls for standards and guidelines for
research into multimorbidity.10–12 Recent systematic
reviews have raised speciﬁc issues regarding the way mul-
timorbidity is deﬁned and/or measured.11 12
The ﬁrst issue is the number of conditions studied.
Fortin et al11 found that this ranged from ﬁve to all condi-
tions. Diederichs et al12 reported a range of 4–102 condi-
tions (mean 18.5 and median 14) and suggested that
conditions may be chosen for pragmatic reasons (such as
data availability), as the majority of authors did not give
reasons for their selection. Where they did, the most
common was those conditions with a high prevalence or
high impact on patients.12 Diederichs et al12 and Fortin
et al11 suggested that studies considering only a few condi-
tions produced lower prevalence estimates than those
examining many conditions. Diederichs et al12 suggested
a list of 11 chronic conditions prevalent in the elderly as
a minimum (cancer, diabetes mellitus, depression, hyper-
tension, myocardial infarction, chronic ischaemic heart
disease, heart arrhythmias, heart insufﬁciency, stroke,
chronic obstructive pulmonary disease and arthritis).
Fortin et al11 suggested that any 12 prevalent conditions
should sufﬁce to measure multimorbidity accurately.
The second issue is how ‘disease entity’ was deﬁned in
multimorbidity studies. Ideally, morbidities being
counted should be ‘distinct’ disease entities. However,
disease entities used across studies varied from very spe-
ciﬁc conditions to groups of conditions. Even Diederichs
et al’s12 suggested list (above) includes some disease
entities that are groups of conditions (such as arthritis
and cancer) and some very speciﬁc, closely related condi-
tions (eg, myocardial infarction and chronic ischaemic
heart disease). It is debatable whether myocardial infarc-
tion and chronic ischaemic heart disease should be con-
sidered as two separate disease entities in measuring
multimorbidity. Some multimorbidity studies have tried
to overcome this problem by only counting chronic con-
ditions that affect different body systems, to ensure that
the count was of distinct disease entities.4 13 These
studies used the Cumulative Illness Rating Scale (CIRS)14
domains to group chronic conditions by body system.4 13
Fortin et al11 suggested that while the use of the CIRS
needed further research, this approach may simplify
coding and data collection. The impact of counting the
different body systems affected by chronic conditions on
multimorbidity prevalence estimates is not known.
Most primary care-based multimorbidity studies rely
on a health record review.11 A disadvantage of using
CIRS in such reviews is that it requires additional
mapping of diagnoses from the classiﬁcation system in
which the health records were coded. The two most
commonly used disease classiﬁcation systems are the
International Classiﬁcation of Primary Care (V.2;
ICPC-2)15 and the International Classiﬁcation of Disease
(10th revision; ICD-10).16 ICPC-2 is used in primary
care, and its chapters (with the exception of ‘General
and unspeciﬁed’ and ‘Social’ chapters) are body system-
based, following the principle that localisation takes pre-
cedence over aetiology.16 ICD-10 is primarily used in
hospitals and its chapters axes include body systems, aeti-
ology and ‘others’.16 ICD-10 lacks speciﬁcity for classiﬁ-
cation of undiagnosed problems or symptoms, both of
which are commonly managed in primary care.17 This
has meant that data from primary healthcare records
classiﬁed in the two systems have looked very different in
the past. However, since most multimorbidity studies
examine only chronic conditions, this problem may be
avoided when conditions are grouped at the chapter
level. It is not known whether counting disease entities
from different CIRS domains, ICPC-2 or ICD-10 chap-
ters produces comparable multimorbidity prevalence
estimates.
The third issue is the number of disease entities
required to deﬁne multimorbidity. Originally, multimor-
bidity was deﬁned as two or more (2+) disease entities,
but recently there has been debate about whether three
or more (3+) may be a better measure. Fortin et al11
argue that using 2+ disease entities identiﬁes such a
high proportion of patients as multimorbid that the
measure lacks speciﬁcity. They found that age-speciﬁc
prevalence of multimorbidity using the 2+ deﬁnition
produced an ‘S’ shaped curve with a ﬂat plateau for
older ages. When using 3+, the increase in prevalence
by age was more linear, with greater differentiation in
older age groups. The authors further argued that using
3+ disease entities results in a lower prevalence estimate,
is likely to identify patients with greater health needs
and is therefore more useful to clinicians.11 They recom-
mended further research to test the 3+ deﬁnition of
multimorbidity.11
The current study was conducted in Australian
general practice. Australia’s universal medical insurance
scheme, Medicare, fully or partially covers the indivi-
dual’s cost of visits to general practitioners (GPs). GPs
provide the bulk of primary medical care and act as gate-
keepers to government-subsidised healthcare from other
medical specialists. There are no patient lists and
patients are free to visit multiple GPs and practices as
they choose.
Our study examines how multimorbidity prevalence
estimates are affected by: the number of chronic condi-
tions studied; how a disease entity is deﬁned; and the
minimum number of disease entities required to deﬁne
multimorbidity. We use a large Australian general
practice-based prospective multimorbidity study, which
allows us to examine the effect of each of these variables
on multimorbidity prevalence estimates while control-
ling for other confounding variables, an approach not
possible in systematic reviews.
METHOD
The BEACH (Bettering the Evaluation And Care of
Health) programme is a continuous, national cross-
sectional survey of general practice activity in Australia.17
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Each year, an ever-changing sample of about 1000 GPs is
randomly selected, and each GP records information
about encounters with 100 consecutive consenting
patients on structured paper forms.17
In substudies of BEACH, the GP records information
additional to the encounter data, in discussion with the
patient. The full methods for this substudy are reported
elsewhere.18 In brief, it measured the prevalence of diag-
nosed chronic conditions in patients attending general
practice in Australia. Over three 5-week recording periods
(August 2008–May 2009), 375 sampled GPs were asked to
record all diagnosed chronic conditions for each of 30
consecutive patients on 30 bespoke forms within their 100
BEACH records. A sample of the instruction sheet
and recording form can be found at www.http://sydney.
edu.au/medicine/fmrc/publications/sand-abstracts/132-
Multimorbidity.pdf
GPs were asked, “Does the patient have any of the fol-
lowing chronic diseases/problems?” Common chronic
conditions were listed (tick boxes) with additional free
text ﬁelds to record other unlisted chronic conditions. A
‘no chronic conditions’ option was also provided. Listed
chronic conditions were primarily those most frequently
managed in Australian general practice17 and were
inclusions in O’Halloran et al’s19 deﬁnition of chronic
conditions. The free text options relied on GPs’ judge-
ment of whether a condition was chronic in this patient.
GPs were instructed to “Use your own knowledge,
patient knowledge and health records as you see ﬁt, in
order to answer these questions.” Additional free text
chronic conditions were coded using the ICPC-2 PLUS
terminology,20 which automatically classiﬁed them into
ICPC-2.15 All chronic conditions were classiﬁed to
ICD-10 chapters16 (n=20), ICPC-2 chapters15 and CIRS
domains14 (table 1). There were some chronic condi-
tions (eg, multisite cancer) that involved multiple
systems. As these would usually be counted multiple
times in different CIRS domains, we created an add-
itional domain called ‘Whole system’, resulting in 15
CIRS domains instead of the usual 14. The ICPC-2 male
and female genital system chapters (chapters Y and X)
were combined as they referred to the same body
system, resulting in 16 ICPC-2 chapters (rather than the
usual 17). This sample was previously shown to be repre-
sentative of the age–sex distribution of patients at all GP
encounters claimed (as items of service) through
Medicare in 2008–2009.18
Using this large prospective study, we examined the
effect of three different dimensions of measuring multi-
morbidity while controlling for other confounding vari-
ables. This is achieved through the structure of the study,
by only changing one of the three variables at a time.
Dimension 1: Does the way disease entities are defined
affect multimorbidity prevalence estimates?
To test this dimension, we deﬁned disease entity in four
different ways. First, each recorded/ticked chronic condi-
tion was treated as a separate disease entity. For the other
three methods, we considered a disease entity to be a
chapter/domain that was affected by at least one chronic
condition in each of the three classiﬁcation systems.
Comparing the resulting multimorbidity prevalence esti-
mates, we were able to test two research questions. First,
whether counting different body systems affected by
chronic conditions produces prevalence estimates com-
parable to counting individual chronic conditions.
Second, whether counting the number of different CIRS
domains, ICPC-2 chapters or ICD-10 chapters affected
produces comparable prevalence estimates.
Dimension 2: Does the minimum number of disease
entities required to define multimorbidity affect
multimorbidity prevalence estimates?
We compared prevalence of multimorbidity using 2+
through to 6+ disease entities. We also compared the age-
speciﬁc prevalence of multimorbidity when it was deﬁned
as 2+ and 3+ disease entities, to see whether we could
reproduce the ‘S’-shaped curve when using the 2+ deﬁn-
ition and test whether using 3+ provided greater differenti-
ation among older patients, as found by Fortin et al.11
Dimension 3: Does the number of chronic conditions
included in the study affect multimorbidity estimates?
We reduced the number of chronic conditions used, in
order to simulate studies that were based on fewer
chronic conditions. We used the 11 minimum chronic
conditions as suggested by Diederichs et al),12 the 12
most prevalent chronic conditions in our study (hyper-
tension, hyperlipidaemia, ischaemic heart disease, type 2
diabetes, obesity, osteoarthritis, chronic back pain,
asthma, depression, anxiety, gastro-oesophageal reﬂux
disease and malignant neoplasms) as suggested by
Fortin et al11 and the 24 listed chronic conditions with a
tick box. We then compared these results with those
generated using all diagnosed chronic conditions.
BEACH substudies have a single stage cluster design,
with each GP having 30 patients clustered around them.
The cluster effect was accounted for using SAS V.9.3.
RESULTS
Completed research packs were returned by 290 GPs
(77.3%) sampling 8707 patients. In total, 66.5% of
patients (n=5777) had at least one chronic condition
and 33.7% (n=2930) had none. The intracluster correl-
ation coefﬁcient was 0.121 for patients with at least one
chronic condition.
Table 1 shows the proportion of patients with at least
one chronic condition in each chapter/domain. For
ICPC-2 and ICD-10, the 11 most prevalent chapters were
body speciﬁc, with the non-body system-speciﬁc chapters
being relatively uncommon. Prevalence estimates of
patients with at least one chronic condition within a
body system-speciﬁc ICD-10 and ICPC-2 chapter were
remarkably similar, the top six chapters being in the
same order, with no signiﬁcant differences in the
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prevalence estimates for these six chapters. There were
larger differences between estimates using CIRS and
those from ICPC-2 and ICD-10. The major differences
were due to CIRS splitting cardiovascular into vascular
and cardiac domains, classifying cerebrovascular disease
as neurological and classifying hyperlipidaemia in the
vascular domain. In all systems, the most frequent chap-
ters/domains were those relating to the: cardiac/vascu-
lar/circulatory; endocrine; musculoskeletal;
psychological; digestive and respiratory systems.
Figure 1 shows the prevalence of multimorbidity
among patients in the sample (representing those in a
GP’s waiting room) using different deﬁnitions of multi-
morbidity. The estimated prevalence of multimorbidity
ranged from 47.4% when using 2+ individual chronic
conditions to 2.8% when using 6+ ICPC-2 chapters. For
all deﬁnitions using 3+ disease entities or more, counting
individual chronic conditions resulted in a signiﬁcantly
higher prevalence estimate than any of the grouped esti-
mates. This difference increased proportionally as the
minimum number of disease entities increased—the indi-
vidual chronic conditions estimate was 23% higher than
the ICPC-2 chapter estimate at 3+ disease entities,
through to 268% higher at 6+ disease entities. Overall,
there was no signiﬁcant difference found between preva-
lence estimates using ICD-10, ICPC-2 and CIRS, from 2+
through to 6+ disease entities.
Using the ICD-10 and ICPC-2 estimates, when multi-
morbidity was deﬁned as two or more disease entities,
about 44% of patients presenting to GPs were identiﬁed
as multimorbid. This prevalence decreased with each
increase in the number of disease entities required, with
about 27% of patients being considered multimorbid
for 3+, about 15% for 4+, 7% for 5+ and only 3% for 6+
disease entities. There was nearly perfect concordance
between patients identiﬁed as having multimorbidity
using the ICD-10 and ICPC-2 classiﬁcation systems. For
example, when using the minimum of three disease
entities as the deﬁnition of multimorbidity, over 99% of
patients identiﬁed using ICD-10 were also identiﬁed
using ICPC-2 and vice versa (table 2). There was also
high concordance between ICPC-2/ICD-10 and CIRS.
For every 12 patients identiﬁed as having multimorbidity
with CIRS, 11 were also identiﬁed using ICPC-2/ICD-10
and vice versa.
Figure 2 shows multimorbidity prevalence estimates
using the 2+ and the 3+ deﬁnitions across the different
number of chronic conditions included. For all classiﬁca-
tion groups, the prevalence estimates derived when using
Diederichs et al’s 11 chronic conditions were signiﬁcantly
lower than those using the 12 most prevalent chronic
conditions, which in turn were signiﬁcantly lower than the
estimates based on all chronic conditions. Prevalence esti-
mates based on the 12 most prevalent chronic conditions
and on the 24 common chronic conditions (tick boxes)
did not signiﬁcantly differ, except that the 24 chronic con-
ditions produced higher estimates when using 3+ individ-
ual chronic conditions or 3+ CIRS domains.
Figure 1 Multiple conditions within patients as defined by different classification systems (CIRS, Cumulative Illness Rating
Scale; GP, general practitioners; ICD, International Classification of Disease; ICPC, International Classification of Primary Care).
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When using a restricted number of chronic conditions
(ie, Diederichs et al’s list or Fortin et al’s 12) rather than
all chronic conditions, the proportion of patients identi-
ﬁed as having multimorbidity was signiﬁcantly less when
multimorbidity was deﬁned as 3+ than when deﬁned as
2+. For example, applying the 2+ deﬁnition to ICPC-2
chapters, using the 12 most prevalent chronic conditions
identiﬁed 79.4% of those identiﬁed as multimorbid
using all chronic conditions. Using the 3+ ICPC-2 chap-
ters deﬁnition, the 12 most prevalent conditions only
identiﬁed 67.5%. Similarly, using Diederichs et al’s list
with the 2+ deﬁnition identiﬁed 54.5% and the 3+ deﬁn-
ition identiﬁed only 32.8% of those identiﬁed using all
chronic conditions.
Figure 3 shows the age-speciﬁc multimorbidity preva-
lence estimates using the 2+ and 3+ deﬁnitions by individ-
ual chronic conditions and ICPC-2 chapters. Only the
ICPC-2 chapters are presented as we have demonstrated
that there was no signiﬁcant difference between estimates
derived using ICPC-2 chapters, ICD-10 chapters or CIRS
domains. The age-speciﬁc prevalence using 2+ individual
chronic conditions and 2+ ICPC-2 chapters increased
rapidly up to the 70–79 years age group, and remained
steady in the older age groups. Compared with 2+, the
increase in prevalence started later for 3+ individual
chronic conditions (between 20–29 and 30–39 years of
age). For 3+ ICPC-2 chapters, this increase started even
later (between 30–39 and 40–49 years of age). For both
the 3+ measures, the prevalence did not plateau until 80–
89 years of age, 10 years later than when using the 2+
deﬁnition.
DISCUSSION
This study has shown that multimorbidity prevalence
estimates are independently affected by the number of
chronic conditions collected in a study, how a disease
entity is deﬁned, and the minimum number of disease
entities used to deﬁne multimorbidity. It has also
demonstrated that health data classiﬁed to ICPC-2 chap-
ters, ICD-10 chapters or CIRS domains produce similar
multimorbidity prevalence estimates.
Table 2 Concordance of patients identified with multimorbidity (3+ definition) between ICPC-2, ICD-10 and CIRS
Proportion of patients identified as having multimorbidity using each classification system
(horizontal) that were also identified using other classification systems (vertical) (%, 95% CIs)
ICPC-2 ICD-10 CIRS
ICPC-2 100.0 99.1 (98.7 to 99.5) 92.1 (90.9 to 93.3)
ICD-10 99.3 (98.9 to 99.6) 100.0 91.9 (90.7 to 93.1)
CIRS 93.7 (92.6 to 94.7) 93.3 (92.2 to 94.4) 100.0
CIRS, Cumulative Illness Rating Scale; ICD-10, International Classification of Disease10th chapter; ICPC-2, International Classification of
Primary Care second chapter.
Figure 2 Estimated prevalence of multimorbidity by different classification systems and by whether 2+ or 3+ minimum number
of disease entities was used (CIRS, Cumulative Illness Rating Scale; GP, general practitioners; ICD, International Classification
of Disease; ICPC, International Classification of Primary Care).
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Dimension 1: Does the way disease entities are defined
affect multimorbidity prevalence estimates?
We found that when multimorbidity is deﬁned as 2+
disease entities, prevalence estimates are similar no
matter how a disease entity is deﬁned, be it an individual
chronic condition or an ICPC-2 chapter, ICD-10 chapter
or CIRS domain involving one or more chronic condi-
tions. This means that studies that deﬁne multimorbidity
as 2+ can be compared even if the morbidity is classiﬁed
differently. However, when multimorbidity is deﬁned as
3+ disease entities, using individual chronic conditions
produces higher prevalence estimates than counting the
different domains/chapters affected. We conclude that
researchers should not compare results from studies
using the 3+ deﬁnition when one study has used
grouped chronic conditions (classiﬁed) and the other
individual chronic conditions.
Our ﬁnding that chronic conditions were predomin-
antly classiﬁed to body system-speciﬁc chapters/domains
for all three classiﬁcations suggests that chapters/
domains could be used to represent the body systems
affected. We also found no difference between the
prevalence estimates produced with any of the three
classiﬁcation systems. Together, these results suggest that
researchers may compare prevalence estimates from
studies that count different ICPC-2 chapters, ICD-10
chapters or CIRS domains affected by chronic condi-
tions. This allows researchers to draw data from primary
care or hospital health records regardless of the classiﬁ-
cation system used (ICPC-2 or ICD-10) and know that
results will be comparable to published studies that have
used CIRS.4 13
Dimension 2: Does the minimum number of disease
entities required to define multimorbidity affect
multimorbidity prevalence estimates?
We found that the higher the minimum number of dif-
ferent disease entities used to deﬁne multimorbidity, the
lower the prevalence estimate. If multimorbidity is
deﬁned as 2+ disease entities, nearly every second
person sitting in front of the GP would have multimor-
bidity, whereas using 3+ decreased the estimate to nearly
one in four. Like Fortin et al, we found that the 3+ deﬁn-
ition provided greater differentiation in the older age
groups than the 2+ deﬁnition. These results support
their argument that using 2+ disease entities identiﬁes
such a large proportion of patients as having multimor-
bidity that it lacks the speciﬁcity to be useful, with a
minimum of three disease entities arguably a better
measure of multimorbidity.
Dimension 3: Does the number of chronic conditions
included in the study affect multimorbidity estimates?
As previous research suggests,11 12 the number of
chronic conditions studied affects the multimorbidity
prevalence estimates—estimates based on a low number
of chronic conditions being a fraction of those based on
all chronic conditions. In our study, Diederichs et al’s list
identiﬁed only half the patients identiﬁed with multi-
morbidity using all chronic conditions when using 2+,
and only a third using 3+. Including the 12 most preva-
lent chronic conditions (suggested by Fortin et al), four
of ﬁve multimorbid patients were identiﬁed using 2+
and two-thirds using 3+. While both used a similar
number of chronic conditions, Diederichs et al’s list
Figure 3 Patient age-specific prevalence of ‘multimorbidity’ (ICPC, International Classification of Primary Care).
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included the most prevalent chronic conditions in
patients aged 65 years and over, whereas Fortin et al sug-
gested the most prevalent overall conditions.
It is clear from these results that no matter how multi-
morbidity is deﬁned, the list of chronic conditions sug-
gested by Diederichs et al as a minimum is not sufﬁcient
to reliably measure multimorbidity prevalence. Using
the 12 most prevalent chronic conditions, as suggested
by Fortin et al, does provide prevalence estimates that
are reasonably close to those gained with all chronic
conditions when using the 2+ deﬁnition. However, when
multimorbidity is deﬁned as 3+, the 12 most prevalent
chronic conditions are not sufﬁcient to measure multi-
morbidity. For the 3+ deﬁnition, ideally researchers
should include all chronic conditions in their study.
This study has some limitations. We only included
chronic conditions, whereas some authors have recently
included acute conditions in their deﬁnition of multi-
morbidity.9 21 Including acute conditions is understand-
able in a clinical setting, as they will temporarily increase
the patient’s complexity of care. However, where the
goal is to measure the prevalence of multimorbidity to
inform planning to meet the health resource require-
ments of these high-need patients, the use of only
chronic conditions is logical.
Fortin et al8 suggest that when studying multimorbidity,
one should also include a measure of severity. This study
did not attempt to measure severity because of the limited
space on the questionnaire and concerns that the add-
itional burden on the GPs may reduce the response rate.
While our study was representative of patients at GP
encounters, it should be remembered that patients are
not representative of the population. Patients at GP
encounters are generally older and therefore more likely
to have a chronic condition.18
While our study was cross-sectional, the variables
tested are relevant to all types of multimorbidity studies,
be they cross-sectional, longitudinal, interview-based or
based on a health record review.
Throughout this study, we have found that multimor-
bidity behaves quite differently when deﬁned as 2+ or 3+
disease entities. With the 2+ deﬁnition, reasonable
prevalence estimates could be obtained using only a
dozen prevalent chronic conditions, regardless of how a
disease entity was deﬁned. With the 3+ deﬁnition, the
way the disease entity was deﬁned was important—
counting individual chronic conditions produced signiﬁ-
cantly higher estimates than counting chapters/
domains. The number of chronic conditions studied was
also important as studying a restricted number of
chronic conditions produced signiﬁcantly lower esti-
mates than studying all chronic conditions. However, the
prevalence estimates gained using 2+ were so encom-
passing that they lacked speciﬁcity—especially in older
patients—whereas 3+ provided greater speciﬁcity and
more differentiation among the elderly patients.
These results suggest that the concepts of 2+ and 3+
multimorbidity are quite different. Rather than having
both these concepts included under the same label, we
propose adding the word ‘complex’ to those patients
with 3+ chronic conditions from different body systems
to clarify the meaning. ‘Multimorbidity’ would be
deﬁned as the “co-occurrence of two or more chronic
conditions within one person without deﬁning an index
chronic condition.” ‘Complex multimorbidity’ would be
deﬁned as the “co-occurrence of three or more chronic
conditions affecting three or more different body
systems within one person without deﬁning an index
chronic condition.” In this way, we still have the more
encompassing 2+ deﬁnition to compare with a previous
work, while also being able to identify patients requiring
additional care.
For consistency, we also propose a similar concept for
comorbidity. We suggest that ‘complex comorbidity’ be
deﬁned as “the existence of two or more additional
chronic conditions from two or more body systems dif-
ferent to that of the index chronic condition under
study.” This would mean that all patients with complex
multimorbidity would also have complex comorbidity,
the only difference being whether there is a chronic
condition of interest.
There are advantages to using body systems affected
(as represented by chapters/domains to which a chronic
condition had been classiﬁed) rather than individual
chronic conditions as ‘disease entities’. Take, for
example, two patients with three chronic conditions:
patient A has peripheral vascular disease, hypertension
and type 2 diabetes; patient B has depression, osteoarth-
ritis and type 2 diabetes. The chronic conditions in
patient A only affect two body systems while those in
patient B affect three. According to our deﬁnitions,
both would have multimorbidity, but patient B would
also have complex multimorbidity. Patients identiﬁed
with chronic conditions in 3+ body systems (complex
multimorbidity) may be those whose care is more
complex, as chronic conditions in different body systems
are likely to compete for treatment, while the treatments
of chronic conditions within the same system are more
likely to be complementary. This is a similar concept to
Piette and Kerr’s22 idea of concordant and discordant
comorbidity.
Counting the body systems affected also provides an
estimate of the specialist types that may be involved in
the care of the patient. This is important for health-
care planning as it reduces double counting of chronic
conditions that may be referred to the same specialist
type; for example, a patient with depression and
anxiety may be referred to one psychiatrist (not two).
It also identiﬁes patients who may need assistance with
coordination of specialist care, as the healthcare of
patients with multimorbidity is more likely to be poorly
coordinated.23 24
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CONCLUSION
For the ﬁrst time, a single large prospective study has
been used to test the effect of the way multimorbidity is
measured on prevalence estimates, while controlling for
other variables, using the same data for all measures.
This is not possible with systematic reviews. We have
shown that multimorbidity behaves differently when
deﬁned as 2+ disease entities, as compared with when it
is deﬁned as 3+ disease entities. To address this, we rec-
ommend that
▸ ‘Multimorbidity’ be deﬁned as the “co-occurrence of
two or more chronic conditions within one person
without deﬁning an index chronic condition”;
▸ ‘Complex multimorbidity’ be deﬁned as the
“co-occurrence of three or more chronic conditions
affecting three or more different body systems within
one person without deﬁning an index chronic
condition.”
This study provides some evidence that complex multi-
morbidity is a more useful measure of multimorbidity as
it results in a lower prevalence estimate and shows
greater differentiation among older patients. However,
further research is needed to assess whether ‘complex
multimorbidity’ is indeed better than alternative mea-
sures of multimorbidity (such as counting individual
chronic conditions, measures of severity, etc) in identify-
ing patients with greater healthcare resource use, com-
plexity of care, lower quality of life and overall severity of
illness.
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56 
In this chapter I have explored how changes in the method used to measure multimorbidity 
alters the proportion of people identified with multimorbidity. I have also proposed a new 
definition of ‘complex multimorbidity’ to help identify high need patients. Due to word 
limitations on a published paper, I did not report the prevalence and patterns of 
multimorbidity and ‘complex multimorbidity’ in this paper. The next chapter contains a 
paper that reports both of these among patients at encounters and in the Australian 
population, using the population adjustment method described in Chapter 3. 
In the introduction of the current paper, I described ‘multimorbidity’, as commonly defined 
as the “co-occurrence of two or more diseases within one person without defining an index 
disease.” with a reference to van den Akker et al’s work. This definition was a paraphrasing 
of van den Akker’s who made the distinction between ‘comorbidity’ and ‘multimorbidity’ 
based on whether or not there was an index condition. In reviewing this paper while 
collating my thesis, I realised that the current manuscript gives a false impression that I was 
directly quoting rather than paraphrasing van den Akker's work. I contacted BMJ Open and 
informed them of this issue. They have published a response online with my clarification. 
A similar issue arose in the next chapter where I discuss researchers using a derivation of 
van den Akker’s definition and using the above definition as an example of this derivation. I 
realise that the quotes around this definition once again give the impression that I am 
directly quoting van den Akker et al. I have also contacted ANZJPH and asked them to make 
a correction. While they have acknowledged this request, they are yet to act on it. 
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Australia’s health care system mainly focuses on single diseases. Payment structures support single disease 
management (e.g. diabetes mellitus and 
asthma cycle of care plans),1 and guidelines 
for care usually take a single-morbidity 
approach.2,3 This ignores the complexity 
in caring for the increasing number of 
patients with multiple chronic conditions, 
or ‘multimorbidity’. It is argued that patients 
with multimorbidity are more than the sum 
of their individual conditions and that, using 
a single-morbidity model, we fail to grasp the 
pattern of the patient’s disease, leading to 
inadequate management.4  Multimorbidity 
has been shown to be associated with 
increased patient mortality, demand on 
health resources and complexity of care, and 
reduced patient quality of life.5,6 If health 
systems are to meet the challenges raised by 
multimorbidity, we must first measure it.
Since we published the first comprehensive 
study on prevalence of multimorbidity in 
Australia,7 several other Australian studies 
have investigated multimorbidity.8-12 While 
valuable, they were often limited in scope 
(e.g. considering only a limited number of 
chronic conditions),8-12 were not nationally 
representative8-10 or only focussed on 
specific age groups.11,12 Most importantly, 
there has been little consistency in the 
way multimorbidity has been defined. 
Most studies use a derivation of Van den 
Akker’s definition: the “co-occurrence of 
two or more diseases within one person 
without defining an index disease”.13 Our 
earlier work suggested this definition may 
be so encompassing that it lacks sufficient 
specificity to be useful.14
We have proposed the concept of ‘complex 
multimorbidity’, defined as the “co-occurrence 
of three or more chronic conditions affecting 
three or more different body systems within 
one person, without defining an index 
chronic condition”.14 It is more discriminating 
than ‘traditional’ multimorbidity and is likely 
to identify patients whose care is more 
complex. Chronic conditions in different body 
systems are likely to compete for treatment, 
while the treatments of chronic conditions 
within the same body system are more likely 
to be complementary, similar to Piette and 
Kerr’s concept of concordant and discordant 
comorbidity.15 Counting body systems 
affected by chronic conditions instead of 
individual chronic conditions has the added 
advantage of identifying the number and 
types of specialised health services that 
may be involved with the patient’s care. 
This will help guide resource planning by 
highlighting the common combinations of 
services required in the care of patients. It also 
identifies patients who may need assistance 
with coordination of specialist care, as the 
health-care of patients with multimorbidity is 
more likely to be poorly coordinated.16,17
In earlier research, we used the International 
Classification of Primary Care – Version 2 
(ICPC-2),18 the International Classification 
of Disease – 10th revision (ICD-10)19 and the 
Cumulative Illness Rating Scale (CIRS)20 to 
classify chronic conditions by body system. 
Each classification’s chapters or domains were 
used to represent body systems. Defining 
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Objective: To measure prevalence of multimorbidity and complex multimorbidity in the 
Australian population from a nationally representative prospective study and to identify the 
most prevalent patterns of chronic conditions and body systems affected. 
Methods: A sub-study of the nationally representative BEACH program, using a random 
sample of 8,707 patients at encounters with 290 general practitioners. All diagnosed chronic 
conditions were recorded for each patient. Multimorbidity was defined as co-occurrence of 
2+ chronic conditions, while complex multimorbidity was defined as 3+ body systems each 
affected by at least one chronic condition.
Results: We estimated: 47.4% of patients at GP encounters and one-third (32.6%) of the 
population had multimorbidity; and 27.4% of patients at GP encounters and 17.0% of the 
Australian population had complex multimorbidity. The most prevalent combination pattern 
of three conditions was hypertension+hyperlipidaemia+ osteoarthritis (5.5% of patient at 
encounters and 3.3% of the population). Most prevalent combination of three body systems 
affected was circulatory+musculoskeletal+endocrine / nutritional/metabolic systems (11.1% of 
patients at encounters and 7.0% of the population).
Conclusions and implications: A significant proportion of Australians have not only 
multimorbidity, but complex multimorbidity. To meet the challenge posed by complex 
multimorbidity, the single disease focus of our healthcare system needs to be re-evaluated.
Key words: multimorbidity, epidemiology, general practice
Article EPIDEMIOLOGY
240 Australian and New Zealand Journal of Public Health 2016 vol. 40 no. 3
© 2015 Public Health Association of Australia
Harrison et al.
complex multimorbidity using each of 
these classification systems provided similar 
multimorbidity prevalence estimates. Patients 
identified as having complex multimorbidity 
with ICPC-2 were also identified using ICD-10 
and visa versa.14 
In our first study of multimorbidity, the 
prevalence of three or more CIRS domains 
with at least one chronic condition 
(which we would now define as complex 
multimorbidity) was estimated to be 10.6% 
among patients at general practitioner (GP) 
encounters and 7.0% among the Australian 
population. However, that study used a 
limited number of chronic conditions and 
CIRS domains.7 A more recent localised 
Australian study of multimorbidity also 
using three or more CIRS domains as their 
definition, found that one-third (34.5%) 
of patients had complex multimorbidity. 
However, it was not nationally representative, 
including patients attending only two general 
practices in Perth (Western Australia).8
This study measures, for the first time, 
the prevalence of multimorbidity and of 
complex multimorbidity in the Australian 
population using all chronic conditions 
(not just a selected group) from a nationally 
representative prospective study. It also aims 
to identify the most prevalent patterns of 
chronic conditions and body systems affected 
among patients with multimorbidity. 
Methods
The BEACH (Bettering the Evaluation and 
Care of Health) program is a continuous, 
representative, national cross-sectional 
survey of general practice activity in Australia. 
Each year an ever-changing random sample 
of about 1,000 GPs drawn by the Australian 
Department of Health participate, and each 
GP records information about encounters 
with 100 consecutive consenting patients, on 
structured paper forms.21
In sub-studies of BEACH, the GP records 
information additional to the encounter 
data, in discussion with the patient. The full 
methods for this sub-study are reported 
elsewhere.22 In brief, we measured the 
prevalence of diagnosed chronic conditions 
in sampled patients seeing a GP in Australia. 
Between August 2008 and May 2009, each 
of 375 sampled GPs were asked to record 
all diagnosed chronic conditions/problems 
for each of 30 consecutive patients on 30 
bespoke forms within their 100 BEACH 
records. We used the term ‘chronic conditions/
problems’ (referred to as chronic conditions 
in this paper) to encompass illnesses, 
diseases, diagnoses, syndromes and other 
health issues. A sample instruction sheet and 
recording form can be found at www.sydney.
edu.au/medicine/fmrc/publications/sand-
abstracts/132-Multimorbidity.pdf
GPs recorded all diagnosed chronic 
conditions in each sampled patient using 
their own knowledge of the patient, the 
patient’s knowledge and the health record. 
Tick boxes were provided for 28 common 
chronic conditions for ease of recording, 
with spaces provided for additional chronic 
conditions to be recorded in free text. All 
chronic conditions recorded in free text were 
coded to ICPC-2 PLUS23 and were secondarily 
classified to ICPC-2.18 Whether a condition 
was chronic in an individual patient was left 
to the clinical opinion of the participating GP. 
Multimorbidity was defined as the “co-
occurrence of two or more chronic conditions 
within one person without defining an 
index chronic condition” and complex 
multimorbidity as the “co-occurrence of three 
or more chronic conditions affecting three 
or more different body systems within one 
person without defining an index chronic 
condition”.14 For the purposes of this paper, 
the chapters of ICPC-2 were used to represent 
the different body systems. The structure of 
ICPC-2 chapters can be found elsewhere.24 
A patient with complex multimorbidity had 
one or more chronic conditions within each 
of three or more different ICPC-2 chapters. 
Body systems were counted only once per 
patient, even if they had two or more chronic 
conditions classified to that body system.
BEACH sub-studies have a single stage cluster 
design, with each GP having 30 patients 
clustered around them. Survey procedures 
in SAS Version 9.3 (SAS Inc, Cary, NC, USA) 
were used to account for the effect of this 
clustering.
As patients were sampled at GP consultations, 
the likelihood of being sampled is dependent 
on visit frequency. Therefore, frequent 
attenders (such as older patients who may 
have more health problems) are more likely 
to be sampled than infrequent attenders. The 
method used to calculate national prevalence 
estimates has been described in detail 
elsewhere22 but, in brief, we first weighted 
the sub-study sample against the age–sex 
distribution of the Australian population in 
June 2008–09.25 We assumed that people 
who did not attend a GP that year had no 
diagnosed chronic conditions. Therefore, 
after the above weighting we multiplied the 
numerator for each patient, by the proportion 
of their age–sex group who saw a GP at least 
once that year. This accounted for those who 
did not see a GP.
The prevalence of all patterns of 
multimorbidity was estimated. The most 
frequent observed combinations were 
compared with the expected prevalence of 
those combinations. The expected prevalence 
of the combinations of conditions/chapters 
was based on the assumption they were 
statistically independent of one another.  
It was calculated by multiplying the 
prevalence of condition A by the prevalence 
of condition B. The ratio of observed over 
expected prevalence was calculated to 
examine whether conditions were more or 
less likely than statistical chance to occur 
together.
Ethics committees of the University of Sydney 
and Australian Institute of Health and Welfare 
approved BEACH and this sub-study.
Results
Completed research packs were returned 
by 290 GPs (77.3%) sampling 8,707 patients. 
There were 18,792 chronic conditions 
recorded, 14,422 (76.7%) using the tick box 
options and 4,370 (23.3%) recorded in free 
text. Two-thirds (66.3%, n=5,777) of patients 
at encounters had at least one chronic 
condition (Figure 1). We estimated that about 
half the Australian population had at least 
one chronic condition (49.6%). Nearly half 
(47.4%) the patients at GP encounters and 
one-third of the population were estimated 
to have multimorbidity (32.6%). This means 
that about two-thirds (65.7%) of the patients 
with at least one chronic condition had two or 
more chronic conditions. We estimated that 
27.4% of patients at GP encounters and 17.0% 
of the Australian population had complex 
multimorbidity (Figure 1).
Table 1 shows the prevalence of the most 
common combinations of two individual 
conditions and two ICPC-2 chapters. 
The 12 most prevalent combinations 
of individual chronic conditions were 
made up of eight prevalent conditions. 
The most common combination was 
hypertension+hyperlipidaemia (12.1% of 
patients at encounters and 8.3% of the 
Australian population). The most common 
combination of body systems affected 
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Table 1: Most prevalent patterns of two chronic conditions or two chapters affected by chronic conditions.
Chronic 
conditions
Most prevalent patterns of two chronic conditions
ICPC-2 chapters
Most prevalent patterns of two ICPC-2 chapters with chronic conditions 
classified to them
Observed 
prevalence 
among patients 
at encounters 
(95% CIs)
Expected 
prevalence 
among patients 
at encounters 
(Ratio)
Observed 
prevalence 
within Australian 
population (95% 
CIs)
Expected 
prevalence 
within 
Australian 
population 
(Ratio)
Observed 
prevalence 
among patients 
at encounters 
(95% CIs)
Expected 
prevalence 
among patients 
at encounters 
(Ratio)
Observed 
prevalence 
within Australian 
population (95% 
CIs)
Expected 
prevalence 
within 
Australian 
population 
(Ratio)
Hypertension 
Hyperlipidaemia
12.1% 
(10.9-13.3)
4.9% 
(2.46)
8.3% 
(7.5-9.2)
2.0% 
(4.07)
Circulatory 
Endocrine*
19.8% 
(18.3-21.4)
9.8% 
(2.02)
13.8% 
(12.6-15.0)
4.3% 
(3.24)
Hypertension 
Osteoarthritis
10.9% 
(9.6-12.1)
4.7% 
(2.30)
6.4% 
(5.6-7.1)
1.7% 
(3.71)
Circulatory 
Musculoskeletal
16.6% 
(15.1-18.2)
8.3% 
(1.99)
10.2% 
(9.2-11.2)
3.3% 
(3.07)
Hyperlipidaemia 
Osteoarthritis
7.3% 
(6.4-8.3)
3.3% 
(2.22)
4.6% 
(4.0-5.2)
1.3% 
(3.60)
Musculoskeletal 
Endocrine*
14.6% 
(13.2-16.0)
8.1% 
(1.80)
9.9% 
(8.9-10.9)
3.6% 
(2.77)
Hypertension  
IHD
6.6% 
(5.7-7.5)
2.3% 
(2.85)
4.0% 
(3.4-4.6)
0.8% 
(4.82)
Circulatory 
Psychological
9.5% 
(8.4-10.7)
7.1% 
(1.34)
6.5% 
(5.8-7.3)
3.3% 
(1.94)
Hypertension 
GORD
6.2% 
(5.5-7.0)
3.1% 
(2.01)
3.9% 
(3.4-4.3)
1.2% 
(3.13)
Digestive 
Circulatory
9.4% 
(8.4-10.4)
5.0% 
(1.86)
5.9% 
(5.3-6.6)
2.1% 
(2.80)
Hypertension 
Type 2 Diabetes
5.9% 
(5.2-6.6)
2.2% 
(2.67)
4.1% 
(3.6-4.6)
0.9% 
(4.49)
Psychological 
Endocrine*
9.2% 
(8.2-10.2)
6.9% 
(1.33)
7.1% 
(6.3-7.9)
3.6% 
(1.97)
Osteoarthritis 
GORD
5.1% 
(4.4-5.8)
2.1% 
(2.47)
3.0% 
(2.6-3.5)
0.8% 
(3.85)
Musculoskeletal 
Psychological
9.1% 
(8.0-10.2)
5.9% 
(1.54)
6.4% 
(5.6-7.2)
2.8% 
(2.28)
Hypertension 
Depression
5.0% 
(4.3-5.6)
3.6% 
(1.37)
3.4% 
(2.9-3.9)
1.7% 
(2.05)
Digestive 
Endocrine*
8.5% 
(7.5-9.6)
4.9% 
(1.73)
6.0% 
(5.2-6.7)
2.3% 
(2.65)
IHD 
Hyperlipidaemia
5.0% 
(4.2-5.7)
1.6% 
(3.11)
3.1% 
(2.7-3.6)
0.6% 
(5.04)
Digestive 
Musculoskeletal
8.4% 
(7.4-9.4)
4.2% 
(2.01)
5.4% 
(4.7-6.0)
1.8% 
(3.05)
Hyperlipidaemia 
GORD
4.8% 
(4.1-5.5)
2.1% 
(2.24)
3.3% 
(2.8-3.8)
0.9% 
(3.58)
Circulatory 
Respiratory
6.1% 
(5.4-6.8)
4.5% 
(1.36)
3.9% 
(3.4-4.4)
2.2% 
(1.80)
IHD Osteoarthritis 4.5% 
(3.7-5.3)
1.5% 
(2.91)
2.4% 
(2.0-2.9)
0.5% 
(4.62)
Respiratory 
Endocrine*
5.9% 
(5.2-6.6)
4.4% 
(1.35)
4.2% 
(3.7-4.8)
2.3% 
(1.80)
Hypertension 
Obesity
4.5% 
(3.8-5.2)
2.1% 
(2.11)
3.5% 
(3.0-4.1)
N/A Musculoskeletal 
Respiratory
5.7% 
(5.0-6.5)
3.7% 
(1.54)
3.8% 
(3.3-4.3)
1.8% 
(2.09)
Note: Patients could have more than two conditions/chapters, these are just the most common combinations of two (regardless of whether they had other conditions/chapters)
*Full name of chapter is Endocrine, nutritional & metabolic
Figure 1: Prevalence of multiple chronic conditions and chapters affected by chornic problems within patients and the community.
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was circulatory+endocrine/nutritional/
metabolic systems, with 19.8% of patients at 
GP encounters and 13.8% of the Australian 
population having at least one chronic 
condition in both systems. 
For all the common combinations of chronic 
conditions/ICPC-2 chapters, the observed 
prevalence was significantly higher than the 
expected prevalence. For prevalence among 
patients at encounters, the combination of 
hypertension+IHD had the highest ratio of 
3.11, while hypertension+depression had 
the lowest at 1.37. Combinations of chapters 
that included the psychological or respiratory 
chapter had comparatively lower observed-
to-expected ratios compared with the 
circulatory+endocrine/nutritional/metabolic 
systems (2.02) and digestive+musculoskeletal 
(2.01). The ratios for population prevalence 
were consistently higher than those for 
encounter prevalence.
Table 2 shows the prevalence of the most 
common combinations of three chronic 
conditions/ICPC-2 chapters. Once again, 
the most prevalent combinations of chronic 
conditions involved eight of the nine most 
prevalent conditions; the most common 
combination being hypertension+ 
hyperlipidaemia+osteoarthritis (5.5% of 
patients at GP encounters and 3.3% of people 
in the population). The most prevalent 
combination of three body systems affected 
was circulatory+musculoskeletal+ 
endocrine/nutritional/metabolic systems 
(11.1% of patients at GP encounters and 
7.0% of the Australian population). As with 
individual chronic conditions, the body 
systems that made up the most prevalent 
combinations were also the most prevalent 
chapters, with only six ICPC-2 chapters 
used. The observed-to-expected ratios were 
considerably higher for the combinations 
of three conditions/chapters than the 
combinations of two conditions/chapters.
Table 2: Most prevalent patterns of three chronic conditions or three chapters affected by chronic conditions.
Chronic 
conditions
Most prevalent patterns of three chronic conditions
ICPC-2 chapters
Most prevalent patterns of three ICPC-2 chapters affected by chronic 
conditions
Observed 
prevalence 
among patients 
at encounters 
(95% CIs)
Expected 
prevalence 
among patients 
at encounters
(Ratio)
Observed 
prevalence 
within Australian 
population
(95% CIs)
Expected 
prevalence 
within 
Australian 
population 
(Ratio)
Observed 
prevalence 
among patients 
at encounters 
(95% CIs)
Expected 
prevalence 
among patients 
at encounters 
(Ratio)
Observed 
prevalence 
within Australian 
population (95% 
CIs)
Expected 
prevalence 
within 
Australian 
population 
(Ratio)
Hypertension 
Hyperlipidaemia 
Osteoarthritis 
5.5% 
(4.7-6.4)
0.9% 
(6.28)
3.3% 
(2.81-3.80)
0.21% 
(15.5)
Circulatory 
Musculoskeletal 
Endocrine*
11.1% 
(9.9-12.4)
2.6% 
(4.31)
7.0% 
(6.2-7.8)
0.71% 
(9.84)
Hypertension  
IHD 
Hyperlipidaemia
4.1% 
(3.5-4.8)
0.4% 
(9.58)
2.6% 
(2.1-3.0)
0.10% 
(25.5)
Digestive 
Circulatory 
Endocrine*
6.3% 
(5.4-7.2)
1.6% 
(4.05)
4.1% 
(3.5-4.6)
0.45% 
(9.08)
Hypertension  
IHD 
Osteoarthritis
3.7% 
(3.0-4.4)
0.4% 
(8.98)
1.9% 
(1.6-2.3)
0.09% 
(22.0)
Digestive 
Circulatory 
Musculoskeletal
6.1% 
(5.2-7.0)
1.3% 
(4.60)
3.5% 
(3.0-4.1)
0.35% 
(9.94)
Hypertension 
Osteoarthritis  
GORD
3.5% 
(2.8-4.1)
0.5% 
(6.37)
1.9% 
(1.6-2.2)
0.13% 
(14.7)
Circulatory 
Musculoskeletal 
Psychological
6.0% 
(5.1-6.9)
1.9% 
(3.21)
3.7% 
(3.2-4.3)
0.56% 
(6.63)
Hypertension 
Hyperlipidaemia 
GORD 
3.3% 
(2.8-3.9)
0.6% 
(5.78)
2.1% 
(1.8-2.5)
0.15% 
(13.7)
Circulatory 
Psychological 
Endocrine*
6.0% 
(5.1-6.8)
2.2% 
(2.73)
4.1% 
(3.5-4.7)
0.72% 
(5.73)
Hypertension 
Hyperlipidaemia 
Type 2 Diabetes 
3.3% 
(2.8-3.7)
0.4% 
(8.08)
2.3% 
(2.0-2.7)
0.11% 
(20.5)
Digestive 
Musculoskeletal 
Endocrine*
5.3% 
(4.5-6.2)
1.3% 
(4.10)
3.4% 
(2.8-3.9)
0.38% 
(8.98)
IHD 
Hyperlipidaemia 
Osteoarthritis
2.7% 
(2.2-3.3)
0.3% 
(9.42)
1.5% 
(1.2-1.8)
0.06% 
(23.5)
Musculoskeletal 
Psychological 
Endocrine*
5.2% 
(4.4-6.0)
1.8% 
(2.86)
3.5% 
(3.0-4.1)
0.60% 
(5.83)
Hypertension 
Type 2 Diabetes 
Osteoarthritis
2.7% 
(2.3-3.2)
0.4% 
(6.87)
1.6% 
(1.3-1.9)
0.09% 
(16.9)
Circulatory 
Respiratory 
Endocrine*
4.3% 
(3.6-4.9)
1.4% 
(3.11)
2.7% 
(2.3-3.1)
0.46% 
(5.82)
Hyperlipidaemia 
Osteoarthritis  
GORD
2.6% 
(2.1-3.1)
0.4% 
(6.81)
1.6% 
(1.3-1.9)
0.10% 
(16.7)
Circulatory 
Musculoskeletal 
Respiratory
4.0% 
(3.4-4.6)
1.2% 
(3.40)
2.4% 
(2.1-2.8)
0.36% 
(6.63)
Hypertension 
Osteoarthritis 
Depression 
2.4% 
(1.9-2.9)
0.6% 
(3.70)
1.4% 
(1.1-1.7)
0.17% 
(8.1)
Musculoskeletal 
Respiratory 
Endocrine*
3.7% 
(3.1-4.2)
1.1% 
(3.23)
2.4% 
(2.0-2.7)
0.39% 
(6.16)
Hypertension 
Hyperlipidaemia 
Obesity 
2.2% 
(1.7-2.7)
0.4% 
(5.59)
1.7% 
(1.4-2.1)
NA Digestive  
Circulatory 
Psychological
3.4%
(2.8-4.0)
1.1% 
(3.01)
2.1% 
(1.8-2.6)
0.35% 
(5.93)
Hypertension 
Hyperlipidaemia 
Depression 
2.2% 
(1.8-2.6)
0.7% 
(3.26)
1.6% 
(1.3-1.9)
0.20% 
(7.8)
Digestive 
Musculoskeletal 
Psychological
3.3% 
(2.7-3.9)
0.9% 
(3.52)
2.2% 
(1.8-2.6)
0.30% 
(7.40)
Note: Patients could have more than three conditions/chapters, these are just the most common combinations of three (regardless of whether they had other conditions/chapters)
* Full name of chapter is Endocrine, nutritional & metabolic
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Discussion
For the first time in Australia, the patterns 
and prevalence of multimorbidity using all 
chronic conditions have been estimated from 
a nationally representative prospective study. 
We estimate that nearly half the patients at 
GP encounters and about one-third of the 
population have multimorbidity. Similar to 
previous studies,7-9,14,26 we have shown that 
multimorbidity is an issue for a significant 
proportion of patients seen in general 
practice.
Our study has shown there are more patients 
at GP encounters with hypertension+ 
hyperlipdaemia+osteoarthritis than patients 
with many common individual conditions 
such as congestive heart failure (2.9%), 
rheumatoid arthritis (1.0%) or chronic 
obstructive pulmonary disease (4.1%).22 It has 
also shown that about two-thirds of people 
with a chronic condition have two or more 
chronic conditions. This high proportion of 
patients with comorbidity suggests that we 
may need to re-examine the focus of our 
health care system on the management 
of single chronic conditions, particularly in 
regards to guidelines and clinical trials.
The prevalence observed for all common 
combinations of multimorbidity was higher 
than that expected by chance. This supports 
previous research that has shown that 
conditions, such as cardiovascular conditions, 
cluster together.27,28 However, our results are 
unadjusted for patient age, which should 
account for some of this clustering as the 
prevalence of many chronic conditions 
increases with age. It is also possible that once 
a patient has been diagnosed with a chronic 
condition, their more frequent attendance 
to have it managed and monitored provides 
greater opportunity for other conditions 
to be diagnosed. Future studies will further 
investigate these relationships.
It has been suggested that multimorbidity 
defined as two or more chronic conditions 
identifies too high a proportion of patients 
with multimorbidity to be useful in resource 
planning and identifying patients with higher 
needs.14,29 Our results support this conclusion, 
as nearly every second patient at encounters 
was identified as having multimorbidity 
using this definition. Complex multimorbidity 
appears to be a more discriminating 
measure, with our study identifying 27.4% 
of patients at encounters as having complex 
multimorbidity, similar to the 34.5% estimate 
among patients attending the two practices 
in Perth.8 Both these estimates are far higher 
than our first study where we estimated that 
only 10.6% of patients at encounters had 
complex multimorbidity. This is because 
the first study used a limited number of 
conditions covering only nine of the fourteen 
CIRS domains,7 and limiting the number of 
conditions studied has been shown to reduce 
prevalence estimates of multimorbidity.14
Measuring the prevalence of complex 
multimorbidity is important as it is likely 
to identify higher-need patients, and this 
will help with allocation of health resources 
such as the number and types of health 
professionals required in an area. Reporting 
the patterns of body systems affected by 
chronic conditions may also help policy 
planners identify services that, if co-located, 
would be beneficial to the optimal care of 
these patients. The complex multimorbidity 
measure would also allow identification of 
patients who may need help in coordinating 
care between multiple health care providers. 
While there is clearly value in measuring 
the patterns of body systems affected by 
chronic conditions, there is still great value 
in measuring the pattern of individual 
conditions. Knowledge of specific patterns 
of chronic conditions within an individual 
patient is crucial to their clinical care. 
Reporting the most prevalent patterns of 
individual chronic conditions in patients 
highlights the need for clinical guidelines for 
managing patients with common patterns of 
chronic conditions. 
In an earlier study, we showed that when 
measuring the prevalence of complex 
multimorbidity it is vital to collect information 
on all chronic conditions – otherwise the 
estimate will be significantly less than the 
true prevalence.14 However, the results 
of the current study suggest that when 
measuring the prevalence of the most 
common combinations of conditions, only 
the presence or absence of eight prevalent 
conditions needs to be collected. These 
conditions account for eight of the nine most 
prevalent conditions in Australia, with asthma 
being the other prevalent condition.22 
Our study has limitations. We assumed that 
people who had not seen their GP in the 
previous year did not have a diagnosed 
chronic condition. This assumption may not 
hold for conditions such as asthma that, if 
mild, may not necessitate a GP attendance 
that year. Also, we can only provide estimates 
for those conditions already diagnosed, 
and we know that not all cases of disease 
are diagnosed.30 However, this limitation is 
shared with most prevalence studies.
Our study did not include a measure of the 
severity of the chronic conditions. This is 
important as, according to our definition, 
a patient with severe COPD and CHF 
would not be considered to have complex 
multimorbidity. In contrast, a patient 
with mild asthma, mild hypertension and 
controlled hyperlipidaemia would be 
considered to have complex multimorbidity. 
The first patient would, however, usually 
be more complex to manage and require 
more health services than the second. In our 
next study we will examine the relationship 
between the number of diagnosed chronic 
conditions/body systems affected and overall 
severity of illness, complexity of care and 
health resource utilisation.
Finally, our sample was drawn from patients 
attending general practice, so we were more 
likely to sample people who attend more 
frequently. While we adjusted for higher 
attendance of female and older patients, 
our method could not adjust for individual 
high attenders within a specific age–sex 
group. If patients with particular conditions 
consistently attend more often than the 
average for their age and sex, this could lead 
to an overestimate of the prevalence of these 
conditions in our study. 
Conclusion
For the first time in Australia, the prevalence 
and patterns of multimorbidity using all 
chronic conditions have been estimated 
from a nationally representative prospective 
study. A significant number of Australians 
not only have multimorbidity, but have 
complex multimorbidity. Some patterns of 
complex multimorbidity are more prevalent 
than single conditions that receive a lot of 
individual attention. If we are to meet the 
challenge posed by the increasing prevalence 
of complex multimorbidity, we need to 
re-evaluate the single disease focus of our 
healthcare system. This will be particularly 
important for health service planning. In 
our next paper, we will examine how well 
complex multimorbidity predicts resource 
utilisation, complexity of care and overall 
severity of illness.
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The study in this chapter explored the prevalence and patterns of multimorbidity and 
complex multimorbidity among patients at encounters and people in the population, using 
the definitions I devised and described in Chapter 4. However, the adjustment of GP 
encounter prevalence estimates to those of the population, based on the method first 
described in Chapter 3, had the limitation of not being able to adjust for high and low 
attenders within each age-sex group. As I said in this paper, if within age-sex groups, 
patients with more chronic conditions attend GPs more often than those with fewer 
conditions, then our multimorbidity will be an overestimate. The next chapter is based on a 
new, larger survey in which I took steps to address this limitation. 
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Abstract
Objectives
To estimate the prevalence of common chronic conditions and multimorbidity among
patients at GP encounters and among people in the Australian population. To assess the
extent to which use of each individual patient’s GP attendance over the previous year,
instead of the average for their age-sex group, affects the precision of national population
prevalence estimates of diagnosed chronic conditions.
Design, setting and participants
A sub-study (between November 2012 and March 2016) of the Bettering the Evaluation and
Care of Health program, a continuous national study of GP activity. Each of 1,449 GPs pro-
vided data for about 30 consecutive patients (total 43,501) indicating for each, number of
GP attendances in previous year and all diagnosed chronic conditions, using their knowl-
edge of the patient, patient self-report, and patient’s health record.
Results
Hypertension (26.5%) was the most prevalent diagnosed chronic condition among patients
surveyed, followed by osteoarthritis (22.7%), hyperlipidaemia (16.6%), depression (16.3%),
anxiety (11.9%), gastroesophageal reflux disease (GORD) (11.3%), chronic back pain
(9.7%) and Type 2 diabetes (9.6%).
After adjustment, we estimated population prevalence of hypertension as 12.4%, 9.5%
osteoarthritis, 8.2% hyperlipidaemia, 8.0% depression, 5.8% anxiety and 5.2% asthma.
Estimates were significantly lower than those derived using the previous method.
About half (51.6%) the patients at GP encounters had two or more diagnosed chronic
conditions and over one third (37.4%) had three or more. Population estimates were: 25.7%
had two or more diagnosed chronic conditions and 15.8% had three or more.
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as the BEACH data contain confidential data about
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under a collaboration between the Australian
Institute of Health andWelfare (AIHW) and the
University of Sydney. The data were therefore
collected under the Australian Institute of Health
andWelfare Act (an Act of the Australian
Parliament). The Act sets out clearly the
Conclusions
Of the three approaches we have tested to date, this study provides the most accurate
method for estimation of population prevalence of chronic conditions using the GP as an
expert interviewer, by adjusting for each patient’s reported attendance.
Introduction
Australia has a universal medical insurance scheme called Medicare which (fully or partially)
covers the individuals cost of visits to general practitioners (GPs). GPs are paid on a fee-for-
service basis. There is no patient registration, patients being free to visit any number practices
and GPs as they choose. In any single year around 85% of Australians see a GP at least once[1]
with GPs providing the bulk of primary care and acting as gate-keepers to government-subsi-
dised health care from other health professionals.
Like all OECD countries, Australia’s population is ageing[2,3]. It is expected this will increase
the prevalence of diagnosed chronic conditions[4,5], of multimorbidity[6–8], and demand on the
health care system[7,9,10]. In response, the Australian federal government recently announced a
“Health Care Home” (Patient Centred Medical Home) initiative whereby patients with chronic
and complex conditions voluntarily enrol at a general practice[11]. This plan will include a “bun-
dled payment” (partial capitation) to the practice for each patient enrolled. While initial reports
implied that patients with multiple chronic conditions would be targeted by the initiative, recent
announcements suggest that patient eligibility will be determined by their risk of hospital admis-
sion[12]. However, hospital admission risk may not accurately predict use of general practice ser-
vices, yet this will be required to calculate fair compensation to GPs under the partial capitation
model of the initiative. Preliminary results have shown that multimorbidity is a strong predictor
of primary care resource use[13]. Therefore to cost this initiative, the prevalence of chronic con-
ditions and multimorbidity needs to be measured accurately.
Large population health surveys that rely on respondent self-report are commonly used
to measure the prevalence of chronic conditions[14–16]. One such study is the National
Health Survey (NHS)[17], one of Australia’s largest health surveys, undertaken by the
Australian Bureau of Statistics every three to six years since 1989. The most recent (2014–
15) surveyed 19,259 people from 14,723 households, and while it used some measured
data (such as respondent’s blood pressure, height, weight and waist circumference) it still
relied on respondent self-report for measurement of the prevalence of chronic conditions.
[17] This is despite concerns about the accuracy of self-reported health information[18–
22].
Due to these concerns, review of health records (paper and/or electronic) is often assumed
to be a more accurate way of estimating prevalence of chronic conditions. However, this
approach has its own issues with the stored information sometimes being inaccurate and often
incomplete[23–25]. There are also concerns around obtaining patient consent to use their
data, with many patients not being informed[26].
The BEACH (Bettering the Evaluation And Care of Health) program was a study of GP
clinical activity in Australia[1]. Sub-studies of the BEACH program allowed us to investigate
aspects of health and health care delivery, free of the limitations of health record audits and
patient self-report. The sub-studies utilised the GP as an expert interviewer and informant,
drawing on the patient’s knowledge, their knowledge of the patient, and the patient’s health
record.
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circumstances under which the data can be used.
Since 2011, the University of Sydney has been fully
responsible for the BEACH program. As such, we
have continued to abide by the regulations of this
Act in our treatment of the data. These methods
were described in our Ethics application 2012 to
2018 and were approved by the Human Ethics
Committee of the University of Sydney. The
continuity of application of the regulations of the
Act also ensured that all 18 years of data sit under
the same ethical rules. A non-author contact for the
BEACH data governance committee is Professor
Lyndal Trevena, who can be contacted at lyndal.
trevena@sydney.edu.au. The University of
Sydney’s human ethics committee can be
contacted at human.ethics@sydney.edu.au The
project does have a Data Governance Committee,
which reviews requests for access to the data on a
case-by-case basis assuring that requests comply
with the Act under which the data were collected.
The first author of this paper, Christopher Harrison,
is a member of this Data Governance Committee
and will process any request for access to the data
for interested researchers who agree to comply
with the Act. Christopher can be contacted at
christopher.harrison@sydney.edu.au The Medicare
and Department of Veteran Affairs data provided to
us to assess the representativeness of our sample
is confidential (required by the Government), so we
cannot provide access to others. However, other
researchers requiring these data can request it
from the Medicare Information Analysis Section of
the Australian Government Department of Health
and from the Australian Government Department
of Veteran Affairs respectively. The Australian
Department of Health can be contacted through an
online form found at this address http://www.
health.gov.au/internet/main/publishing.nsf/Content/
health-comments.htm. The Australian Department
of Veterans’ Affairs can be contacted at
GeneralEnquiries@dva.gov.au.
Funding: This study was a sub-study of the BEACH
project. The overall BEACH project was funded by
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data for this study were collected: Australian
Government Department of Health and Ageing and
Department of Veterans’ Affairs, AstraZeneca Pty
Ltd (Australia), Merck, Sharp and Dohme
(Australia) Pty Ltd, Pfizer Australia Pty Ltd, Sanofi-
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Ltd, Seqirus (Australia) Pty Ltd (then bioCSL
(Australia) Pty Ltd), Bayer Australia Ltd, AbbVie Pty
Ltd. The sub-studies reported in this paper were
conducted by the Family Medicine Research Centre
and the funding bodies had no role in study design,
A study conducted in 2005 showed that sub-studies embedded within the national BEACH
program could provide timely, accurate prevalence estimates of common chronic conditions
in Australia[4].
In 2008–09, we conducted another sub-study which built on our earlier methods by
expanding the study’s scope to include all chronic conditions (rather than a selection of com-
mon chronic conditions) and by improving the methods of dealing with non-attenders when
estimating population prevalence[5].
However, in the earlier studies we were not able to adjust for high and low attenders to gen-
eral practice within each age-sex group of patients. This meant that our national estimates may
have been inflated if, within a specific age-sex group, people with more diagnosed chronic con-
ditions attend more often than people without chronic conditions. This may be true as our
2008–09 study estimated that 32.6% of the population had two or more diagnosed chronic
conditions, a significantly higher proportion than that of the 2014–15 NHS (23.0%)[17].
Since the 2008–09 study, we introduced an additional question asking how many times the
patient had seen a GP in previous 12 months (including today’s visit). This will allow adjust-
ment for attendance for each individual patient and overcomes the major limitation of the
2008–09 study.
If it is decided that the compensation paid to GPs for each patient enrolled in the health
care home initiative is based on the patient’s multimorbidity load, the way multimorbidity is
measured will also need to be decided. The most common way of measuring multimorbidity is
a simple count of the number of diagnosed chronic conditions within a patient[7,27]. Alterna-
tively, it has been suggested that it is not the number of individual chronic conditions that is
important, but the number of body systems affected by these chronic conditions[8,27].
The aims of this study were to:
1. estimate the prevalence of common chronic conditions among patients at GP encounters
and among people in the Australian population.
2. assess the extent to which use of each individual patient’s reported GP attendance over the
previous year, instead of the average for their age-sex group, affects the precision of national
population prevalence estimates of diagnosed chronic conditions.
3. estimate the prevalence of multimorbidity among patients at GP encounters and among
people in the Australian population.
Method
This study was undertaken as a sub-study of the BEACH program. BEACH was a continuous,
national cross-sectional study of general practice activity in Australia operating from April
1998–March 2016 inclusive. Its methods are described in detail elsewhere.[1] In summary,
each year an ever-changing, random sample of about 1,000 GPs each recorded information
about encounters with 100 consecutive consenting patients, on structured paper forms.
In BEACH sub-studies, the GP recorded information additional to the encounter data, in
discussion with the patient. In this sub-study, 1,800 participating GPs were each asked to
record all diagnosed chronic conditions present in each of 30 consecutive patients within their
100 BEACH encounter forms over twelve five-week recording periods between 27th Novem-
ber 2012 and 28th March 2016.
GPs were instructed to ‘‘Use your own knowledge, patient knowledge and health records as
you see fit, in order to answer these questions”. GPs were first asked, “Approx. how many
times has this patient seen any GP in the past 12 months? (Including today)”. They were then
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asked ‘‘Does the patient have any chronic diseases/problems?”. If ‘No’, the GP ended the ques-
tions for that patient. If ‘Yes’, the GP indicated all the diagnosed chronic conditions for that
patient. Tick boxes were provided for common chronic conditions and additional blank spaces
were provided to allow free text recording of other unlisted chronic condition.
Chronic conditions listed were primarily those that were included in the previous preva-
lence study[5] based on those most frequently managed in Australian general practice[1].
Chronic conditions were classified according to the International Classification of Primary
Care (Version 2) (ICPC-2)[28].
Examples of the instruction sheet and the recording form provided to the GP are attached
in S2 and S3 Files. The final question (which was not analysed for this paper) varied over the
sub-studies, however the variables analysed in this paper were asked consistently across the
sub-studies.
Data analysis
In previous studies[4,5] we found that patients for whom no response was recorded for the
chronic condition question were similar in terms of age and problems managed at their
encounters, to patients for whom the “no chronic conditions” option was recorded. Based on
these similarities, we assumed that some GPs were leaving this question blank for patients who
had no diagnosed chronic conditions. To account for this, patients with missing chronic con-
dition data were counted as having “No chronic conditions” to ensure we did not overestimate
the prevalence of chronic conditions. We then examined these same patient’s encounter
record to see whether any chronic conditions (as defined by O’Halloran et al[29]) were man-
aged at their encounter. If chronic conditions were managed at the encounter, they were no
longer considered to have “No chronic conditions” and those chronic conditions managed at
their encounter were assigned to the patient in the sub-study. If in the current study we find
that patients with missing chronic condition data were similar to those who had the “No
chronic conditions” option ticked, we will follow the steps described above from previous
studies.
When the number of GP visits in the previous year was not recorded (missing data), the
average number of visits for a patient in the same 10 year age group, the same sex and the same
number of diagnosed chronic conditions (0,1,2,3+ chronic conditions) was assigned.
Multimorbidity was defined as the “co-occurrence of two or more chronic conditions
within one person without defining an index chronic condition” and complex multimorbidity
as the “co-occurrence of three or more chronic conditions affecting three or more different
body systems within one person without defining an index chronic condition”[27]. The chap-
ters of ICPC-2 were used to represent the different body systems. A patient with complex mul-
timorbidity had at least one diagnosed chronic condition in each of three or more different
ICPC-2 chapters. Body systems were counted only once per patient, even if they had multiple
chronic conditions classified to that body system.
The proportion of patients with morbidity X in the unweighted sample can be interpreted
as the prevalence of that condition among patients found in GP waiting rooms or at GP
encounters. We compared the prevalence of common chronic conditions at GP encounters
with two earlier studies (Knox et al.[4] & Harrison et al.[5]) that used the same method. The
only differences between the studies were that Knox et al. used a limited number of conditions
and the conditions listed in Harrison et al[5] were listed in a different order.
As patients were sampled at GP consultations, the likelihood of being sampled is dependent
on visit frequency. Therefore frequent attenders (such as older patients who may have more
health problems) were more likely to be sampled than infrequent attenders.
The prevalence of diagnosed chronic conditions and multimorbidity in Australia
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In Harrison et al.[5], to estimate national prevalence, we weighted the data to match the
age–sex distribution of the Australian population. We assumed that people who did not attend
a GP that year had no diagnosed chronic conditions. After the above weighting we multiplied
the outcome (condition count) for each patient, by the proportion of their age-sex group who
saw a GP at least once that year (data supplied by the Australian Government Department of
Health). This accounted for those who did not see a GP that year. However, this method did
not account for high attenders within specific age-sex groups.
In the current study, we were able to adjust for high or low attenders by weighting each
patient’s data by the number of times they reported seeing a GP in the previous year, with high
attenders being weighted down and low attenders being weighted up. We then followed the
previous method using the weighted data instead of the raw data. Table 1 demonstrates how
the weightings were calculated for each of the two methods using two example patients.
To test the effect of this new method on our estimates, we weighted the current data
using both methods. We compared these national prevalence estimates with those of the
previous study. If it is true that within an age-sex group, patients with chronic conditions
attend more often than those without chronic conditions, then the prevalence estimates
resulting from the new method should produce lower estimates than those produced by the
previous method.
BEACH sub-studies have a single stage cluster design, with each GP having 30 patients clus-
tered around them. Survey procedures (in SAS 9.3) were used to account for the effect of this
clustering. Significant differences were determined by non-overlapping 95% confidence inter-
vals (CIs). This is a more conservative estimate of difference than the usual p<0.05[30].
Ethics statement
During the data collection period for this study the BEACH program was approved by the
Human Research Ethics Committee of the University of Sydney (Reference number 2012/
130). Our method involved the collection of data from unidentifiable, consenting patients. In
the research kit, a patient information card was supplied and GPs were instructed to show this
to patients in order to obtain informed consent (an example shown in Britt et al.[1]). If the
patient chose not to participate, their encounter details were not recorded. GPs were instructed
to note the patient’s consent in the patient’s record, but were not asked to provide written con-
sent to the research body, to preserve patient anonymity. These methods comply with the Eth-
ics requirements for the BEACH program.
Table 1. New and previousmethods to weight “encounter” data to reflect “population” prevalence.
Example 1: Male patient
aged 10–14 years
Example 2: Female
patient aged 80–84 years
Old Method New Method Old Method NewMethod
Reported number of GP visits in previous year (A) — 8 — 6
Average number of GP visits for total sample(B) — 4.54 — 4.54
C = B/A (Weight to adjust for attendance) 1 0.57 1 0.76
Proportion of the Australian population (D) 3.10% 3.10% 1.09% 1.09%
Proportion of sample that was in the selected age-sex group (after weighting in the New method)
(E)
1.18% 2.03% 3.15 1.47%
F = D/E (National weight) 2.63 1.53 0.35 0.74
G = Proportion of age-sex group that saw a GP at least once that year 74.85% 74.85% 96.53% 96.53%
Final adjustment of outcome (or numerator) to estimate national prevalence = C*F*G 1.97 0.65 0.34 0.54
Denominator for national estimates (for both patients with and without condition) = C*F 2.63 0.87 0.35 0.56
doi:10.1371/journal.pone.0172935.t001
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Results
Of the 1,800 GPs recruited, 1,449 GPs (80.5%) returned completed recording forms. Of the
43,501 patients in this sample, 41,722 (95.9%) reported the number of times they had seen a
GP in the previous year and 42,185 (97.0%) responded to the chronic condition questions. The
1,316 patients with missing chronic condition data were examined and found to be similar to
those patients with no chronic conditions, with both groups being younger on average than
the total sample. Further, the most frequently managed problems at their encounters were
acute, whereas in the total sample the most frequently managed conditions were chronic. Of
these 1,316 patients, 323 (24.5%) had one or more chronic conditions managed at the encoun-
ter and were included as having these conditions while the remaining 993 (75.5%) were added
to the no chronic conditions group (results not tabled).
On average, patients in the sample had seen a GP 9.66 times in the previous 12 months.
After adjusting for this attendance, we estimated that all people who had seen a GP at least
once in the previous 12 months, visited a GP 4.54 times on average.
Overall, the age-sex distribution of the sample was similar (range 0.80–1.14) to that of
patients at all Medicare or Department of Veteran Affairs (DVA) claimed GP consultations,
with the exception of patients aged less than 15 years (80–83% of expected) (Table 2). After
Table 2. Age-sex distribution of the sample.
Patient
Age/Sex
Number in
sample
Percent of
sample (95%
CI)
Percent of Australian
general practice service
claims
Precision
ratio
Percent of sample
after adjusting for
attendance
Percent of the Australian
general practice
population@
Precision
ratio
Male
15 years 2,369 5.5% (5.2–5.8) 6.9% 0.80 8.1% (7.7–8.6) 9.4% 0.86
15–24
years
1,246 2.9% (2.7–3.1) 3.2% 0.91 5.0% (4.7–5.4) 5.5% 0.92
25–44
years
3,210 7.5% (7.1–7.9) 8.8% 0.85 11.0% (10.4–11.6) 12.3% 0.89
45–64
years
4,735 11.0% (10.6–
11.4)
11.2% 0.99 11.6% (11.1–12.2) 12.3% 0.95
65–74
years
2,756 6.4% (6.1–6.7) 6.0% 1.07 4.8% (4.5–5.1) 4.5% 1.06
75+ years 3,011 7.0% (6.6–7.4) 6.8% 1.03 3.5% (3.3–3.8) 3.3% 1.09
Female
15 years 2,236 5.2% (4.9–5.5) 6.3% 0.83 7.7% (7.2–8.2) 8.9% 0.87
15–24
years
2,159 5.0% (4.7–5.3) 5.5% 0.91 6.6% (6.1–7.0) 6.3% 1.04
25–44
years
6,057 14.1% (13.6–
14.6)
14.4% 0.98 15.7% (15.0–16.3) 14.8% 1.06
45–64
years
6,927 16.1% (15.7–
16.6)
14.6% 1.10 15.0% (14.4–15.6) 13.6% 1.11
65–74
years
3,593 8.4% (8.0–8.7) 6.8% 1.22 5.7% (5.4–6.0) 4.9% 1.18
75+ years 4,605 10.7% (10.2–
11.3)
9.4% 1.14 5.2% (4.9–5.5) 4.2% 1.23
There were 492 patients who had either/both age and/or sex missing.
*All general practice Medicare Beneﬁts Schedule (MBS) items claimed GPs in 2014–15 and all Department of Veteran Affairs GP claims in 2012–13 (Most
recent year available). MBS data supplied by the Medicare Information Analysis Section and Department of Veteran Affairs data was supplied by the
Department of Veteran Affairs.
@Distribution of all patients who had at least one MBS GP service item claimed in 2014–15
doi:10.1371/journal.pone.0172935.t002
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adjusting for each patient’s attendance over the previous year, the age-sex distribution of the
weighted sample was similar to that of all patients who had claimed at least one Medicare GP
item of service within the previous year, with the exception of female patients aged 75 years
and over (23% more than expected).
Sample prevalence of individual chronic conditions
The circulatory system was the body system most commonly affected by a chronic condition,
with nearly a third (32.4%) of patients at GP encounters having at least one diagnosed circula-
tory chronic condition (Table 3). The musculoskeletal system and connective tissue (32.1%);
and the endocrine, nutritional and metabolic disease system (30.7%) were also commonly
affected by at least one diagnosed chronic condition. About one quarter (26.7%) of patients at
GP encounters had a diagnosed psychological problem.
Table 3. Prevalence of common diagnosed chronic conditions among patients at GP encounters across three studies.
Knox et al. estimates (2005,
n = 9,156)
Harrison et al. (2008–09,
n = 8,707)
Current estimates (2012–16,
n = 43,501)
Circulatory 30.0% (28.1–31.7) 31.3% (29.4–33.1) 32.4% (31.5–33.4)
Hypertension 23.3% (21.8–24.9) 26.6% (24.9–33.1) 26.5% (25.6–27.3)
Ischaemic Heart Disease 9.5% (8.5–10.5) 8.7% (7.7–9.8) 7.8% (7.4–8.2)
Cerebrovascular Accident 3.7% (3.0–4.5) 2.9% (2.3–3.5) 2.6% (2.4–2.8)
Congestive Heart Failure 3.2% (2.7–3.7) 2.9% (2.4–3.4) 2.6% (2.4–2.8)
Peripheral Vascular Disease 2.0% (1.5–2.5) N/A 1.8% (1.7–2.0)
Musculoskeletal system and connective
tissue
N/A 26.4 (24.6–28.2) 32.1% (31.1–33.0)
Any Arthritis 22.8% (21.1–24.5) 19.7% (18.1–21.4) 25.0% (24.1–25.9)
Rheumatoid 1.0% (0.8–1.2) 1.0% (0.7–1.2) 1.3% (1.2–1.5)
Osteoarthritis 20.0% (18.3–21.6) 17.8% (16.2–19.4) 22.7% (21.8–23.6)
Other and unknown N/A 2.0% (1.7–2.4) 2.0% (1.9–2.2)
Chronic Back Pain 10.1% (9.0–11.1) 6.4% (5.5–7.2) 9.7% (9.2–10.2)
Osteoporosis N/A 4.8% (4.2–5.5) 5.8% (5.4–6.1)
Endocrine, nutritional and metabolic
diseases
N/A 30.8% (29.0–32.6) 30.7% (29.9–31.6)
Hyperlipidaemia 15.9% (14.7–17.2) 18.5% (17.0–20.0) 16.6% (15.9–17.3)
Diabetes all 8.3% (7.5–9.0) 9.2% (8.3–10.1) 10.4% (10.0–10.8)
Type 1 0.6% (0.4–0.8) 0.9% (0.6–1.2) 0.9% (0.8–1.0)
Type 2 7.2% (6.5–7.9) 8.3% (7.5–9.1) 9.6% (9.2–10.0)
Psychological Problems 24.8% (23.2–26.3) 22.1% (20.6–23.7) 26.7% (25.9–27.5)
Depression 14.2% (13.0–15.4) 13.7% (12.6–14.7) 16.3% (15.8–16.9)
Anxiety 10.7% (9.6–11.8) 8.3% (7.3–9.4) 11.9% (11.4–12.4)
Insomnia 5.5% (4.6–6.4) N/A 3.7% (3.4–4.0)
Digestive N/A 14.6% (13.4–15.8) 15.1% (14.5–15.7)
GORD 13.1% (11.9–14.4) 11.6% (10.5–12.6) 11.3% (10.7–11.8)
Respiratory Disease N/A 13.7% (12.6–14.7) 14.6% (14.1–15.1)
Asthma 10.7% (9.8–11.6) 9.5% (8.7–10.3) 8.3% (8.0–8.7)
COAD/COPD 3.6% (3.1–4.2) 4.1% (3.4–4.7) 4.5% (4.2–4.7)
Malignant Neoplasms 3.1% (2.6–3.6) 5.0% (4.4–5.7) 6.2% (5.9–6.5)
Note: GORD = gastro oesophageal reﬂux disease, COAD/COPD chronic obstructive airways disease/chronic obstructive pulmonary disease
N/A: Result not available due to chronic condition not being measured
doi:10.1371/journal.pone.0172935.t003
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Hypertension (26.5%) was the most prevalent individual diagnosed chronic condition, fol-
lowed by osteoarthritis (22.7%), hyperlipidaemia (16.6%), depression (16.3%), anxiety (11.9%),
gastroesophageal reflux disease (GORD) (11.3%), chronic back pain (9.7%) and Type 2 diabe-
tes (9.6%).
The prevalence estimates for diagnosed ischaemic heart disease, cerebrovascular accidents,
GORD and asthma among patients at GP encounters were significantly lower than the 2005
study estimates. Conversely, the prevalence estimates of diagnosed hypertension, osteoarthri-
tis, Type 2 diabetes, depression and malignant neoplasms were each significantly higher than
in the 2005 study.
Population prevalence of individual conditions
After adjustment, we estimated that 16.0% of people in the population had at least one endo-
crine, nutritional and metabolic disease, 15.0% had at least one circulatory condition and
14.4% had at least one musculoskeletal system and connective tissue chronic condition
(Table 4).
Hypertension was the most prevalent condition (12.4% of the population) followed by oste-
oarthritis (9.5%), hyperlipidaemia (8.2%), depression (8.0%), anxiety (5.8%), asthma (5.2%),
GORD (4.9%), Type 2 diabetes (4.2%) and chronic back pain (4.1%).
Almost all the population prevalence estimates using the new ‘revised’ method were signifi-
cantly lower than the 2008–09 prevalence estimates. However, when the current study’s data
were analysed using the older method (which adjusted for age-sex group attendance averages
rather than individual patient’s attendance) the prevalence estimates did not significantly differ
from those found in the previous study. The population prevalence estimates produced using
the new method were significantly lower (between 18% lower for dementia to 40% lower for
insomnia) than those derived using the previous method when using the same data.
Compared with the 2014–15 NHS estimates, our prevalence estimates were significantly
higher for circulatory conditions (including congestive heart failure), endocrine, nutritional
and metabolic disease (including hyperlipidaemia), gastrointestinal conditions and malignant
neoplasms. Our prevalence estimates were significantly lower for total arthritis, rheumatoid
arthritis, other arthritis, osteoporosis, asthma and chronic obstructive pulmonary disease than
the 2014–15 NHS estimates.
Prevalence of multimorbidity
About half (51.6%) the patients at GP encounters had two or more diagnosed chronic condi-
tions and over one third (37.4%) had three or more. Nearly half (47.8%) had two or more body
systems affected by chronic conditions and 30.4% had complex multimorbidity (Fig 1).
After adjustment we estimated that: 25.7% of the population had two or more diagnosed
chronic conditions: 15.8% had three or more; 23.0% had two or more body systems affected by
chronic conditions; and 12.1% of the population had complex multimorbidity (Fig 1).
Discussion
Adjusting for each individual patient’s GP attendances over the previous 12 months provided
prevalence estimates that were significantly lower than those generated by our previous
method. This suggests that within an age-sex group, patients with diagnosed chronic condi-
tions attend more often than those patients without. Adjusting for this variance will have made
our population estimates more accurate than our previous estimates. We found that the clear
majority of patients at GP encounters had at least one diagnosed chronic condition and about
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half had two or more. The most prevalent conditions among both patients at GP encounters
and among people in the population were hypertension, osteoarthritis and hyperlipidaemia.
In our earlier prevalence papers we suggested that some of the differences between our
prevalence estimates and those of the NHS may be due to respondent self-report error[4,5].
For instance the relatively high NHS prevalence estimates for rheumatoid arthritis may be due
to respondents confusing it with ‘rheumatism’[5]. We found a similar difference in the current
study. One of the great advantages of using the GP as an expert interviewer with access to the
patient health record is that any such confusion from the patient can be clarified by the GP.
We estimated that about a quarter (25.7%) of the population had multimorbidity, two or
more diagnosed chronic conditions, which is significantly smaller than the 32.6% estimated in
our previous study(7). The lower estimates are due to using the new, more reliable method of
Table 4. Population prevalence of common diagnosed chronic conditions andmultimorbidity.
Harrison et al. (2008–
09, n = 8,707) (95%
CIs)
Current using previous
method (2012–15, n = 43,501)
(95% CIs)
Current using revised
method (2012–15, n = 43,501)
(95% CIs)
National Health Survey
(2014–15, n = 19,259) (95%
CIs)
Circulatory 19.6% (18.3–20.9) 18.5% (17.9–19.2) 15.0% (14.3–15.6) 18.3% (17.7–18.9)
Hypertension 16.6% (15.4–17.8) 15.1% (14.5–15.7) 12.4% (11.8–12.9) 11.3% (10.8–11.8)
Ischaemic Heart Disease 5.0% (4.4–5.6) 4.0% (3.8–4.2) 2.9% (2.7–3.1) **
Cerebrovascular Accident 1.5% (1.2–1.8) 1.3% (1.2–1.4) 0.9% (0.8–1.0) 0.8% (0.6–1.0)
Congestive Heart Failure 1.5% (1.2–1.8) 1.2% (1.1–1.3) 0.8% (0.7–0.8) 0.5% (0.4–0.6)
Peripheral Vascular
Disease
N/A 0.9% (0.8–1.0) 0.6% (0.5–0.6) **
Musculoskeletal system
and connective tissue
16.7% (15.5–18.0) 19.2% (18.5–19.9) 14.4% (13.8–15.1) **
Any Arthritis 11.9% (10.8–12.9) 13.9% (13.3–14.5) 10.7% (10.1–11.2) 15.3% (14.8–15.8)
Rheumatoid 0.6% (0.4–0.7) 0.8% (0.7–0.9) 0.6% (0.5–0.6) 1.8% (1.6–2.0)
Osteoarthritis 10.4% (9.4–11.4) 12.3% (11.7–12.8) 9.5% (9.0–10.0) 9.0% (8.6–9.4)
Other and unknown 1.5% (1.2–1.7) 1.4% (1.3–1.6) 1.0% (0.9–1.2) 5.3% (4.9–5.7)
Chronic Back Pain 4.4% (3.8–5.0) 6.5% (6.2–6.9) 4.1% (3.8–4.3) **
Osteoporosis 2.4% (2.1–2.8) 2.6% (2.4–2.8) 2.1% (1.9–2.2) 3.5% (3.2–3.8)
Endocrine, nutritional and
metabolic diseases
21.3% (19.9–22.6) 20.0% (19.4–20.6) 16.0% (15.3–16.6) 13.8% (13.3–14.3)
Hyperlipidaemia 12.3% (11.3–13.4) 10.0% (9.5–10.4) 8.2% (7.7–8.6) 7.1% (6.7–7.5)
Diabetes all 6.1% (5.5–6.7) 6.4% (6.2–6.7) 4.6% (4.4–4.9) 5.1% (4.8–5.4)
Type 1 0.7% (0.5–0.9) 0.7% (0.6–0.8) 0.5% (0.4–0.6) 0.7% (0.5–0.9)
Type 2 5.5% (4.9–6.0) 5.8% (5.5–6.0) 4.2% (3.9–4.4) 4.4% (4.1–4.7)
Psychological Problems 16.6% (15.3–17.8) 20.5% (19.8–21.2) 13.7% (13.1–14.2) 17.5% (16.8–18.2)
Depression 10.0% (9.2–10.8) 12.5% (12.0–13.0) 8.0% (7.6–8.4) 8.9% (8.4–9.4)
Anxiety 6.2% (5.4–7.0) 9.3% (8.9–9.8) 5.8% (5.5–6.2) **
Insomnia N/A 2.4% (2.2–2.6) 1.5% (1.3–1.6) N/A
Digestive 9.6% (8.8–10.4) 9.9% (9.4–10.3) 7.1% (6.7–7.5) 6.2% (5.8–6.6)
GORD 7.5% (6.8–8.2) 6.9% (6.5–7.2) 4.9% (4.6–5.2) N/A
Respiratory Disease 10.5% (9.7–11.4) 11.1% (10.7–11.5) 7.9% (7.6–8.3) **
Asthma 7.8% (7.1–8.5) 7.1% (6.8–7.4) 5.2% (4.9–5.5) 10.8% (10.2–11.4)
COPD 2.5% (2.1–2.9) 2.4% (2.2–2.6) 1.6% (1.5–1.7) 2.6% (2.3–2.9)
Malignant Neoplasms 3.1% (2.7–3.6) 3.4% (3.2–3.6) 2.8% (2.6–3.0) 1.6% (1.4–1.8)
Note: GORD = gastro oesophageal reﬂux disease, COPD chronic obstructive pulmonary disease
** Inclusions used by NHS too different for reasonable comparison, N/A Results not available
doi:10.1371/journal.pone.0172935.t004
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estimating population prevalence of chronic conditions. However this revised estimate of the
population prevalence multimorbidity remains significantly higher than the 23.0% estimated
by the 2014–15 NHS[17]. This difference is probably due to the NHS only counting a selected
list of chronic conditions while our study counted all chronic conditions. Previous research
has shown that counting all chronic conditions provides the most reliable estimates of multi-
morbidity[27]. The issues of respondent accuracy noted above and the restricted list of chronic
conditions used by the NHS, suggest that our estimates of multimorbidity may be more reli-
able than those of the NHS.
Our estimate of multimorbidity infers that 6.2 million patients would have been eligible to
enrol in a Health Care Home’ if eligibility was based on two or more diagnosed chronic condi-
tions, as suggested from earlier Government statements. Our estimate of the proportion of
patients at GP encounters with complex multimorbidity (30.4%) was higher than that found in
our earlier study[7] (27.4%) and lower than that estimated by Brett et al (34.5%) among
patients attending two GP practices in Perth[8].
Our study does have limitations. We have assumed that people who did not see a GP in the
previous year, did not have a diagnosed chronic condition. This assumption may not hold for
conditions such as mild asthma where a patient may not need to see a GP in a single chosen
Fig 1. Prevalence of the number of chronic conditions among patients at encounters and people in the Australian population. (Note to go below
Fig 1). Note: ICPC-2 chapters used as a proxy for body system.
doi:10.1371/journal.pone.0172935.g001
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year. This may explain why our prevalence estimate for asthma was lower than that of the
NHS.
The apparent over-representation of older patients attending a GP at least once in our
study is probably due to comparing our sample to only the Medicare data. Medicare data
would not include patients who only claimed DVA services that year. However, since patients
who are covered by the DVA can also claim through Medicare, we could not combine those
who made at least one claim in both datasets for fear of double counting the same patients.
The DVA data is heavily skewed towards older patients (veterans of World War Two and their
partners). It is likely that our estimated distribution of patients who attend general practice at
least once in the previous year is actually far closer to reality than is implied by our comparison
with Medicare claims data alone.
Our estimate of the average number of GP visits (4.54) for patients who had seen a GP at
least once, was significantly lower than the average number of Medicare GP consultation items
claimed per person, by those who claimed at least once (6.8 in 2014–15[31]). This means that
the patients and GPs were under-reporting the number of GP visits made in the previous 12
months. This may be because the patient had seen another GP but had forgotten the visit(s)
and/or did not wish the current GP to know of it. This under-reporting could have affected
our national prevalence estimates if there was a bias for high or low attenders to under-report
more often, and this cannot be assessed from the data.
Conclusion
Of the three approaches we have tested to date, this study provides the most accurate method
for estimation of population prevalence of chronic conditions using the GP as an expert inter-
viewer, by adjusting for each patient’s reported attendance. The results provide the ground-
work for the Australian Federal Government to cost and plan the rollout of the ’health care
homes’ initiative. If this initiative results in GPs enrolling high-need patients with multiple
chronic conditions, the GPs will need to be properly compensated for switching from full fee-
for-service to partial capitation. Further research is underway, examining the extent to which
measures of multimorbidity can provide a structure for scientific calculation of appropriate
capitation payments.
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The paper in this chapter introduced the second survey of my thesis, Australia’s largest 
study of multimorbidity. This survey allowed me to improve my method for estimating 
population prevalence from general practice data by overcoming the limitation of not being 
able to adjust for high and low attenders in the earlier method. I estimated the prevalence 
of multimorbidity and complex multimorbidity including all the diagnosed chronic 
conditions among patients in the sample, as recommended by the guidelines outlined in 
chapter 4. 
However, a practical measure of multimorbidity should predict a wide range of outcomes 
such as health resource utilisation, complexity of care, quality of life and mortality. As 
discussed in this chapter, the second survey included a question asking how often the 
patient had visited a GP in the previous 12 months. The second survey also added a 
changing set of questions about the patient, including patient complexity of care and 
severity of illness. The next study examines how well multimorbidity predicts patient GP-
visit rate. The end of the next chapter also provides early results on how well it predicts 
patient complexity of care. 
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Chapter 7: Predicting patient use of general 
practice services in Australia  
(Paper submitted March 2017, under review: Australian and New Zealand Journal of Public 
Health) 
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Abstract 
Objective: To develop a parsimonious model that predicts patient visit rate to general 
practice.  
Methods: In 2012 to 2016, 1,449 randomly selected general practitioners (GPs) recorded 
details for 43,501 patients in sub-studies of the Bettering the Evaluation and Care of Health 
(BEACH) program. Details included patient characteristics, all diagnosed chronic conditions 
and number of GP visits in previous 12 months. Models predicting patient GP visit rates 
were tested. 
Results: Number of diagnosed chronic conditions alone accounted for 25.48% of variance 
(R-square) in number of visits in previous year. The final parsimonious model accounted for 
27.58% of variance and estimated that each year: female patients had 0.52 more visits; 
Commonwealth Concessional Health Care Card holders had 1.06 more visits; for each 
chronic condition patients made 1.06 more visits; and visit rate initially decreased with age 
before increasing exponentially. 
Conclusions: Number of diagnosed chronic conditions was the best individual predictor of 
the number of GP visits. Adding patient age, sex and concession card status explained 
significantly more variance. 
Implications for public health: This model will assist health care planning by providing an 
accurate prediction of patient use of GP services. 
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Predicting patient use of general practice services in 
Australia  
The ageing of the population and an increasing prevalence of multimorbidity, are expected 
to place greater demands on the Australian health system.1-3 Being able to accurately 
predict patient use of general practice services is important for health workforce planning. 
Traditionally, in Australia, a simple ratio of full time equivalent general practitioners (GPs) 
to population has been used to estimate adequacy of GP supply for a geographic area.4 
However this method fails to consider differing levels of health care demand by different 
types of patients. A patient’s age and sex have been shown to influence the length of their 
GP encounters5 and the number of times they see a GP in a year.2 For example, on average, 
an 85 year old male patient will spend 291 minutes with a GP over a year while his 12 year 
old granddaughter will spend only 28 minutes.2 This variance is important as inner regional 
areas of Australia have higher proportions of older residents than other areas and therefore 
have higher demand for GP services than an average GP:population ratio would estimate.2 
The ability to predict patient demand would improve the accuracy of policy planners' 
projections of required GP workforce. 
Australian GPs are paid on a fee-for-service basis, covered (fully or in part) by a universal 
health insurance scheme called Medicare. GP remuneration is primarily based on the 
number of times they see patients. The Australian Federal Government is planning a trial of 
'Health Care Homes' in which GPs will receive capitation payments for managing the 
chronic conditions (but not non-chronic conditions) of enrolled patients.6 Ideally, the 
capitation payment should at least reflect the amount the GP would have earned through 
fee-for-service for managing that patient. Each patient will be assigned to one of three tiers 
of “complexity and need” with higher GP remuneration for care of those in higher tiers 
($591 tier 1, $1,267 tier 2 and $1,795 tier 3).6 However, there is concern that the planned 
tier assignment tools may not accurately reflect patient demand for GP care.7 If it does not, 
GPs may choose not to enrol in the program, or those who do may only enrol patients with 
relatively low demand for services. An accurate measure of patient demand would provide 
a structure on which an appropriate reimbursement for GPs could be calculated.  
In 2000, Knox et al found a range of patient characteristics were associated with the 
number of times a patient sampled at a GP encounter had seen a GP in the previous year.8 
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After adjustment for other factors, characteristics related to visit rate were: patient age 
(older patients visiting more often); holding a Commonwealth Concession Health Care Card 
(CCHCC) (attended more often) and number of chronic conditions (increase in visits for 
every additional chronic condition). Patient sex was not independently associated. 
Since Knox’s study, the population has aged considerably, with a corresponding increase in 
the number of GP consultations with patients aged 65 years or older.9 To better identify 
future demand, geographic areas of need and appropriate capitation payments, a 
scientifically based tool is required to predict patient demand for GP services. We therefore 
examined known predictors of patient use of GP services with a particular focus on the 
number of diagnosed chronic conditions in an individual patient. For ease of reading, we 
will refer to 'diagnosed chronic conditions' simply as ‘chronic conditions’. 
Multimorbidity is the term commonly used to describe patients with multiple chronic 
conditions.10 While multimorbidity has commonly been measured by counting the number 
of individual conditions, some researchers believe there are advantages in counting the 
number of ‘groups’ of similar conditions.10 Examples of ‘groups’ of conditions are the 
domains of the Cumulative Illness Rating Scale (CIRS),11 the chapters of the International 
Classification of Primary Care Version 2 (ICPC-2)12 or those of the International Classification 
of Diseases Version 10 (ICD 10).13 Previous research has shown that using CIRS domains, 
ICPC-2 or ICD-10 chapters, the same patients were identified as having three or more 
domains/chapters with at least one chronic condition in each.10 Using groups of conditions 
may improve reliability of results. For instance, two inter-related conditions (e.g. chronic 
ischaemic heart disease and myocardial infarction) may be recorded as two separate 
conditions by one clinician while another may consider them to be a single entity. Only 
counting the body system of these conditions once would ameliorate labelling 
inconsistency. In another scenario, a condition such as hypertension, that over time 
develops into complicated hypertension, might then receive a slightly different label or 
code in the medical record. Once again, counting only the body system to which the 
conditions were classified would remove the double-count. 
It has been argued that the diagnosis of a chronic condition in a body system previously 
free of any condition will have a greater impact on the patient’s care than the diagnosis of 
an additional chronic condition in a body system.10 This is because chronic conditions in 
different body systems are more likely to compete for treatment, while treatments for 
those in the same system are more likely to be complementary.10 While the number of 
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chronic conditions has been shown to be a predictor of patient visits to GPs,8 the predictive 
value of the number of different body systems has yet to be tested. In future we will refer 
to the concept of 'body systems with at least one chronic condition classified' simply as 
'body systems'. 
In a separate analysis Knox et al examined the effect of each of nine prevalent individual 
chronic conditions.8 After accounting for other significant variables, including total number 
of chronic conditions, they found that patients attended more often if they had depression, 
anxiety or chronic back pain. Ideally, a wider range of chronic conditions should be tested 
for their independent effect on visit rate. 
Some researchers believe that both the number of chronic conditions and the severity of 
illness are important.14,15 The CIRS11 is a widely used example that includes severity of 
illness in the measurement of multimorbidity. Without accounting for severity of illness, a 
patient with well controlled hypertension, hyperlipidaemia and mild asthma (and no 
others), and another patient with the same conditions, but severe and uncontrolled, would 
be considered to have the same level of multimorbidity. However, whether a patient 
severity of illness is an independent predictor of GP use has not yet been established. 
The aim of this study is to develop a parsimonious model that predicts patient visit rate to 
GPs, by examining the predictive power of: 
• the number of chronic conditions. 
• the number of body systems. This is to test whether a count of body systems is as 
good a predictor as a count of individual conditions. 
• patient age and sex 
• the patient characteristics examined by Knox et al(8) with the addition of number 
of body systems  
• the presence of specific chronic conditions. We will examine a wider range than 
Knox et al.8 
• overall severity of patient illness. 
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Methods 
These data were collected through a series of sub-studies of the BEACH program.16 BEACH 
was a continuous, national cross-sectional study of Australian general practice activity 
running from April 1998 to March 2016. Full methods of the BEACH program are described 
in detail elsewhere.16 In summary, each year an ever-changing, random sample of about 
1,000 GPs participated, each recording information about the content of encounters with 
100 consecutive consenting patients, on structured paper forms. 
BEACH sub-studies allowed for collection of patient-based data not necessarily related to 
the encounter. The methods for this sub-study are described in greater detail elsewhere.7 
In brief, 1,800 participating GPs over twelve five-week recording periods between 27th 
November 2012 and 28th March 2016, collected information on each of a preordained 30 
consecutive patients within their 100 BEACH encounter forms. GPs recorded the number of 
times the patient had seen any GP in the previous 12 months (including the recorded visit) 
and all diagnosed chronic conditions in that patient. For ease of completion, tick boxes 
were provided for 28 prevalent chronic conditions and additional blank spaces were 
supplied for free text recording of other chronic conditions. The order of listed chronic 
conditions was changed throughout the sub-studies to reduce any order effect bias. 
Examples of the instruction sheet and the recording form provided to the GPs have been 
published elsewhere.16 The final question varied over the sub-studies. For two of the 18 
sub-studies the GPs were also asked to rate the patient’s overall severity of illness (based 
on their clinical opinion) using a 0-10 point Likert scale where ‘0’ is least and ‘10’ is most, 
severe. 
The instructions given to the GP on how to measure patient’s severity of illness were based 
on a modification of the Duke University Severity of illness (DUSOI) scale.17 GPs were 
instructed to “Please mark the line with an X to indicate how you would rate this patient’s 
overall severity of illness during the past week.” For guidance GPs were told that “Lowest 
severity applies to someone whose total set of diagnoses results in the fewest symptoms 
and complications, the least disability and threat to life, the least need for treatment, and 
the best expected response to treatment if needed. 
Highest severity applies to someone whose total set of diagnoses results in the most 
symptoms and complications, the most disability and greatest threat to life, the most need 
for treatment, and the worst expected response to treatment.” 
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Data analysis 
Where number of GP visits in previous year was not recorded, the patient was assigned the 
average number of visits for patients of the same sex, in the same 10 year age group, with 
the same number of chronic conditions (0,1,2,3+ chronic conditions). 
The likelihood of a patient being sampled was directly related to how often they visited a 
GP. Frequent attenders were more likely to be sampled than infrequent attenders, since 
they account for more GP encounters. We adjusted for low or high attenders by weighting 
each patient’s data by the number of times they were said to have seen a GP in the 
previous year, with low attenders being weighted up and high attenders being weighted 
down. The resulting weighted data set represents those patients who visited a GP at least 
once in the previous year, which we will call ‘active patients’. 
Patient Indigenous status included patients who self-identified as Aboriginal and/or Torres 
Strait Islander. A patient’s relative level of advantage/disadvantage was determined using 
the Australian Bureau of Statistic’s (ABS) Index of Relative Socio-Economic Advantage and 
Disadvantage (IRSAD),18 patient residential postcodes in the lower 5 deciles being 
considered ‘Disadvantaged’ and postcodes in the upper 5 deciles considered ‘Advantaged’. 
Patient rurality was defined using the ABS‘s Australian Statistical Geography Standard 
(ASGS),19 their residential postcode being classified ‘Major city’ or ‘Regional/remote’. 
Different body systems were represented using ICPC-2 Chapters.12 A body system was only 
counted once per patient, even if the patient had multiple chronic conditions classified to 
one body system. 
Table S1 shows the models we tested and the initial explanatory variables for each model. 
The number of times patients saw a GP in the previous year was the outcome for all 
models. The R-square value was used to measure how well each model predicts GP 
attendance. An adjusted R-square was calculated for all models with more than one 
explanatory variable. Previous results on the relationship between age and patient GP visit 
rate showed that the rate decreased from very young patients to adolescents before 
increasing steadily with older age,2 suggesting likelihood that the relationship was quadratic 
in nature. This was also tested (i.e. age2). 
Statistically insignificant variables were removed through backwards elimination. Due to 
the large sample size, we used p<0.01 rather than p<0.05 as our level of significance. Any 
variable removed that had a significance of p<0.05 will be reported in the text.  
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Table S1: Initial variables included in models tested 
Model 
Number 
Variables initially included in models as explanatory variables 
Model 1 Number of chronic conditions 
Model 2 Number of body systems (ICPC-2 chapters) 
Model 3 Age, Age2 and sex 
Model 4 Number of chronic conditions 
Number of body systems 
Age  Age2  Sex 
Indigenous status (self-identified) 
Level of relative disadvantage/advantage (1-5 and 6-10 on IRSAD) 
Major city Vs regional/remote area (ASGC) 
Commonwealth Concession Health Care Card (CCHCC) holder  
Model 4A All variables from Model 4 with the addition of the presence/absence of 
each the following: 
Anxiety       Asthma    
Atrial fibrillation      Chronic back pain  
Chronic obstructive pulmonary disease   Chronic renal failure  
Congestive heart failure     Dementia 
Depression      Gastroesophageal reflux disease 
Glaucoma      Hyperlipidaemia  
Hypertension      Hyperthyroidism  
Hypothyroidism     Insomnia 
Ischaemic heart disease     Malignant neoplasm 
Obesity       Osteoarthritis 
Osteoporosis      Other arthritis  
Peripheral vascular disease     Rheumatoid arthritis  
Sleep apnoea       Stroke/cerebrovascular accident 
Type 1 diabetes      Type 2 diabetes 
Model 4B
  
All variables from Model 4 with the addition of: 
Patient overall severity of illness 
 
Models 4A and 4B were extensions of Model 4. In Model 4A, the presence/absence of each 
of the 28 common chronic conditions listed on the recording form was added. In Model 4B 
we added GP assessment of patient severity of illness from the sub-sample previously 
described. As the data for Model 4B is a subset of the data used in the original test of 
Model 4, we first retested Model 4 with only this subset to ensure that any changes in 
variables retained in Model 4B (compared with Model 4) were the result of inclusion of 
severity of overall illness. 
BEACH sub-studies have a single stage cluster design, with each GP having 30 patients 
clustered around them. Survey procedures in SAS version 9.3 (SAS Inc, Cary, NC, USA) 
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were used to account for the effect of this clustering. The BEACH program and all sub-
studies were approved by the Human Research Ethics Committee of the University of 
Sydney (Reference number 2012/130).  
Results 
Completed recording forms were returned by 1,449 GPs of the 1,800 (80.5%) recruited. 
There were 43,501 patients in this sample, of whom 41,722 (95.9%) had a reported number 
of GP visits in the previous year. These patients had an average 9.66 GP visits in that time, 
and after weighting, we estimated that active patients had an average 4.54 GP visits over 
the previous 12 months. 
The age-sex distribution of the sample is reported elsewhere.7 In summary it was similar to 
that of patients at all Medicare or Department of Veteran Affairs (DVA) claimed GP 
consultations (precision ratio range 0.80-1.14). After weighting for each patient’s 
attendance over the previous year to create our ‘active patients’ sample, the age-sex 
distribution was similar to that of all patients who had claimed at least one Medicare GP 
service item in the previous year.  
 
Patients at encounters R-square = 20.36% (p<.0001), Active patients R-square = 25.48% (p<0.0001) 
0 1 2 3 4 5 6 7 8 9 10+
Patients at encounters 5.0 7.7 9.4 11.4 13.1 14.6 16.9 17.1 18.7 19.8 22.0
Active patients 2.9 4.4 5.6 6.9 8.3 9.3 10.9 11.7 13.3 13.9 15.1
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Figure 1: Number of GP visits in the previous 12 months by the 
number of individual diagnosed chronic conditions
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Model 1 
Among sampled patients the number of GP visits in the previous 12 months (visit rate) 
significantly increased with the number of chronic conditions, from 5.0 visits for sampled 
patients with no chronic conditions to 22 visits for those with 10 or more. For active 
patients, the average visit rate increased from 2.9 for those with no chronic conditions to 
15.1 for those with 10 or more. A simple linear regression model found that the number of 
chronic conditions alone accounted for 20.36% of all the variance (R-square) in the visit rate 
of patients at encounters and 25.48% of the variance among active patients (Figure 1). 
Model 2 
The GP visit rate increased with the number of body systems, from 5.0 visits for sampled 
patients with no chronic conditions to 20.1 visits for those with at least one condition in 
eight or more different body systems. For active patients, the average visit rate increased 
from 2.9 for those with no chronic conditions to 15.2 for those with chronic conditions in 
eight or more different body systems. A simple linear regression model found that the 
number of body systems accounted for 18.77% of all the variance (R-square) in the GP visit 
rate of sampled patients and 23.91% of the variance among active patients (Figure 2). 
 
Patients at encounters R-square = 18.77% (p<.0001), Active patients R-square = 23.91% (p<0.0001) 
0 1 2 3 4 5 6 7 8+
Patients at encounters 5.0 8.1 10.4 13.1 15.0 17.5 19.7 20.4 20.1
Active patients 2.9 4.5 6.1 8.0 9.7 11.8 13.5 14.0 15.2
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Figure 2: Number of GP visits in the previous 12 months by 
the number of body systems affected by at least one 
diagnosed chronic condition
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Model 3 
For each of the four decade age-groups from 10 to 49 years, sampled female patients had a 
significantly higher GP visit rate than male patients. Among females, the visit rate increased 
significantly with age, especially after the 60-69 years age group. Among male patients the 
visit rate decreased between the 0-9 and 10-19 years age groups, but then increased 
significantly with age. A regression model found that the sex of patient and the age of 
patient accounted for 9.24% of the variance in the visit rate of sampled patients. When age2 
was added to the model, the amount of variance explained increased to 10.15% (Figure 
3).The pattern for active patients was similar. For the six decade age groups from 10 to 69 
years, female active patients had significantly higher visit rates on average than active male 
patients (Figure 4). From the age group of 10-19 years, the GP visit rate increased 
significantly with age for female active patients. For active male patients the visit rate 
decreased between the age groups of 0-9 years and 10-19 years before increasing with 
older age. A regression model showed that the sex and the age of patients accounted for 
11.23% of all the variance in GP visit rate for active patients. When age2 was included in the 
model, the variance explained increased to 14.28%. The adjusted R-square of this model 
was very similar at 14.27% (Figure 4). 
 
Patient age and sex: R-square = 9.24% (p<.0001) Adjusted R-square 9.23% 
Patient sex, age, and age2: R-square = 10.15% (p<.0001) Adjusted R-square 10.14% 
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
Male 6.1 4.8 5.4 7.0 8.0 9.1 10.0 12.5 15.4 16.1
Female 5.8 5.8 7.3 8.1 9.2 9.6 10.6 13.0 15.5 17.4
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Figure 3: Number of GP visits in the previous 12 months among 
patients at encounters - by patient age and sex (95% CIs)
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Patient age and sex = R-square: 11.23% (p<0.0001) Adjusted R-square 11.22% 
Patient sex, age, and age2: R-square = 14.28% (p<0.0001) Adjusted R-square 14.27% 
 
Model 4 
Through backward elimination, patient Indigenous status, patient relative advantage/ 
disadvantage, number of body systems, and patient rurality were removed. Patient rurality 
was the last to be removed, with a p-value of 0.0284 and an effect size of 0.334 more visits 
for major city patients. The final model accounted for 27.59% of the variance in GP visit 
rate. The adjusted R-square was very similar (27.58%). After adjusting for all other 
significant variables: female patients had about half a visit (0.52) more per year than male 
patients; those with a CCHCC had 1.06 more GP visits in the year than those without; the 
number of visits initially decreased with age before increasing exponentially; for each of 
their chronic conditions patients made 1.06 more visits in the year (Table 1). 
Model 4A 
After adding to the model each of the 28 individual listed chronic conditions (see Box 1), 
backwards elimination removed all bar seven: hyperlipidaemia; hypertension; peripheral 
vascular disease; glaucoma; asthma; obesity; and atrial fibrillation. The number of body 
systems remained significant in this model. Variables removed that had a significance of 
p<0.5 were: patient rurality (p=0.0328 and effect size of 0.322 extra visits for ‘major city’ 
0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90+
Male 3.3 2.7 2.7 3.1 3.8 4.4 5.3 7.5 9.7 9.6
Female 3.3 3.0 3.8 4.2 4.6 5.0 5.9 8.0 9.8 11.2
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Figure 4: Number of GP visits in the previous 12 months among 
active patients - by patient age and sex (95% CIs)
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patients) and the presence of rheumatoid arthritis (p=0.0360 and effect size of -0.008). 
While statistically significant, the effect of each retained specific individual condition on the 
GP visit rate was small, ranging from 0.003 fewer visits for a patient with asthma, to 0.014 
additional visits for one with atrial fibrillation. This model accounted for 28.40% of the 
variance in the number of times active patients saw a GP in the previous year, with an 
adjusted R-square of 28.37%.(Table 1). 
Table 1: Final variables models 4, 4A and 4B 
Parameter Estimate (Visits) t-Value p-Value 
Model 4 (p<0.0001) R-square = 27.59%, Adjusted R-square = 27.58% 
Intercept 2.789 40.63 <0.0001 
Female (over male) 0.516 11.56 <0.0001 
Age (years) -0.032 -8.02 <0.0001 
Age2 (years) 0.00052 9.13 <0.0001 
Commonwealth Concession Health Care Card 1.056 14.43 <0.0001 
Number of chronic conditions 1.061 38.82 <0.0001 
Model 4A (p<0.0001) R-square = 28.40%, Adjusted R-square = 28.37% 
Intercept 2.735 40.14 <0.0001 
Female (over male) 0.495 11.04 <0.0001 
Age (years) -0.030 -7.52 <0.0001 
Age2 (years) 0.0005 8.59 <0.0001 
Commonwealth Concession Health Care Card 1.031 14.06 <0.0001 
Number of body systems 0.355 4.75 <0.0001 
Number of chronic conditions 0.980 14.75 <0.0001 
Atrial fibrillation 0.014 4.79 <0.0001 
Peripheral vascular disease 0.009 2.65 0.0082 
Hyperlipidaemia -0.012 -9.59 <0.0001 
Hypertension -0.005 -5.56 <0.0001 
Glaucoma -0.008 -3.07 0.0022 
Obesity -0.006 -4.04 <0.0001 
Asthma -0.003 -2.85 0.0044 
Model 4B (p<0.0001) R-square = 19.97%, Adjusted R-square = 19.88% 
Intercept 3.797 7.95 <0.0001 
Age (years) -0.065 -3.33 0.0010 
Age2 (years) 0.0009 3.97 <0.0001 
Commonwealth Health Care Card 1.744 6.71 <0.0001 
Indigenous -2.310 -2.65 0.0088 
Number of chronic conditions 0.817 9.49 <0.0001 
 
  
93 
Model 4B 
Of the 250 GPs who were sent recording forms that included the severity of illness 
question, 211 (84.4%) completed the sub-study for 6,339 patients. Of these, 4,610 (72.7%) 
had at least one chronic condition, for whom a GP-estimated overall severity of illness had 
been requested. GPs reported severity for 4,461 patients (96.8% of those eligible). The 
average active patient with at least one chronic condition had an overall severity of illness 
score of 3.5/10. 
After retesting the variables from Model 4 on this sub-sample, backwards elimination 
removed: patient sex; patient advantage/disadvantage; number of body systems; and 
patient rurality. This model accounted for 19.97% of the variance (R-square) in active 
patients' GP visit rate. The adjusted R-square was similar at 19.88%. 
After adding severity of illness to the model, the same variables were removed by 
backwards elimination, as was severity of illness. Severity of illness was the last variable to 
be removed with a p-value of 0.0139 and an effect size of 0.172. The final model is 
presented in the lower third of Table 1.  
Discussion 
Number of chronic conditions was the best predictor of GP visit rate in the previous 12 
months, far better than the age and sex of the patient combined. The number of chronic 
conditions alone accounted for 92.4% of the variance explained by a model including all 
other significant patient characteristics and 89.7% of a model including all significant 
patient characteristics and the presence or absence of individual chronic conditions.  
The model explaining the most variance included significant patient characteristics, the 
number of chronic conditions, the number of body systems, and the presence/absence of 
seven specific chronic conditions. While statistically significant, the effects that the 
presence of specific chronic conditions had on patient visit rate were so small they are 
unlikely to be clinically significant. For example, atrial fibrillation had the largest effect size, 
but a patient would need to have had this condition for 70 years before it resulted in one 
extra GP visit. We therefore conclude that the most practical parsimonious model is Model 
4, which includes patient age and sex, the number of chronic conditions and whether the 
patient held a CCHCC. This more practical model accounted for 97.1% of the variance 
explained by the larger model. 
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The number of body systems was almost as useful in predicting the GP visit rate as the 
number of chronic conditions (Model 2 c.f. Model 1). This suggests that body systems can 
be used in lieu of individual chronic conditions when they are not available or there is 
concern around the robustness of the data. 
The number of body systems was removed from our final parsimonious model (Model 4) as 
it did not significantly explain any more variance than already explained by the count of 
individual chronic conditions. However, the number of body systems remained significant in 
the model that included adjustment for the presence/absence of specific conditions (Model 
4A). Further investigation is required to assess why body systems were significant in Model 
4A, especially since the effect size of the presence of specific individual conditions was so 
small. 
Our results largely reflect those of Knox et al8 which found that the number of chronic 
conditions, patient age and holding a CCHCC all increased the patient GP visit rate. 
However, unlike Knox et al we found in our much larger sample that, after adjusting for all 
other confounding variables, female patients attended more often than males. This is likely 
a reflection of higher attendance rates of younger women, often for reproductive issues,20 
many of which would not usually be classed as chronic conditions. 
In Australia, the GP workforce is maldistributed, with fewer GPs in rural and remote than in 
metropolitan areas.2 The Government currently funds several initiatives to attract GPs to 
rural/remote areas.21 We did not find rurality to be a significant predictor of GP visits at our 
p<0.01 level. However, if we considered it significant at the p<0.05 level, it showed that 
patients in rural areas attended less often. Lower visit rates may reflect restricted access to 
care caused by the current GP shortages in rural areas.2 Including rurality in any model to 
predict required GP workforce or to calculate capitation payment levels would exacerbate 
rural patient healthcare disadvantage and would be antithetical to Government initiatives 
currently in place. For similar reasons no model should pay less for the care provided to 
Indigenous patients even though Indigenous status was a significant predictor of fewer GP 
visits in Model 4B. 
Severity of illness did not significantly add to our model at the p<0.01 level. However, if 
included at the p<0.05 level, its effect on GP visit rate was minimal, with a patient needing a 
6 point increase in their overall severity of illness to generate one more GP visit in the year. 
Further, it may be difficult for a GP to objectively judge a patient’s severity of illness 
knowing they will be reimbursed at a higher rate if the patient is classed as more severe.  
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The Health Care Homes model will probably result in the transfer of some services currently 
provided by GPs, to other health professionals in the team. While our model predicts the 
number of GP visits by a patient over a year, in the Health Care Homes model it is likely to 
represent overall patient demand for services from general practices. 
This study does have a limitation. Our estimate of the average number of GP visits for 
active patients (4.54) was significantly lower than the average number of Medicare GP 
consultation items claimed by people who made at least one claim (6.8 in 2014–15).9 As 
discussed in our earlier paper, this means that our GPs and patients were likely to have 
under-reported the number of GP visits in the previous 12 months.7 This could be due to 
the patient seeing another GP that they had forgotten and/or did not wish to disclose to 
the current GP. If the under-reporting was evenly and proportionally spread among high 
and low attenders, it would be possible to weight the results of our model up to reflect the 
observed number of GP visits. However, if the under-reporting was skewed in some way, it 
is unlikely that reweighting the data would be accurate. The final model should be validated 
on another independent data source. 
Conclusion 
While there are multiple factors that influence the number of times a patient sees a GP in a 
year, our study found the most parsimonious model included patient age and sex, the 
number of chronic conditions, and whether the patient holds a Commonwealth Concession 
Health Care Card. The results of this study will assist with workforce planning and the 
proposed trial of capitation payments for GP care of diagnosed chronic conditions in 
enrolled patients. Further research is planned to test whether this model also predicts 
patient complexity of care.  
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Further discussion – international comparisons 
Due to a restricted word limit and the parochial nature of the Australian and New Zealand 
Journal of Public Health, in this paper I focussed my Introduction and Discussion on the 
Australian context. However, these results support similar research that was undertaken 
around the same time. 
A study in Germany found a linear relationship between the number of diagnosed chronic 
conditions and the number of contacts the patient had with physicians in ambulatory care.1 
They did not find that age was an independent predictor, though this may be because they 
only examined patients aged 65 years and older. 
A study of patients in the UK found that patient age, sex and the number of chronic 
conditions predicted patient consultation rate.2 However, a study published two years later 
suggested that it was the number of prescribed medications (and not the number of 
morbidities) that predicted future consultations.3 I was unable to test this new result with 
the data I collected through the BEACH sub-studies. Due to space restrictions on the form, 
one could either ask for all chronic conditions diagnosed for a patient, or for all the 
medications the patient was taking, but not both. When attempts to replicate our model 
using an independent data source are undertaken, efforts should be made to also include 
the number of medications the patient is taking.  
Early results from complexity of care sub-studies 
Two of the sub-studies used in survey 2 asked the GP to rate the patient’s complexity of 
care on a 10 point Likert scale. Each form asked the GP to “Mark the line with an X to 
indicate how complex you find the management of this patient”. The instruction sheet that 
accompanied this set of sub-studies provided a more detailed explanation of what was 
meant by ‘complexity of care’. (See Appendix E for full instruction sheet) The explanations 
for this particular question were: 
“This question aims to assess, in your clinical opinion, the complexity of managing each 
patient who has at least one chronic condition. 
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Complexity could be influenced by many factors, including: 
• the mix of conditions 
• overall severity of illness 
• contradictory clinical care guidelines 
• interactions between medications 
• access to other health services 
• patient compliance 
• patient expectations 
• patient cultural background 
• patient health literacy 
• patient socio economic status 
• contradictory advice to patient 
• other environmental factors 
• frailty of the patient 
This list is not exhaustive and not all factors will relate to every patient.” 
I presented early results from this set of sub-studies at the North America Primary Care 
Research Group Conference in Cancun in 20154. I will briefly describe these early results in 
this section. 
Early results 
250 GPs agreed to take part in the sub-studies conducted 6th May-14th July 2014. Of these 
210 GPs returned completed recording packs for a completion rate of 84.0%. Of the 6,309 
patients sampled at these sub-study encounters, 4,402 patients (69.8%) had at least one 
diagnosed chronic conditions and were eligible to answer the complexity of care question. 
GPs provided their judgement of complexity of care for 4,257 of the 4,402 eligible patients 
(96.7%). 
GPs rated the complexity of care as 4.5 out of 10 (95% CIs: 4.3–4.7) for patients at 
encounters with at least one diagnosed chronic condition and (after adjustment) 3.9 (95% 
CIs: 3.7–4.1) for active patients with 1+ diagnosed chronic condition. 
99 
Patient complexity of care increased significantly with the number of diagnosed chronic 
conditions for both patients at GP encounters and for active patients (Figure 5). Number of 
diagnosed chronic conditions accounted for 19.98% of variance (R-Square) in the 
complexity of care of patients at GP encounters and 17.49% in active patients.  
Complexity of care also increased significantly with the number of ‘body systems’ (Figure 6). 
Number of ‘body systems’ alone accounted for 15.72% of variance in the complexity of care 
for patients at encounters and 13.67% in active patients. 
 
1 2 3 4 5 6 7 8 9 10+
Patients at encounters 3.2 4.0 4.6 4.9 5.4 5.8 6.0 6.6 6.9 7.3
Active patients 3.0 3.6 4.2 4.7 5.0 5.6 6.0 6.3 7.0 7.3
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Figure 5: Patient complexity of care by number 
of diagnosed chronic conditions
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Multivariate modelling was performed including the same variables as listed in model 4 
(Table S1) for ‘active patients’. After backwards elimination, the only variable to remain in 
the model was the number of individual chronic conditions with patient complexity of care 
increasing 0.49 for every additional diagnosed chronic condition. Patient CHCC status was 
the last variable to be eliminated with a p value of 0.021 with patients holding a CHCC being 
slightly more complex to care for (0.32 extra). 
Multivariate modelling was then performed including the same variables as listed in Model 
4A (Table S1) for ‘active patients’. After backwards elimination, the final model included the 
number of diagnosed chronic conditions, hypertension, hyperlipidaemia, GORD, asthma 
and chronic renal failure (Table 2). The final model accounted for 19.62% (R-Square) of the 
variance in patent complexity of care, while the adjusted R-Square was 19.50% for the final 
model. Anxiety (p = 0.0487, effect size = 0.0026), Type 1 diabetes (p = 0.0310, ES = 0.0080), 
osteoporosis (p = 0.0217, ES = -0.0046), and CHCC status (p = 0.0176, ES = 0.3173) were the 
last variables to be eliminated. 
1 2 3 4 5 6 7+
Patients at encounters 3.4 4.2 5.0 5.4 6.0 6.6 7.3
Active patients 3.1 3.8 4.6 5.0 5.8 6.3 7.5
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Figure 6: Patients complexity of care by number 
of body systems (ICPC-2 chapters)
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Table 2: Final model predicting patient complexity of care 
Parameter Estimate 
(Visits) 
t-Value p-Value 
Intercept 2.651 19.69 <0.0001 
Number of chronic conditions 0.590 18.56 <0.0001 
GORD -0.0060 -4.53 <0.0001 
Asthma -0.0050 -4.12 <0.0001 
Hypertension -0.0041 -3.75 0.0002 
Hyperlipidaemia -0.0042 -3.18 0.0017 
Chronic renal failure 0.0075 2.98 0.0033 
Discussion 
The number of chronic conditions is the strongest predictor of GP-judged patient 
complexity of care. This parallels the results found for patient GP-visit rate. However, other 
patient characteristics (e.g. patient age and sex and CHCC status) were not found to 
significantly predict complexity of care, though they were for GP-visit rate. While the 
presence/absence of several individual chronic conditions added significantly to the 
statistical model, the effect size of each condition was negligible. In contrast, the presence 
of asthma, hypertension and hyperlipidaemia were significant negative predictors of GP-
visit rate and patient complexity of care. 
As discussed in the Introduction to this chapter, in the Australian Federal Government’s 
planned trial of “Health Care Homes” participating practices will be given a capitation 
payment for the care of each enrolled patient’s chronic conditions. This capitation payment 
will supposedly be based on the “complexity and need” of the patient’s care.5 This chapter 
has shown that the number of chronic conditions is the strongest driver of patient GP-
service use and of patient complexity of care, so it would be the simplest measure by which 
each enrolled patient in the trial could be categorised in terms of ‘complexity and need’.  
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Chapter 8: Discussion 
There is a fear that the projected increase in the number of people living with multiple 
chronic conditions will strain Australia’s healthcare system, with its single disease structure 
unable to provide optimal healthcare for these patients. This has created an urgent need 
for research to assist in the development of evidence based health policy. The prevalence 
of multiple diagnosed chronic conditions, the patterns of coexisting conditions, and the 
wide variety of negative outcomes associated with care of these people need to be 
examined. However, researchers have not been using the same terms or the same metrics 
in their investigations, which limits the generalisability and application of their results. The 
metrics used need to balance the priorities of being: sufficiently specific to be easily 
replicable by other researchers; able to predict a wide array of outcomes; sufficiently 
adaptable to be applied in a range of settings; and pragmatic in terms of resources 
required. 
In response, I have measured the patterns and prevalence of multimorbidity in the 
Australian population using unique methods that I developed. I did so by undertaking the 
largest prospective national study of multimorbidity in Australia using a series of sub-
studies from the continuous BEACH project. I converted this GP encounter data to 
population prevalence data using a method I devised. These results will inform the Primary 
Health Care reform processes currently underway in Australia, and highlight the need for 
holistic care of these patients. They also show the need to improve clinical care guidelines 
so that they take into account the most common comorbidities and possibly create new 
guidelines for the total care of patients with the most common clusters of chronic 
conditions.  
I have shown that the individuals identified with multimorbidity, and therefore the 
estimated prevalence of multimorbidity, changes significantly if researchers alter the: 
population under study; number of chronic conditions studied; definitions of ‘morbidity’; 
and minimum numbers of morbidities required to have multimorbidity. These results will 
help other researchers decide which metrics they will use in their studies of multimorbidity. 
This thesis has shown that multimorbidity is the strongest driver of patient utilisation of GP 
services. I have suggested a measure of complex multimorbidity that identifies people with 
high health care needs, and that could be deployed across various healthcare settings. 
These results will facilitate better targeting of funding based on patient healthcare need. 
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This thesis had six aims, each of which will now be address in detail. 
Converting the prevalence of diagnosed chronic 
conditions among patients at GP-encounters to 
population prevalence (AIM 1) 
While the use of a GP as an expert interviewer/respondent to record the presence of 
chronic conditions among patients avoids the issues of using respondent self-report1-8 or 
chart review5,7,9-12 alone, patients at GP encounters are not representative of people in 
the population. 13,14 This thesis describes the only series of studies that has attempted to 
convert GP-encounter prevalence estimates to reflect population prevalence.  
In the earlier work by Britt et al,15 the method that I employed to convert prevalence 
estimates was crude, making the statistical assumption that in all ages and sexes the 
same proportion of people saw a GP at least once in the year of measurement. The first 
paper of this thesis16 (Chapter 3) outlined an improved adjustment method that took 
into account the difference in the proportion of people in each age-sex group that saw a 
GP at least once in a year. However, this new method did not take into account high or 
low attenders within age-sex group. Therefore this approach overestimated population 
prevalence of the chronic conditions under study (as shown in Chapter 6), because 
within age-sex groups people with more chronic conditions attended more often than 
people with fewer (Chapter 7). Also, this method could not provide a population 
prevalence estimate for any specific age-sex group because the method relied on 
weighting age-sex groups against each other, to create national prevalence estimates for 
the whole population. 
In survey 2, I was able to adjust for each individual patient’s chance of being in my 
sample by collecting the number of times the patient had seen a GP in the previous year 
(Chapter 6).17 This allowed me to adjust for high or low attenders in each age-sex group, 
which provided more reliable population prevalence estimates. This method also had 
the advantage of being able to provide population prevalence estimates for a specific 
age-sex group, since the adjustment was done at an individual patient level rather than 
at the age-sex group level. For example, this final method will allow estimation of the 
prevalence of a specific diagnosed condition among a specific sex (e.g. population 
prevalence of cervical cancer among women) or among a specific age group (e.g. 
prevalence of diagnosed depression among people of working age). 
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While this adjustment method was initially developed so that the BEACH study could 
provide an alternative to the ABS National Health Survey,18 the only source of national 
chronic condition prevalence, the method can be applied to any study that draws its 
sample from patients at general practice encounters or in waiting rooms. All that is 
required is that the number of GP-visits in the previous year be recorded for each 
patient. This method is not restricted to adjusting the prevalence of chronic conditions 
from a patient sample to ‘active patients’ or to the population— it can be used for a 
wide range of health-related topics. Examples might include the proportion of active 
patients who: are currently taking certain prescribed medication; have had a specific 
test ordered; have ever been referred to a certain type of specialist. To adjust the 
measure to the population level, one must be able to assume that whatever is being 
measured requires at least a yearly visit to a GP. This allows one to take the logical step 
that if a patient does not see a GP in a year; they do not have the variable of interest. 
Examples could include the proportion of people in the population who have had a 
medication review performed by a GP in the previous 12 months or the proportion of 
people are currently taking oxycodone that was prescribed by a GP. Finally, this method 
also requires the researcher to know the proportion of each age-sex group in the 
population that visit a GP in a 12-month period. Such information may be difficult to find 
in countries that do not have a single payer system. 
Prevalence of chronic conditions (AIM 2) 
There is a need to measure the prevalence of individual chronic conditions both among 
patients at GP encounters and among people in the Australian population. In Chapter 6, 
I estimated that over two-thirds of patients at GP-encounters had at least one diagnosed 
chronic condition. The extrapolated result suggested that, of the 143 million Medicare 
claimed GP-patient encounters in Australia in 2015–16: about 100 million were with 
patients with at least one chronic condition; about 38 million were with patients with 
hypertension; 32 million were with patients with osteoarthritis, and 24 million with 
those who had diagnosed hyperlipidaemia. While the BEACH annual GP activity books19 
report the management rate of specific conditions at GP encounters, patients with a 
diagnosed chronic condition may not have it managed at every GP encounter. 
Measuring the prevalence of conditions among patients at encounters highlights the 
fact that even though the GP may not be actively managing the condition at this 
particular encounter, they must take the presence of this condition into consideration 
when managing the patient. One can use the encounter prevalence estimates to 
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measure the proportion of GP encounters with patients who have the diagnosed 
condition, at which the condition is managed. I applied this method to people aged 65 
years and over in Table 14.1 of the 2014–15 BEACH annual GP activity book.20 Using 
Type 2 diabetes as an example, I estimated that 19.4% of patients aged 65 years and 
over at GP-encounters had diagnosed Type 2 diabetes. BEACH encounter data estimated 
that Type 2 diabetes was managed at 6.9% of encounters with patients aged 65+. Type 2 
diabetes was therefore managed at 35.8% of the GP-encounters with patients aged 65+, 
who had diagnosed Type 2 diabetes. From my data, we also know that on average, 
‘active patients’ aged 65+ with Type 2 diabetes visited their GP 9.3 times a year. This 
suggests that Type 2 diabetes was managed by a GP around 3.3 times a year on average 
for each of these patients.  
Knowing the proportion of people with a specific diagnosed chronic condition will 
improve health resource planning, by providing guidance for more accurate allocation of 
disease-specific resources (such as medications, specialists, and medical equipment). 
Using my final weighting method, I estimated that in 2015–16 about 4 out of 10 (i.e. 
about 10 million) people in the Australian population had at least one diagnosed chronic 
condition. Further, my results suggest that in that year, there were about 2.9 million 
people with diagnosed hypertension, 2.3 million with diagnosed osteoarthritis and 2.0 
million with diagnosed hyperlipidaemia. 
The effect different methods of measuring 
multimorbidity has on who is identified as having 
multimorbidity (AIM 3) 
The way in which multimorbidity has been researched has varied widely between 
studies. The definition of multimorbidity has ranged from the extremely comprehensive 
European General Practice Research Network’s definition,21 through the common 2+ 
chronic conditions definition,22,23 to my definition of complex multimorbidity.24 The 
estimated prevalence of multimorbidity has ranged from 3.5%25 to 98.5%26 between 
studies. It had been hypothesised that it is the methods and definitions used in the 
measurement of multimorbidity that are greatly affecting which individuals are 
identified as having multimorbidity, and therefore the multimorbidity prevalence 
estimates.27-29  
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This thesis has shown that the proportion of people identified as having multimorbidity 
is independently affected by multiple factors. I was able to determine the effects of each 
of these variables by using a single large prospective study allowing me to control for all 
other variables, something that is not possible in systematic reviews. 
The first issue to consider when measuring multimorbidity is the study population. I 
have shown that there are significant differences between patients at GP encounters, 
‘active patients’ (and ‘active patient’ lists) and the population. Patients at GP-encounters 
have a significantly higher prevalence of individual chronic conditions and 
multimorbidity than people in the wider population.17 Researchers need to be mindful of 
this when generalising their results from clinical samples. 
All the other factors in how multimorbidity is defined and measured are interrelated, 
with the biggest differences in prevalence estimates being dependant on whether 
multimorbidity was defined as 2+, or 3+, morbidities. Overall, using the 2+ definition 
provides more statistical sensitivity and provides reliable results across methods, while 
the 3+ definition provides greater specificity and identifies patients with higher resource 
use and complexity of care. 
My results show that the prevalence of people identified with multimorbidity defined as 
2+ would be similar across studies, even if those studies had major methodological 
differences between them. For example, defining multimorbidity as 2+ morbidities 
identified a similar proportion of patients as having multimorbidity when the morbidities 
being counted were individual chronic conditions or groups of chronic conditions (such 
ICPC-2 chapters). Defining multimorbidity as 2+ also allows comparison between studies 
that include all diagnosed chronic conditions and those that only consider a limited 
number of chronic conditions. However, I also found that using 2+ as the definition of 
multimorbidity identifies too large a proportion of people to be useful, especially among 
older age groups. 
Conversely, when multimorbidity is defined as 3+, the number of people identified with 
multimorbidity changes significantly depending on the methods used to measure it. For 
example, significantly more people were identified as having multimorbidity 3+ when 
individual chronic conditions were counted, than when the number of groups of 
conditions was counted. Using the 3+ definition also identified far fewer people with 
multimorbidity when the number of conditions considered was limited, than when all 
diagnosed chronic conditions were considered.  
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However, the 3+ definition has several advantages over the 2+ definition. The 3+ 
definition identifies patients with higher GP visit rates and provides far greater 
specificity than the 2+ definition, especially among older patients. Early results from my 
next study suggest that compared with the 2+ definition, the 3+ definition identifies 
patients whose care is more complex.30  
Using a higher minimum number of morbidities than two when defining multimorbidity, 
may align more closely with how clinicians think of multimorbidity. While there have 
been no formal publications investigating this hypothesis, it was demonstrated by 
Professor Martin Fortin during a presentation on multimorbidity at the 2011 North 
America Primary Care Research Group Annual Meeting.31 He asked the clinicians in the 
audience to stand up and to imagine a patient of theirs with multimorbidity. He then 
asked them to sit down if the patient had only 2 chronic conditions, and then asked 
those who were thinking of a patient with 3 chronic conditions to sit and so on. Very few 
clinicians were thinking of a patient with only 2 conditions, and most were thinking of 
patients with 5 or 6 chronic conditions. It makes sense that clinicians would imagine a 
patient with many chronic conditions, as my results suggest they would be regular 
visitors whose care is complex. A more rigorous scientific study is required to confirm or 
dismiss this hypothesis. 
Due to these advantages, I believe researchers and policy makers should agree to use a 
higher minimum than two morbidities when defining multimorbidity. If it is agreed that 
a higher minimum, (e.g. 3+) must be used in defining multimorbidity, my results show 
that more stringent standards are going to be required across studies if results are to be 
comparable. Ideally as many chronic conditions as possible should be considered. The 
minimum number of conditions considered would need to be significantly higher than 
those suggested by either Fortin et al28 or Diederichs et al,29 as using their minimum 
suggested numbers identifies only a fraction of the number identified when all chronic 
conditions are considered.(Chapter 4) 
A choice will also need to be made on whether the ‘morbidities’ counted are individual 
conditions or groups of conditions, as counting individual chronic conditions identifies 
far more people with multimorbidity than counting groups of chronic conditions when 
multimorbidity is defined as 3+.  
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A method to measure multimorbidity in Australia 
(AIM 4) 
In this thesis I have suggested a definition of multimorbidity that counts groups of 
chronic conditions based on the body systems to which they are classified. I defined the 
concept of ‘complex multimorbidity’ (from Chapter 4), as the “co-occurrence of three or 
more chronic conditions affecting three or more different body systems within one 
person without defining an index chronic condition.”24 I believe this would be a simple 
metric for identification of high need patients. Counting the number of body systems: 
reduces the chance of double counting the same individual condition recorded under 
multiple labels; facilitates estimation of the number (and types) of specialists likely to be 
involved in the care of the patient or sub-population; and helps identify patients who 
may require assistance coordinating the care provided to them by a range of other 
health professionals.  
While using the chapter structure of ICPC-2 or ICD-10 may seem a simplistic way of 
grouping chronic conditions, in this thesis I have shown that using either of these two 
classifications to group of conditions identifies the same individual patients as having 
multimorbidity. This is particularly useful as it will allow comparable identification of 
people with complex multimorbidity irrespective of whether the data are drawn from 
primary care (ICPC-2) or from hospital (ICD-10) health records. In Chapter 7, I showed 
that patients with diagnosed chronic conditions classified in 3 or more body systems had 
a significantly higher average GP-visit rate than those with 3 or more individual chronic 
conditions. Early results from my next study suggest this difference is also true of the 
patient’s overall complexity of care.30 
The relationship between multimorbidity and 
utilisation of GP services (AIM 5) 
The ability to accurately predict patient utilisation of GP services will greatly assist policy 
makers with GP-workforce planning, future health care costing and implementation of 
policies such as the health care homes initiative. I found that multiple factors influence a 
patient’s GP visit rate. The most parsimonious model includes patient age and sex, the 
number of diagnosed chronic conditions, and whether the patient holds a 
Commonwealth Concession Health Care Card. Going forward, this model should be 
validated independently on a comparable dataset.  
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The number of individual diagnosed chronic conditions and the number of ‘body 
systems’ were strongly positively associated with the patient’s GP-visit rate (Chapter 7). 
This supports similar results found earlier in Australia32 and around the same time 
internationally. 33,34 
While I have explored only patient utilisation as an outcome of multimorbidity in this 
thesis, early results from my next study suggest a similar pattern emerges when 
complexity of the patient’s care is the outcome.30 These results suggest that the number 
of diagnosed chronic conditions and the number of ‘body systems’ are both strongly 
positively associated with complexity of care, with the number of chronic conditions 
being a slightly better predictor. 
The linear relationships between the number of chronic conditions/body systems with 
patient GP-visit rates and complexity of care suggest that multimorbidity is actually a 
continuum. If multimorbidity is really a continuum, as my results suggest, do we then 
need a minimum number of conditions? I would argue that the need for a minimum is 
dependent on the reason multimorbidity is being measured. Conceptualising 
multimorbidity as a continuum is useful when it is being applied in a model to predict 
outcomes (such as patient GP-visit rate). However, when its prevalence is being 
measured, a standard minimum number of morbidities is required so that comparisons 
can be made between studies and over time.  
The prevalence and patterns of multimorbidity in 
Australia (AIM 6) 
For the first time in Australia, this thesis has measured the patterns and prevalence of 
multimorbidity using all chronic conditions from a nationally representative prospective 
study. This study had a larger sample of respondents than any of the previous ABS 
National Health Surveys.18 I estimated that about a quarter (25.7%) of the population 
had two or more diagnosed chronic conditions while about one in eight people had 
complex multimorbidity, equating to about 6.2 and 2.9 million people respectively. 
This high proportion of patients with multimorbidity strengthens the argument that we 
need to re-examine the focus of our health care system on the management of single 
chronic conditions, particularly in regards to its structure, to guidelines, and to clinical 
trials. About half the patients at GP encounters had two or more chronic conditions 
while about 3 in 10 had complex multimorbidity. When these figures are compared with 
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the 26.5% of patients at encounters who had diagnosed hypertension, the most 
prevalent individual chronic condition, one understands Tinetti et al’s quip that the 
“most common chronic condition experienced by adults is multimorbidity”. 35 There are 
combinations of chronic conditions that are more prevalent than some common 
individual conditions. For example, in Chapter 5, I showed that 5.5% of patients at GP 
encounters had diagnosed hypertension + hyperlipidaemia + osteoarthritis, while only 
4.1% had COPD, 2.9% had congestive heart failure and 1.0% rheumatoid arthritis. I have 
also shown that it is uncommon for patients to have just one single chronic condition, 
with about two-thirds of people with at least one chronic condition having two or more. 
These results point to a clear need for clinical trials and guidelines for care to expand 
from their current single disease focus to incorporate patients with multiple chronic 
conditions. While creating a set of guidelines for every possible combination of chronic 
conditions would be impractical, my results could be used to prioritise the creation of 
guidelines for the care of patients who have the most common combinations of chronic 
conditions. 
This thesis also reports the most common patterns of body systems with at least one 
chronic condition classified to them. These may also help policy planners identify 
services that, if co-located, would be beneficial for optimal care of these patients.  
Within this thesis I have primarily focussed on the methodology associated with measuring 
multimorbidity in Australia. As such, I have prioritised the reliability and generalisability of 
the method over the clinical outcomes associated with multimorbidity. This is not because I 
believe that clinical outcomes and patient’s experience with multimorbidity are any less 
important.  
In contrast the European General Practice Research Network (EGPRN) prioritised measuring 
the clinical complexity of multimorbidity. They undertook a systematic review in 
consultation with experts to define multimorbidity, though it has been criticised because 
many leaders in the field of multimorbidity were not involved.36 The EGPRN sought a 
“comprehensive” definition of multimorbidity which incorporated most of the 
characteristics of the definitions found during their review. Importantly they stressed that 
the health outcomes of a patient happen in a context wider than the number of diagnosed 
chronic conditions, and so they explicitly included other factors that impact a patient’s 
health. Their full definition of multimorbidity is  
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“any combination of chronic disease with at least one other disease (acute or chronic) or 
biopsychosocial factor (associated or not) or somatic risk factor.  
Any biopsychosocial factor, any somatic risk factor, the social network, the burden of 
diseases, the health care consumption, and the patient’s coping strategies may function 
as modifiers (of the effects of multimorbidity).  
Multimorbidity may modify the health outcomes and lead to an increased disability or a 
decreased quality of life or frailty”21 
My thesis suggests that the common definition of multimorbidity as 2+ chronic conditions 
would identify too high a proportion of people with multimorbidity to be useful in targeting 
high need patients. This conclusion is even more applicable to the EGPRN’s comprehensive 
definition. Since this definition also includes acute conditions, biopsychosocial factors and 
somatic risk factors among the ‘morbidities’ being counted, people with at least one 
diagnosed chronic condition may be considered to have multimorbidity at some point in 
time (such as when the contract an acute illness). If I applied this definition to my data, it 
may identify the 18% of patients at GP encounters (and the 17% of the population) who 
have only one chronic condition as having multimorbidity at some time. This would provide 
multimorbidity prevalence estimates of up to 70% for patients at GP-encounters and 40% 
for people in the population. It would also no doubt identify almost all older people as 
having multimorbidity. 
The other issue with this definition is the sheer number of variables that would have to be 
collected by researchers, or recorded by clinicians, planning to apply it in their work. Further, 
there will be difficulties standardising which acute conditions, biopsychosocial factors and 
somatic risk factors are included across studies. 
As one of my collaborators, Maxime Sasseville, said “This definition speaks to the conflict 
between providing a definition that is comprehensive enough to capture the clinical 
reality of multimorbidity and a definition that is specific enough for the development of 
functional measures or tools.”(Personal communication) 
While my definition of complex multimorbidity has been shown to be a reliable measure of 
multimorbidity and to predict patient GP-visit rate and complexity of care, it has yet to be 
shown as a strong indicator of a wide variety of other outcomes. Further research on how 
well it predicts other outcomes, such as patient quality of life and mortality needs to be 
undertaken. 
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I also acknowledge that by proposing an additional measure of multimorbidity, no matter 
how useful and valid, I am contributing to the number of already existing definitions of 
multimorbidity and furthering the lack of standardisation. Ideally the leaders in the field of 
multimorbidity research need to agree on a set of guidelines that define multimorbidity and 
how it should be measured. If the guidelines advocated by these leaders provided a 
pragmatic method for measuring multimorbidity, then it is more likely that it will be widely 
adopted as the standard. 
This thesis provides a clear basis for these guidelines. For reliability, distinct groups of 
conditions should be counted. Using groups of like conditions reduces the occurrence of 
double counting of the same condition due to it receiving a different label over time.34 
Grouping conditions also reduces the variance between clinicians where some decide to 
record two inter-related conditions as two separate conditions, while others record them as 
a single condition. In my definition, I suggested the use of the chapter structure of ICD-1037 
and ICPC-238 to group conditions. These chapter structures were created by committees of 
clinical classification experts, e.g. ICPC-2 is a product of the Classification Committee of the 
World Organization of Family Doctors.38 The other option is to use data driven groups of 
chronic conditions, using methods such as factor analysis39 or cluster analysis.40,41 The issue 
with data driven groups of conditions is that the groups that are formed may not make 
clinical sense.  
If groups of conditions are accepted as the standard, my results show that researchers 
should include as many chronic conditions as possible to produce reliable results. While it 
has been suggested that conditions should be chosen based on their impact on patient 
outcomes, my studies have found little evidence of any major difference between 
individual chronic conditions in their impact on patient GP-visit rates or the complexity of 
their care. This suggests that including as many chronic conditions as possible not only 
improves the reliability of prevalence estimates, but also the ability to predict outcomes. 
For increased specificity in targeting higher need patients, the minimum number of chronic 
conditions defining multimorbidity should be at least three. This would rule out the 
common current definition of multimorbidity as 2+ chronic conditions and the EGPRN’s 
comprehensive definition. 
Whatever is agreed upon should not be restricted by propriety licensing (such as the Johns 
Hopskins Adjusted Clinical Groups),42 but be accessible to all researchers so that it can be 
widely applied and critiqued. The method adopted should predict a wide variety of 
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outcomes instead of focusing on single outcomes (such as health service utilisation or 
mortality). 
Apart from my definition of complex multimorbidity, there is also work being conducted by 
the Patient-Centred Innovations for Persons with Multimorbidity (PACE in MM) study.43 
Early publications suggest that researchers are planning to measure multimorbidity using 
20 specified chronic disease categories (groups). These categories each correspond to a 
defined list of ICD-9 codes, which when combined, cover most chronic conditions managed 
in general practice.44 It will be interesting to see how good this new measure of 
multimorbidity is as a predictor of a wide range of outcomes. 
In an ideal world, the methods I have developed in this thesis to measure the prevalence of 
chronic conditions in the population from general practice data would soon be made 
redundant. In this world, Australia would have a system whereby all people had an 
electronic medical record (EHR). These EHRs would be linked, not just between general 
practices, but to all arms of the health care system (e.g. hospitals, medical specialists, allied 
health professionals) and would have a record of every contact the patient made with the 
healthcare system. The EHRs would have a minimum data set about the patient including 
elements describing their past history, family history and each of their encounters with the 
system. All EHRs would have a standardised structure, ideally a problem oriented structure 
similar to that described by Dr L Weed.45 The data elements would have consistent 
definitions and labels and they would be stored using standardised clinical terminology and 
classifications. This system of EHRs would make it relatively simple to measure the 
prevalence of individual chronic conditions and multimorbidity in the population. In depth 
models examining patient utilisation of all healthcare resources could be undertaken across 
the whole population. Patients could be followed longitudinally, so that the progress of 
multimorbidity could be examined over time, allowing for statistical modelling to predict 
multimorbidity and its outcomes, which in turn may provide an evidence base for effective 
prevention.  
However, as Gordon et al shows,46 this ideal system is still a long way off in Australia with 
our current EHR systems lacking the required characteristics described above. Projects such 
as MedicineInsight (run by the National Prescribing Service MedicineWise heavily funded by 
the Australian Government) have been attempting to extract clinical data from general 
practice EHRs. However, the quality of their data is not only hampered by the lack of 
standardisation described above, but also by the quality of the data being entered (or not 
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entered) into the EHR. For example, they found that when an antibiotic prescription was 
recorded in the patient’s EHR, the indication for the antibiotic was only recorded in about 
30% of instances.47 
The prevalence of chronic conditions and multimorbidity is expected to continue rising, due 
to the ageing of the population and increasing prevalence of obesity. This in turn creates a 
continued need to measure these prevalence and associated outcomes. In the environment 
of poor standardisation and linkage of electronic health data, collection of GP-encounter-
based data is still highly valuable, suggesting that the methods described in my thesis will 
be relevant for years to come. While these methods were designed for the BEACH project 
which has now sadly been shut down, I am currently piloting another study examining the 
feasibility of having GPs record the same information about their patient encounters using 
an electronic data collection form. The structure of this form borrows heavily from lessons 
learnt from the BEACH project. A similar attempt a decade ago found that this type of data 
collection was too burdensome for GPs. However, since then a new generation of younger 
GPs have started practising who may be more computer savvy than those who have since 
retired. Also there have been improvements in user interface that may also make the 
process easier for GPs. If this new project is viable, the methods described in my thesis 
could be applied to the data from this new study.  
Primary care, and general practice in particular, may provide an ideal home for the study of 
multimorbidity. As discussed previously, the use of GPs as expert interviewers/participants 
avoids the issues of collecting data through patient self-report1-8 or chart review5,7,9-12 alone. 
Data collected using my method is likely to be more reliable than that of respondent self-
report used in the National Health Survey.18 It has been commonly suggested that primary 
care holds our best hope of dealing with the complexity of caring for patients with 
multimorbidity.48-50 It therefore follows that multimorbidity research should be based in 
primary care, with primary care informing research and the results from this research 
informing primary care. However for this to happen, there needs to be greater incentive for 
GPs to undertake research. An adaptation of the ‘Health Care Homes’ model may provide 
the structure, support and incentive for GPs to undertake this research. At the very least, 
there needs to be some incentive for GPs to improve their recording of data in patient 
EHRs. 
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Limitations 
As I have discussed earlier, my first survey had the limitation of assuming no variance in the 
attendance patterns between patients in the same each age-sex group. Using this method 
overestimated the prevalence of chronic conditions (and multimorbidity) due to patients 
with more chronic conditions visiting GPs more often regardless of their age and sex. The 
final method applied to the second survey overcame this limitation by taking into account 
each individual patient’s attendance when weighting their data.  
However, this new adjustment method still has limitations. The newest method still 
assumes people who do not see a GP in a year do not have a diagnosed chronic condition. 
As I have mentioned in earlier chapters this may not apply to a chronic condition such as 
mild asthma (in an otherwise healthy person) that did not necessitate a GP visit in that 
year. It would also apply to a small number of people that are being managed solely by 
specialists (such as hospital outpatients). In the case of conditions such as asthma, the NHS 
is likely to be a more reliable source of prevalence data. 
As with all studies of diagnosed chronic conditions, the GP must recognise that the patient 
has the chronic condition for it to be recorded. As the AusDiab study showed, there is a 
significant proportion of society with undiagnosed hypertension and/or with undiagnosed 
Type 2 Diabetes.51  
While not a limitation of the new adjustment method, there was a limitation in the data 
collected in my second survey. The patient/GP reported number of GP-visits in the previous 
12 months was under-reported when compared with Medicare claims statistics. This under-
reporting is likely due to recall bias. This may be because the patient had seen another GP 
but had forgotten the visit(s) and/or did not wish the current GP to know of it or the 
current GP did not ask the patient whether they had seen another GP and had only 
recorded the visits at their practice. This under-reporting may have affected my national 
prevalence estimates if there was a bias for high or low attenders to more often under-
report their visit rate. Whether this bias exists cannot be assessed from the current data. 
What is certain is that this under-reporting means that the models I built in Chapter 7 
would underestimate the number of times a patient would see a GP in a year. While it is 
possible that weighting the effect size of the variables in the model could account for this 
under-reporting, it would only do so if there was no bias in the under-reporting for each of 
the variables in our model (i.e. patient age and sex, the number of diagnosed chronic 
conditions and whether the patient holds a CCHCC). 
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It has been suggested that any measure of multimorbidity should include some measure of 
the severity of the conditions.26,52-54 In my research I was unable to include an individual 
measure of severity for each chronic condition due to space limitations on the research 
questionnaire and concern that the additional burden on GPs would lower their response 
rate. However in some of the sub-studies I did ask for the GP's opinion of the overall 
severity of illness of the patient.  
As I showed in Chapter 7, overall severity of illness had little effect on GP-visit rates and we 
found it not to be a significant independent predictor. The fact that severity of illness was 
not an independent predictor of GP visit rate may be due to a strong relationship between 
the number of diagnosed chronic conditions and the overall severity of illness. It could also 
suggest that well controlled conditions require a similar amount of GP visits as conditions 
with a high severity. 
While patient use of GP services is important, it is just one of many outcomes associated 
with multimorbidity. Further research into whether there is a relationship between severity 
of illness and these other outcomes needs to be undertaken.  
Conclusion 
I have taken the opportunity provided by the BEACH program to create and undertake 
Australia’s largest national study of chronic conditions. I have measured the prevalence of 
chronic conditions not only among patients at GP encounters, but the prevalence in the 
Australian population, using methods I developed over the course of this thesis. For the 
first time, a single large prospective study has been used to test the effect of the way 
multimorbidity is measured on prevalence estimates, while controlling for other variables, 
using the same data for all measures. This has provided clear guidelines for other 
researchers to follow in their studies of multimorbidity. Using these same guidelines, I 
estimated the prevalence and patterns of multimorbidity in the Australian population. 
Finally, this thesis showed that multimorbidity was the largest driver of patient demand for 
GP services. 
The results of this thesis could be used to inform the ‘Primary Health Care’ reform currently 
underway in Australia. The model predicting patient GP-visit rate will assist with future 
workforce planning and provide a scientific basis for calculation of suitable capitation 
payments for patients enrolled in the Health Care Homes trial. The high prevalence of 
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multimorbidity among patients at GP encounters and among people in the population, 
once again supports calls to change the healthcare system’s single disease focus to a 
patient-centred focus. This is especially true of clinical trials and guidelines for care. 
My concept of ‘complex multimorbidity’ may be useful in identification of high need 
patients. However, further testing of the extent to which it is associated with a wider array 
of outcomes is required. Further, the models I developed predicting patient GP-visit rate 
and complexity of care need to be independently validated using a comparable data source. 
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e
 e
.g
. 
“s
c
ri
p
t 
fo
r 
B
P
”,
 “
re
fe
rr
a
l”
. 
 

o
th
e
r 
e
x
a
m
p
le
s
  
- 
“W
o
rr
ie
d
 a
b
o
u
t…
”,
 “
fo
llo
w
-u
p
”,
 “
c
h
e
c
k
-u
p
 
 
c
ir
c
u
la
to
ry
” 

S
p
e
c
if
y
 t
h
e
 b
o
d
y
 s
y
s
te
m
 e
v
e
n
 w
h
e
n
 t
h
is
 is
 n
o
t 
s
ta
te
d
 b
y
 t
h
e
 p
a
ti
e
n
t 
b
u
t
is
 u
n
d
e
rs
to
o
d
 b
e
tw
e
e
n
 y
o
u
. 
PR
O
B
LE
M
 S
TA
TU
S:
 
T
ic
k
 ‘
N
ew
’ i
f:

th
is
 i
s
 a
 n
e
w
 p
ro
b
le
m
 t
o
 t
h
e
 p
a
ti
e
n
t,
 o
r

th
is
 i
s
 a
 n
e
w
 e
p
is
o
d
e
 o
f 
a
 r
e
c
u
rr
e
n
t 
p
ro
b
le
m
 (
e
.g
. 
U
R
T
I)
, 
A
N
D

th
e
 p
a
ti
e
n
t 
h
a
s
 n
o
t 
b
e
e
n
 t
re
a
te
d
 f
o
r 
th
a
t 
p
ro
b
le
m
 o
r 
e
p
is
o
d
e
 b
y
a
n
y
 m
e
d
ic
a
l 
p
ra
c
ti
ti
o
n
e
r 
b
e
fo
re
.
T
ic
k
 ‘
O
ld
’ i
f 
th
e
 p
a
ti
e
n
t 
h
a
s
 b
e
e
n
 s
e
e
n
 b
e
fo
re
 b
y
 A
N
Y
 m
e
d
ic
a
l 
p
ra
c
ti
ti
o
n
e
r 
fo
r 
th
is
  
c
h
ro
n
ic
 p
ro
b
le
m
 o
r 
th
is
 e
p
is
o
d
e
 o
f 
a
n
 a
c
u
te
 p
ro
b
le
m
.
ST
A
R
T 
TI
M
E
R
e
c
o
rd
 t
h
e
 t
im
e
 t
h
e
 c
o
n
s
u
lt
a
ti
o
n
S
T
A
R
T
E
D
 i
n
 h
o
u
rs
 a
n
d
 m
in
s
 a
n
d
c
ir
c
le
 w
h
e
th
e
r 
th
e
 t
im
e
 w
a
s
 A
M
 o
r 
P
M
.
e
g
. 
 
A
M
 /
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M
9
  
 1
0
: /
D
IA
G
N
O
SI
S/
PR
O
B
LE
M
: 
 R
e
c
o
rd
 a
t 
le
a
s
t
o
n
e
 a
n
d
 u
p
 t
o
fo
u
r 
p
ro
b
le
m
s
. 
r

U
s
e
 o
n
e
 D
ia
g
n
o
s
is
/p
ro
b
le
m
 b
o
x
 f
o
r 
e
a
c
h
 d
ia
g
n
o
s
is
/p
ro
b
le
m
 

O
n
ly
 r
e
c
o
rd
 p
ro
b
le
m
s
 a
c
tu
a
lly
 d
e
a
lt
 w
it
h
 a
t 
th
is
 e
n
c
o
u
n
te
r

,QF
OXG
HL
OOG
H¿
QH
GF
RQ
GLW
LRQ
V
H
J
³FR
XJ
K´
S
UHY
HQ
WLY
HF
DUH
H
J

“p
a
p
 s
m
e
a
r”
, 
“c
o
n
tr
a
c
e
p
ti
o
n
”,
 “
im
m
u
n
is
a
ti
o
n
” 
o
r 
“c
h
e
c
k
u
p
”)
, 
a
n
d
s
o
c
ia
l 
p
ro
b
le
m
s
 (
e
.g
. 
“p
ro
b
le
m
s
 w
it
h
 s
p
o
u
s
e
”)
. 

D
ia
g
n
o
s
e
 a
t 
th
e
 h
ig
h
e
s
t 
le
v
e
l 
p
o
s
s
ib
le
 w
it
h
 t
h
e
 i
n
fo
rm
a
ti
o
n
 a
v
a
ila
b
le
(e
.g
. 
fo
r 
d
ia
b
e
te
s
, 
d
if
fe
re
n
ti
a
te
 b
e
tw
e
e
n
 I
D
D
M
/N
ID
D
M
/T
y
p
e
 1
/T
y
p
e
 2
e
tc
.)

7K
HR
UGH
ULQ
Z
KLF
K\
RX
UH
FR
UG
WKH
SU
RE
OHP
VL
VQ
RW
VLJ
QL¿
FD
QW
WK
H\
d
o
 n
o
t 
h
a
v
e
 t
o
 m
a
tc
h
 t
h
e
 o
rd
e
r 
o
f 
th
e
 R
F
E
s
. 

If
 m
o
re
 t
h
a
n
 f
o
u
r 
p
ro
b
le
m
s
 a
re
 m
a
n
a
g
e
d
 a
t 
th
e
 c
o
n
s
u
lt
a
ti
o
n
, 
re
c
o
rd
 
th
e
 f
o
u
r 
p
ro
b
le
m
s
 t
h
a
t 
b
e
s
t 
d
e
s
c
ri
b
e
 t
h
e
 b
re
a
d
th
 o
f 
th
e
 c
o
n
s
u
lt
a
ti
o
n
.
PR
O
C
ED
U
R
ES
, O
TH
ER
 T
R
EA
TM
EN
TS
, C
O
U
N
SE
LL
IN
G
: 
F
o
r 
e
a
c
h
 p
ro
b
le
m
:
 
R
e
c
o
rd
 u
p
 t
o
 t
w
o
 p
ro
c
e
d
u
re
s
, 
o
th
e
r 
tr
e
a
tm
e
n
ts
 o
r 
c
o
u
n
s
e
lli
n
g
.
 
O
n
ly
 i
n
c
lu
d
e
 t
h
o
s
e
 A
C
T
U
A
L
L
Y
 P
R
O
V
ID
E
D
 a
t 
th
e
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n
c
o
u
n
te
r.
 
 
In
cl
ud
e 
in
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tio
n 
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tio
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 
p
a
p
 s
m
e
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rs
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c
ti
o
n
s
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e
x
c
is
io
n
s
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e
a
r 
s
y
ri
n
g
e
 
 
p
s
y
c
h
o
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o
c
ia
l 
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o
u
n
s
e
lli
n
g
 
 
 
d
ie
t 
a
n
d
 e
x
e
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e
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d
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e
 

PH
GLF
DO
FH
UWL¿
FD
WHV
 
D
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N
O
T 
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cl
ud
e 
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ec
tio
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 
h
is
to
ry
 
 
ro
u
ti
n
e
 p
h
y
s
ic
a
l 
e
x
a
m
in
a
ti
o
n
s
 e
.g
. 
b
lo
o
d
 p
re
s
s
u
re
 c
h
e
c
k
s
 
 
d
is
c
u
s
s
io
n
 
 
re
fe
rr
a
ls
, 
im
a
g
in
g
, 
o
r 
p
a
th
o
lo
g
y
 o
rd
e
re
d
 (
th
e
re
 a
re
 s
e
c
ti
o
n
s
 f
o
r 
th
e
s
e
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N
B
 -
 I
f 
a
pr
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tic
e
nu
rs
e
pe
rf
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m
s 
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e 
pr
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ed
ur
e,
 p
le
a
s
e
 
tic
k 
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e 
bo
x 
m
a
rk
e
d
‘P
ra
c
 N
u
rs
e
?
’
PR
O
C
ED
U
R
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, O
TH
ER
 T
R
EA
TM
EN
TS
, C
O
U
N
SE
LL
IN
G
: 
F
o
r 
e
a
c
h
 p
ro
b
le
m
:

R
e
c
o
rd
 u
p
 t
o
 t
w
o
 p
ro
c
e
d
u
re
s
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o
th
e
r 
tr
e
a
tm
e
n
ts
 o
r 
c
o
u
n
s
e
lli
n
g
.

O
n
ly
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n
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e
 t
h
o
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 A
C
T
U
A
L
L
Y
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R
O
V
ID
E
D
 a
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th
e
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n
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o
u
n
te
r.

In
cl
ud
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in
 th
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tio
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tio
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uc
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
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e
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rs
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in
je
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ti
o
n
s
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e
x
c
is
io
n
s
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e
a
r 
s
y
ri
n
g
e

p
s
y
c
h
o
s
o
c
ia
l 
c
o
u
n
s
e
lli
n
g

d
ie
t 
a
n
d
 e
x
e
rc
is
e
 a
d
v
ic
e

PH
GLF
DO
FH
UWL¿
FD
WHV

D
o 
N
O
T 
in
cl
ud
e 
in
 th
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 s
ec
tio
n:

h
is
to
ry

ro
u
ti
n
e
 p
h
y
s
ic
a
l 
e
x
a
m
in
a
ti
o
n
s
 e
.g
. 
b
lo
o
d
 p
re
s
s
u
re
 c
h
e
c
k
s

d
is
c
u
s
s
io
n

re
fe
rr
a
ls
, 
im
a
g
in
g
, 
o
r 
p
a
th
o
lo
g
y
 o
rd
e
re
d
 (
th
e
re
 a
re
 s
e
c
ti
o
n
s
 f
o
r 
th
e
s
e
).
M
ED
IC
AT
IO
N
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N
B
 -
 O
N
LY
 r
e
c
o
rd
 m
e
d
ic
a
ti
o
n
s
 t
h
a
t 
w
e
re
 p
re
s
c
ri
b
e
d
 /
 a
d
v
is
e
d
 /
 s
u
p
p
lie
d
 a
t t
hi
s 
en
co
un
te
r 
R
e
c
o
rd
 m
e
d
ic
a
ti
o
n
s
 w
h
e
n
 

a
 p
re
s
c
ri
p
ti
o
n
 i
s
 w
ri
tt
e
n
 a
t 
th
is
 e
n
c
o
u
n
te
r,
 
 

y
o
u
 r
e
c
o
m
m
e
n
d
 t
h
a
t 
th
e
 p
a
ti
e
n
t 
ta
k
e
 a
n
 “
o
v
e
r 
th
e
 c
o
u
n
te
r”
 (
O
T
C
) 
m
e
d
ic
a
ti
o
n
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
y
o
u
 a
d
m
in
is
te
r 
o
r 
s
u
p
p
ly
 a
 m
e
d
ic
a
ti
o
n
/v
a
c
c
in
e
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e
g
. 
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Im
m
u
n
is
a
ti
o
n
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s
 t
h
e
 p
ro
b
le
m
 m
a
n
a
g
e
d
, 
p
le
a
s
e
 e
n
te
r 
d
ru
g
s
 a
d
m
in
is
te
re
d
 
a
t 
th
is
 e
n
c
o
u
n
te
r,
 (
e
.g
. 
IP
V
, 
D
T
P
) 
o
r 
a
n
y
 d
ru
g
 s
a
m
p
le
s
 y
o
u
 p
ro
v
id
e
.
D
ru
g
 s
ta
tu
s
N
e
w
C
o
n
t.
1
.
9
Pr
ob
le
m
 S
ta
tu
s
Dr
ug
 N
am
e 
AN
D 
Fo
rm
 fo
r 
th
is
 p
ro
b
le
m
S
tr
e
n
g
th
 o
f 
p
ro
d
u
c
t
D
o
s
e
F
re
q
u
e
n
c
y
N
o
. 
o
f 
R
p
ts
O
T
C
G
P
 
S
u
p
p
ly
D
ru
g
 s
ta
tu
s
N
e
w
C
o
n
t.
Pr
ob
le
m
 S
ta
tu
s
Dr
ug
 N
am
e 
AN
D 
Fo
rm
 f
o
r 
th
is
 p
ro
b
le
m
S
tr
e
n
g
th
 o
f 
p
ro
d
u
c
t
D
o
s
e
F
re
q
u
e
n
c
y
N
o
. 
o
f 
R
p
ts
O
T
C
G
P
 
S
u
p
p
ly
Pr
oc
ed
ur
es
, o
th
er
 tr
ea
tm
en
ts
, c
ou
ns
el
lin
g 
th
is
 c
on
su
lt 
fo
r 
th
is
 p
ro
b
le
m
P
ra
c
 
N
u
rs
e
?
 
P
ra
c
 
N
u
rs
e
?
 
1
.
2
.
3
.
4
.
D
ia
gn
os
is
/
Pr
ob
le
m
 
:
c
D
ia
gn
os
is
/
Pr
ob
le
m
 
:
d
9
H
yp
er
te
n
si
o
n
In
ju
ry
 –
 r
ib
s
P
a
n
a
d
o
l 
ta
b
le
ts
 
 5
0
0
m
g
  2
 t
a
bs
  
qi
d
 
St
re
ng
th
 o
f p
ro
du
ct
:
P
le
a
s
e
 s
p
e
c
if
y
 t
h
e
 
st
re
ng
th
 o
f 
th
e
 p
ro
d
u
c
t 
y
o
u
 a
re
 p
re
s
c
ri
b
in
g
/
s
u
p
p
ly
in
g
/a
d
v
is
in
g
.
W
e
 a
re
 a
tt
e
m
p
ti
n
g
 t
o
 
d
if
fe
re
n
ti
a
te
 b
e
tw
e
e
n
 
p
ro
d
u
c
t 
s
tr
e
n
g
th
s
, 
e
.g
. 
2
5
0
m
g
 o
r 
5
0
0
m
g
 o
f 
th
e
 
s
a
m
e
 p
ro
d
u
c
t.
Fr
eq
ue
nc
y:
 
 
ho
w
 o
fte
n 
th
e
 d
o
s
e
 i
s
  
 
to
 b
e
 t
a
k
e
n
. 
 
re
c
o
rd
 i
n
 a
c
c
e
p
te
d
  
 
a
b
b
re
v
ia
ti
o
n
s
 e
.g
. 
“b
d
”,
  
 
“t
d
s
”,
 e
tc
. 
 
if
 d
ru
g
 i
s
 t
o
 b
e
 t
a
k
e
n
 “
a
s
  
 
re
q
u
ir
e
d
”,
 w
ri
te
 P
R
N
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N
o.
 o
f R
pt
s:
 f
o
r 
a
ll 
pr
es
cr
ip
tio
ns
 
p
le
a
s
e
 s
p
e
c
if
y
 t
h
e
 n
um
be
r o
f 
re
pe
at
s 
o
rd
e
re
d
. 
If
 n
o
 r
e
p
e
a
ts
 
a
re
 g
iv
e
n
, 
p
le
a
s
e
 w
ri
te
 ‘
0
’ o
r 
‘ 
- 
’.
 
Pl
ea
se
 d
o 
no
t l
ea
ve
 b
la
nk
.
D
ru
g 
st
at
us
:  
If
 t
h
e
 m
e
d
ic
a
ti
o
n
 i
s
 b
e
in
g
 u
s
e
d
 f
o
r 
th
e
 
m
a
n
a
g
e
m
e
n
t 
o
f 
th
is
 p
ro
b
le
m
 f
o
r 
th
e
 ¿U
VW
WLP
H t
h
e
n
 
ti
c
k
 t
h
e
 ‘
N
ew
’ b
o
x
. 
If
 i
t 
is
 a
 c
on
tin
ua
tio
n 
o
r 
re
p
e
a
t 
o
f 
p
re
v
io
u
s
 t
h
e
ra
p
y
 t
h
e
n
 t
ic
k
 t
h
e
 ‘
C
on
t.’
 b
o
x
.
PL
EA
SE
 R
EC
O
R
D
 
IN
FO
R
M
AT
IO
N
 IN
 A
S 
M
U
C
H
 
D
ET
A
IL
 A
S 
YO
U
 W
O
U
LD
 W
R
IT
E 
O
N
 A
 P
R
ES
C
R
IP
TI
O
N
.
Fo
r O
TC
s,
 p
ro
vi
de
 a
s 
m
uc
h 
de
ta
il 
as
 th
e 
pa
tie
nt
 w
ou
ld
 n
ee
d 
to
 b
uy
 th
e 
m
ed
ic
at
io
n 
ov
er
 th
e 
co
un
te
r.
D
ru
g 
na
m
e 
an
d 
Fo
rm
: t
h
e
 b
ra
n
d
 o
r 
g
e
n
e
ri
c
 n
am
e 
o
f 
th
e
 
m
e
d
ic
a
ti
o
n
 a
nd
 it
s 
fo
rm
 e
g
 C
a
rd
iz
e
m
 C
D
 
ta
b
le
ts
; 
P
a
n
a
d
o
l 
s
y
ru
p
; 
V
e
n
to
lin
 n
e
b
u
le
s
 e
tc
. 
D
os
e:
 th
e
 
qu
an
tit
y 
o
f 
m
e
d
ic
a
ti
o
n
 t
o
 
b
e
 t
a
k
e
n
  
e
.g
. 
2
 t
a
b
s
; 
 
2
5
 m
ls
; 
1
 i
n
j;
  
2
 p
u
ff
s
 e
tc
.
O
TC
: 
ti
c
k
 i
f 
th
e
 
m
e
d
ic
a
ti
o
n
 
a
d
v
is
e
d
 i
s
 t
o
 
b
e
 b
o
u
g
h
t 
 
O
ve
r T
he
 
C
ou
nt
er
 
i.
e
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a
n
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2
 o
r 
S
3
 p
ro
d
u
c
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O
th
er
w
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e 
bl
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k.
  G
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c
k
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o
x
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f 
m
e
d
ic
a
ti
o
n
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s
 f
ro
m
 t
h
e
 
pr
ac
tic
e 
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pp
lie
s 
e
g
 
d
ru
g
 s
a
m
p
le
 o
r 
v
a
c
c
in
e
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O
th
er
w
is
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 le
av
e 
bl
an
k.
D
O
 N
O
T 
TI
C
K
 IF
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O
U
 
H
AV
E 
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O
VI
D
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 A
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C
R
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TI
O
N
, O
N
LY
 IF
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U
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AV
E 
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O
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D
ED
 A
 
M
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e
m
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 C
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b
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n
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b
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b
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 m
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 p
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b
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p
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ra
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 b
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f p
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e
c
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y
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c
t
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 p
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c
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g
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u
p
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in
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W
e
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re
 a
tt
e
m
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n
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o
 
d
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fe
re
n
ti
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te
 b
e
tw
e
e
n
 
p
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u
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e
n
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e
.g
. 
2
5
0
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5
0
0
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a
m
e
 p
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d
u
c
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Fr
eq
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
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w
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fte
n 
th
e
 d
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s
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 b
e
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a
k
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n
.

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Appendix B: Patient information card 
A patient information card, that described the survey and its purpose to the patient 
including the option for the patient to opt out if they wish 
  
FMRC, Acacia House, Westmead Hospital, PO Box 533,WENTWORTHVILLE, 2145. 
Ph: 02 9845 8151 fax: 02 9845 8155         email: clare.bayram@sydney.edu.au         Web: http://sydney.edu.au/medicine/fmrc/ 
 
Family Medicine Research Centre 
INFORMATION FOR PATIENTS 
 
The  BEACH © Project  
 
 
Today your doctor is taking part in a National Survey of general practice called 
BEACH © (Bettering the Evaluation and Care of Health).  This study is being done 
by the Family Medicine Research Centre, University of Sydney. 
 
Your Doctor will be recording information about each patient he/she sees (age, 
gender etc), the problems that you see the Doctor about and the treatments given 
to you.  There are no names on the forms so you cannot be identified.  The 
information about today’s visit to the doctor will be one record in a set of 100,000 
records collected in general practices across Australia every year. 
 
This information will be used by researchers to describe what happens in general 
practice and to look at different aspects of health care; by government 
departments to help them plan for our future health; and by pharmaceutical 
companies to gain a picture of the problems being treated with the drugs they 
produce. 
 
Remember: your name will not be on the form and no information will ever 
be released which could possibly let anyone know who you are.  However, if 
you do not wish your doctor to record any unidentified information about you or 
your visit please tell your Doctor as soon as you go in. Such a decision will not 
affect the consultation with your doctor in any way. 
 
 
SEE OVER FOR PROJECT DETAILS 
(page 1 / 2) 
BEACH © Program details  
This program has been approved by the Ethics Committee of the University of 
Sydney. The data are being collected in accordance with the Privacy Act 1988 as 
amended. 
BEACH is endorsed  
by  
the Royal Australian College 
of General Practitioners 
BEACH is endorsed  
by  
the Australian Medical Association   
 
 
Any person with concerns or complaints about the conduct of this research study 
can contact The Manager, Research Integrity and Ethics Administration, University 
of Sydney on +61 2 8627 8176 (Telephone); +61 2 8627 8177 (Facsimile); 
ro.humanethics@sydney.edu.au  (Email).        (page 2/2) 
Organisations contributing financially to the conduct of this study in 
2015–2016 are: 
 The Australian Government Department of Health 
 AstraZeneca Pty Ltd (Australia) 
 bioCSL (Australia) Pty Ltd 
 Novartis Pharmaceuticals Australia Pty Ltd  
FURTHER INFORMATION 
 
Family Medicine Research Centre 
The University of Sydney 
Acacia House, Westmead Hospital 
Westmead 2145 
 
 
Phone: (02) 9845 8151 
Fax: (02) 9845 8155 
Email: clare.bayram@sydney.edu.au  
Web: sydney.edu.au/medicine/fmrc/ 
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Appendix C: GP questionnaire 
A short questionnaire about the GP and their practice 
  
Family Medicine 
Research Centre
Doctor Identification Number
6. Are you a GP Registrar (i.e. in training)? ....Yes / No
7. Do you hold FRACGP? ...........................Yes / No
5. How many direct patient care hours do you  
 work per week?
Please answer the following questions ABOUT YOU
2. Age ..................................................................
3. How many years have you spent in  
 general practice? ...................................
14. Postcode of major practice? .................
(Include hours of direct patient care, instructions, 
counselling etc and other services such as  
referrals, prescriptions, phone calls etc.) ..............
Thank you for participating in the BEACH PROGRAM.  
Please return this form with the completed BEACH pad.
FMRC, PO Box 533, Westmead Hospital, Wentworthville, 2145.
Ph: 02 9845 8151     fax: 02 9845 8155 email: beach@fmrc.org.au  Web: sydney.edu.au/medicine/fmrc/
20. Normal after-hours arrangements? 
 (Circle all that apply)
12. Did any of your BEACH consultations take place in  
 an Aboriginal Community Controlled Health Service?
8. Do you hold FACRRM? ...........................Yes / No
4. Country of graduation (primary medical degree):
Other: (specify)Australia
GP profile
GP18 (V2)
1. Sex ...................................... Male / Female (Please circle)
No ..................................................................................1
Yes - all .........................................................................2
Yes - some (which dates?)       3
*Each FTE is defined as working 35-45 hours per week e.g. 
2 GPs each working 20 hours/wk is recorded as 2 individual 
GPs and 1 FTE; 1 practice nurse working 20 hours/wk is 
recorded as 1 individual and 0.5 FTE.
18. How many individuals (ie. headcount) and how   
 many full-time equivalents (FTE*) for each type of  
 professional listed below?
(a) GPs (including yourself) .....
(b) Practice nurses ...................
No. FTEsNo. individuals
 BEACH The University of Sydney 1996
Practice does its own .................................................1
Co-operative with other practices .............................2
Deputising service .....................................................3
Other (specify) 4
None  .........................................................................5
9. Do YOU use a computer at your major  
 practice? ................................................ Yes / No 
If ‘yes’, which clinical software 
is used? (specify) 
10. Over the past four weeks have you provided any 
 patient care...
(a) in a residential aged care facility? ............Yes / No
(b) as a salaried/sessional hospital medical  
	 	officer? .....................................................Yes / No
11. At how many practice locations do you  
 usually work, in a regular week ...............
(Circle one option)
19. Health services located or available (on a daily or  
 regular basis) at the practice site? 
(Tick all that apply)
Physiotherapist .........................
Psychologist .............................
Dietitian ....................................
Podiatrist ..................................
Pathology collection centre/lab ..
Imaging ....................................
Diabetes educator .....................
   
   
   
   
 
 
   
In the 
practice
Not in the practice, 
but in the building 
or within 50 metres
.......
.......
.......
.......
.......
.......
.......
      .......NONE .....................................
Specialist(s)  
(specify):
Other  
(specify):       .......
   
    
   
   
.......
.......
17. Is the practice accredited?.....................Yes / No
   
   
   
   
 
 
   
16. What was your Medicare  
 Local?
15. Which Primary Health Network?
13. Is your major practice a teaching practice? 
 (Circle all that apply):
For undergraduates ........................................................1
For junior doctors ..........................................................2
For GP registrars ...........................................................3
No  .................................................................................4
Please answer the following questions ABOUT 
YOUR MAJOR PRACTICE
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Appendix D: Patient encounter recording form 
A patient encounter recording form. These came in a pad of 100.  
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Appendix E: Instructions for sub-studies used in this 
thesis 
Presented in order 
Instructions for survey 1 
Instructions for survey 2 – part 1: Consultation length 
Instructions for survey 2 – part 2: Severity of illness 
Instructions for survey 2 – part 3: Complexity of care 
Instructions for survey 2 – part 4: Health resource utilisation #1 
Instructions for survey 2 – part 5: Health resource utilisation #2 
Instructions for survey 2 – part 6: Health resource utilisation #3 
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In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
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these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id-410895.html
Other Terms and Conditions:
v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Appendix H: Ethics approval 
  
  
Research Integrity 
Human Research Ethics Committee 
 
 
Tuesday, 16 February 2016 
 
Prof Helena Britt 
School of Public Health: Public Health; Sydney Medical School 
Email: helena.britt@sydney.edu.au 
 
 
 
Dear Helena 
 
Your request to modify the above project submitted on 05 February 2016 was considered by the Chair 
of Executive of the Human Research Ethics Committee on 09 February 2016. 
 
The Committee had no ethical objections to the modification/s and has approved the project to 
proceed. 
 
 
Details of the approval are as follows: 
 
Project No.:  2012/130 
 
Project Title:  BEACH (Bettering the Evaluation and Care of Health) 
 
Approved Documents: 
 
Date Uploaded Type Document Name 
05/02/2016  Questionnaires/Surveys   BEACH GP profile  
 
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
 
Yours sincerely 
 
 
 
 
Dr Stephen Assinder 
Chair 
Human Research Ethics Committee 
 
 
This HREC is constituted and operates in accordance with the National Health and Medical 
Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research 
(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 
 
Research Integrity 
Research Portfolio 
Level 2, Margaret Telfer 
The University of Sydney  
NSW 2006 Australia 
T +61 2 8627 8111 
F +61 2 8627 8177 
E ro.humanethics@sydney.edu.au 
sydney.edu.au 
ABN 15 211 513 464 
CRICOS 00026A 
 
